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Chapter 1
Introduction and outline of the thesis.
Chapter 1
INTRODUCTION
Malaria, a hematological disease
Malaria is one of the most important parasitic diseases worldwide and it remains a major health 
problem in many tropical countries. Approximately 250 million people are infected every year 
and up to 1 million die, most of them young children and pregnant women. Countries in Sub- 
Saharan Africa are most affected by malaria, although the burden in some areas in Asia is prob­
ably underestimated. The disease is caused by a parasite of the genus Plasmodium that is trans­
mitted by female Anopheles mosquitoes. Five malaria species can infect humans: Plasmodium 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. The first, P. falciparum, is responsible for 
by far the most deaths and severe illness. In recent years, an increasing number of reports of se­
vere and fatal disease associated with P. vivax infection have challenged the perception of vivax 
malaria being merely a benign disease [1].
The life cycle of P. falciparum is shown in figure 1. Broadly, two stages can be described in 
the human host: a) the liver stage, which takes approximately 7 days during which parasites ma­
ture and multiply in hepatocytes and which is not associated with clinical symptoms; b) the 
blood stage, during which parasites mature and multiply within erythrocytes and which is char­
acterized by the typical clinical features of malaria, such as fever, shivers, headache and myalgia. 
These typical malaria symptoms - often referred to as acute or febrile malaria - are especially 
seen in young children and non-immune adults. As people living in malaria endemic areas are 
being infected repeatedly, a form of immunity develops that is sufficient to control, but insuf­
ficient to eliminate infection. This leads to malaria parasites being present in the bloodstream 
without clinical manifestations of malaria, a condition called asymptomatic parasitemia.
Malaria parasites thus directly interact with blood cells and several hematological changes 
are observed during a malaria infection. Anemia is a frequent complication of malaria and re­
sponsible for a considerable part of the malaria associated deaths. The pathogenesis of malaria 
anemia is complex and involves far more than just hemolysis of infected red blood cells (RBC)
[3]. However, the hematological consequences of malaria extend beyond anemia. A low circulat­
ing platelet count (thrombocytopenia) is also a common finding in subjects with a malaria infec­
tion and several studies have reported an association between the degree of thrombocytopenia 
and the severity of malaria [4].
So far, most research efforts have focused on malarial anemia. The role of iron has been 
studied in this context although these studies were hampered by limited insight in iron homeo­
stasis. Surprisingly, malaria-associated thrombocytopenia has received only little attention. The 
present thesis focuses on malaria anemia and thrombocytopenia with special emphasize on 
the interaction of malaria with iron homeostasis and the causes and consequences of malaria- 
associated thrombocytopenia.
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Figure 1. Malaria life cycle.
Plasmodium parasites reside in the salivary glands of female Anopheles mosquitoes. Within minutes after 
injection in the human host, the parasites, named sporozoites in this stage travel to the liver where they 
start to mature and multiply within liver cells (hepatocytes). After around one week, the infected hepato- 
cytes burst open and the malaria parasites, named merozoites, are released into the blood, where they 
invade red blood cells. Maturation and asexual multiplication takes place in red blood cells during approxi­
mately 48 hours (in case of P. falciparum infections; other Plasmodia take longer) during which a young 
trophozoite ('ring stage') develops into a red blood cell schizont and the red blood cell ruptures and new 
merozoites are released into the blood. A fraction of the trophozoites develops into sexual forms, called ga- 
metocytes. Upon ingestion by mosquitoes during a blood meal, sexual replication occurs in the mosquito 
midgut followed by migration of new sporozoites to the salivary gland of the mosquito.
Anemia, iron homeostasis and hepcidin
Anemia is an important public health problem with an estimated number of over 2 billion ane­
mic persons worldwide - over 30% of the world population [5, 6]. In resource poor areas, malaria 
and iron deficiency are important causes of anemia [7, 8]. The etiology of malaria-associated 
anemia is multifactorial and complex [3]. Key mechanisms include the suppression of RBC pro­
duction in the bone marrow (erythropoiesis) and increased clearance of infected and uninfected 
RBC. The latter is especially important as around ten uninfected RBC are removed for every in­
fected RBC and loss of uninfected RBC may thus be a major pathogenic mechanism in malaria- 
induced anemia [9].
Several mechanisms account for the suppression of the erythropoiesis, including functional 
iron deficiency (see below) and inhibition of the RBC precursors by parasite products (hemozo-
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ine and glycosylphosphatidylinositol) and proinflammatory cytokines. Levels of the proinflam- 
matory cytokine TNF-a relative to its regulator, the anti-inflammatory cytokine IL-10, are closely 
associated with malaria anemia [10, 11]. The role of macrophage migration inhibitory factor 
(MIF) in the pathogenesis of malaria anemia is less clear. MIF is predominantly produced by acti­
vated T-lymphocytes and has been shown to inhibit erythropoiesis. However, both high and low 
circulating levels of MIF have been reported in subjects with malaria [12, 13]. The pathogenesis 
of premature removal of uninfected RBC is also still only partly understood. In vitro studies using 
cultured P. falciparum have suggested that RBC membrane changes occur mimicking acceler­
ated RBC senescence [14, 15].
Iron deficiency is the most prevalent micronutrient deficiency in the world and probably the 
most common cause of anemia worldwide. Its complications are not restricted to anemia, but 
include impaired growth, cognitive development and physical capacity [16]. In addition, iron 
deficiency has been associated with increased perinatal risks for mothers and neonates and 
increased overall infant mortality. Iron supplementation or iron fortification of foods have been 
considered important public health interventions [8], but there is nowadays growing concern 
about the safety of iron supplementation in people exposed to malaria, as iron might increase 
malaria-associated morbidity and mortality [17, 18]. In addition, infectious diseases induce alter­
ations in the distribution of iron in the human body which may contribute to the development 
of anemia, and limit the response to iron supplements. A stunted compensatory erythropoiesis 
in combination with enhanced clearance of RBCs may especially increase the risk for severe ma­
laria anemia.
A complex web of possible serious interactions seems to exist between malaria, iron homeo­
stasis and iron supplementation, although detailed knowledge about the nature of these inter­
actions is largely absent. The past decade has seen the identification of new proteins involved 
in iron metabolism that has greatly increased the insight in iron uptake and distribution [19]. 
Especially the identification of the hormone hepcidin has led to a shift in our perception of iron 
homeostasis [20-22]. Hepcidin is predominantly produced in the liver and now appears to be 
the long sought regulator of iron homeostasis. It inhibits the absorption of iron from the duo­
denum and impairs iron release by macrophages through degradation of the sole iron exporter 
ferroportin. Figure 2 summarizes the pathways of iron uptake and iron recycling in humans and 
the central role of hepcidin in these processes. In recent years, reliable immunochemical and 
mass spectrometry assays have become available for quantifying the concentration of hepcidin 
in serum and urine [23, 24]. These assays can help to improve our insight in how the host's iron 
homeostasis changes during a malaria infection and the consequences for current iron supple­
mentation practices.
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Figure 2. Iron uptake and recycling. (A) By far the largest amount of the body's iron is incorporated in 
hemoglobin. Only a small amount of iron - approximately 1-2 mg of iron - is absorbed and lost every day. 
Iron is absorbed from the duodenum via DMT1 at the apical membrane of enterocytes and is taken up 
in the serum through ferroportin; loss of iron occurs passively (B). The central step in iron metabolism is 
erythrophagocytosis of senescent red blood cells with recycling of red cell iron by macrophages in the liver 
and the reticuloendothelial system via the iron exporter ferroportin (C). The liver-produced peptide hep- 
cidin controls plasma iron concentration by internalizing and degrading ferroportin, which leads to low 
serum iron and increased macrophage iron sequestration. Hepcidin expression is regulated by body iron 
stores, inflammation, erythroid iron demand, and hypoxia via regulation pathways involving expression of 
HFE, TfR2, TfR1 and HJVgenes. DMT1: divalent metal transporter 1; Hb: hemoglobin; HO: heme oxygenase; 
NTBI: non-transferrin bound iron; Tf: transferrin; Cp: ceruloplasmin; HCP1: heme carrier protein 1; DcytB: 
duodenal cytochrome B.
Adapted and reproduced with permission from Swinkels et al. [2]
Difficulties in the assessment of iron status in inflammatory conditions
Pro-inflammatory cytokines and suppressed erythropoiesis stimulate hepcidin expression [20, 
22]. This leads to hypoferremia and increased iron storage in the reticuloendothelial system, 
both typical features of the anemia of inflammation, also called the anemia of chronic disease
[25]. Iron status is traditionally categorized as either iron deficient or iron replete purely on the 
basis of the estimated total amount of body iron. This is an oversimplification as it completely 
neglects the distribution of iron in the body. During inflammation, elevated hepcidin levels in­
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duce iron maldistribution (also called iron delocalization), i.e. iron sequestration in storage sites 
together with low serum iron concentrations. So, both the absolute iron status and the distribu­
tion of iron in the body determine the availability of iron for hemoglobin synthesis (Figure 3). A 
common finding in inflammatory conditions is a low iron supply to the bone marrow despite a 
normal or elevated total body iron amount and this situation is called functional iron deficiency.
The use of traditional biochemical iron parameters, such as serum ferritin and transferrin, for 
estimation of the absolute iron status during inflammation or for differentiating absolute iron 
deficiency from functional iron deficiency is hampered by inflammation-induced iron maldistri­
bution and by the fact that many of these parameters are acute phase proteins. This is especially 
problematic in many resource poor countries, where (asymptomatic) malaria infections and 
other chronic infections are highly prevalent. The need for new iron parameters is even more ur­
gent, since the World Health Organization has recently advised to restrict iron supplementation 
in malaria endemic regions to individuals with proven iron deficiency [6]. This advice was based 
on the results of a large iron supplementation trial in Tanzania, which showed an adverse effect 
of universal iron supplementation [18].
Normal iron distribution
Figure 3. Absolute iron status versus iron distribution
In conclusion, there is a complex interaction between malaria and iron homeostasis. Recent 
advances in the understanding of iron homeostasis and the recent development of hepcidin 
assays have opened new opportunities to unravel this interaction. The use of traditional bio­
chemical iron parameters in malaria-endemic regions should be critically reappraised, and new 
iron parameters are urgently needed. All this knowledge can be used to optimize current iron 
supplementation policies in resource poor countries.
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Malaria-induced thrombocytopenia
Platelets
Thrombocytopenia is a common finding in patients with a malaria infection. Platelets are pri­
marily known for their role in primary hemostasis, but the number of circulating platelets is 
at least tenfold higher than required for prevention of bleeding. The explanation for this high 
number of platelets may lie in their additional properties and functions. Platelets contain a wide 
range of inflammatory, immune modulating and angiogenic factors and there is increasing evi­
dence that their role in the innate immune response against a wide range of micro-organisms 
is underestimated [26, 27]. Recently, it was reported that purified platelets have a lethal effect 
on P. falciparum [28].
Bleeding is rare in malaria patients and the malaria-associated thrombocytopenia has often 
been regarded as a rather innocent epiphenomenon. Observations that platelets accumulate in 
the brain microvasculature in children dying of cerebral malaria and the finding that platelets 
can mediate sequestration of infected RBC have led to a gradual change in this perception [29, 
30]. Yet, our current understanding of the causes and consequences of the low platelet counts 
in malaria is still limited. Various etiological mechanisms for the thrombocytopenia have been 
suggested in the literature, including platelet activation, consumptive coagulopathy, splenic 
pooling and auto-immune clearance [31-34]. These mechanisms may indeed all play a role in 
severe malaria, but their contribution in the earlier stages of malaria is unknown. So far, no stud­
ies have systematically investigated the importance of these mechanisms in malaria-associated 
thrombocytopenia.
Von Willebrand factor
An early and profound activation of the endothelium is important during the blood stage of a 
malaria infection. Endothelial activation with upregulation of several endothelial adhesion re­
ceptors (e.g. CD36, intercellular adhesion molecule-1) promotes the adhesion of infected RBC to 
the endothelium, which prevents premature removal of infected RBC by the spleen. At the start 
of the research described in this thesis, we hypothesized that endothelial activation with release 
of the platelet binding protein von Willebrand factor (VWF) is primarily responsible for the early 
development of thrombocytopenia.
VWF is a large multimeric glycoprotein that serves as a carrier for coagulation factor VIII 
and as an adhesive surface for platelets at sites of vessel injury. It is predominantly synthesized 
in vascular endothelial cells, where it undergoes extensive processing after synthesis - includ­
ing dimerization, multimerization and endoproteolytic cleavage of a propeptide. Large VWF 
multimers and VWF propeptide are stored in specialized secretory granules in endothelial cells, 
known as Weibel-Palade bodies. These granules are released during endothelial cell activation 
and both VWF and VWF-propeptide are thus markers for endothelial cell activation. Freshly re­
leased VWF remains temporarily attached to the surface of endothelial cells where it unfolds
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from a tubular conformation into an elongated form. These long VWF filaments are known as 
ultra-large VWF strings (UL-VWF) and they can bind platelets spontaneously. This mechanism 
is essential in situations of vascular injury but can be harmful under normal circumstances. The 
metalloprotease ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin-1-like 
domains) functions as a natural regulator that rapidly cleaves and inactivates the prothrom- 
bogenic UL-VWF [35]. UL-VWF accumulation due to absent or markedly reduced ADAMTS13 
activity is characteristic for the rare microangiopathic disease thrombotic thrombocytopenic 
purpura [36]. This disease is characterized by formation of platelet rich microthrombi, which 
block the microcirculation leading to thrombocytopenia, neurologic symptoms, hemolysis and 
organ dysfunction.
Under normal conditions, VWF circulating in the plasma is different from freshly released 
VWF as it is in an inactive state, i.e. in a more globular conformation in which the binding site for 
its platelet-receptor glycoprotein-Iba (GpIba) is not exposed. Exposure of VWF to subendothe­
lial matrix leads to conversion of inactive to active VWF. A shift in the balance between inactive 
and active VWF has also been described in a range of other pathological conditions, including 
the HELLP syndrome, hypertensive crisis, the antiphospholipid syndrome and severe menin­
gococcal infections [37-40]. Increased platelet-VWF interaction in these conditions may lead to 
intravascular platelet adhesion and aggregation with thrombocytopenia and organ failure. De­
termination of active VWF levels in plasma has recently become available with the introduction 
of a llama-derived nanobody (designated AU/VWFa-11), which displays preferential binding to 
the GPIba-binding conformation of the VWF A1 domain [37].
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OUTLINE OF THIS THESIS
This thesis is divided in two parts. Part I deals with malaria-associated anemia and focuses on 
the effect of malaria on iron homeostasis, the cytokine macrophage migration inhibitory factor 
(MIF) and on malaria-induced changes in the RBC membrane. Part II focuses on the malaria- 
associated thrombocytopenia and the importance of endothelial cell activation.
Studies described in this thesis were largely done in: a) healthy Dutch volunteers who were 
experimentally infected with P. falciparum in Nijmegen, b) patients with naturally acquired ma­
laria in Tanzania and Indonesia, and c) in vitro experiments in the laboratory. The objectives of 
the studies described in the following chapters were to determine:
Part I
o Disturbances in iron homeostasis in anemic Tanzanian children with febrile P. falciparum ma­
laria (chapter 2)
o The effects of low density P. falciparum malaria on concentrations of serum hepcidin and 
other iron status parameters and the consequences for iron incorporation in the bone mar­
row (chapter 3)
o Disturbances in iron homeostasis in Indonesian children with asymptomatic P. falciparum 
and P. vivax malaria (chapter 4) 
o Iron homeostasis in women with placental malaria and their offspring (chapter 5) 
o Changes in Macrophage Migration Inhibitory Factor levels in malaria (chapter 6) 
o Changes in the composition of the RBC membrane in malaria patients (chapter 7)
Part II
o Endothelial cell activation and release of von Willebrand factor in relation to thrombocyto­
penia in early P. falciparum malaria (chapter 8) 
o Von Willebrand factor and ADAMTS13 in natural acquired P. falciparum and P. vivax malaria 
(chapter 9)
o The cause of malaria-associated thrombocytopenia (chapter 10)
o Finally, a case of an acute cardiac event in a volunteer experimentally infected with P. falci­
parum malaria is described and the possible pathogenesis is discussed (chapter 11)
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Chapter 2
SUMMARY
Disturbances in iron homeostasis are frequently observed in individuals with malaria. To study 
the effect of malaria and its treatment on iron homeostasis and to provide a mechanistic expla­
nation for observed alterations in iron distribution, we studied the course of the iron regulatory 
hormone hepcidin in anemic Tanzanian children with febrile Plasmodium falciparum malaria. 
Before initiation of antimalarial treatment, urinary concentrations of hepcidin were strongly el­
evated and were associated with iron maldistribution, as was suggested by the presence of hy- 
poferremia and high serum concentrations of ferritin. Antimalarial treatment resulted in a rapid 
decrease in urinary concentrations of hepcidin and reversal of the hypoferremia. Exploration 
of regulatory pathways of hepcidin production by analysis of iron, erythropoietic, and inflam­
matory indices suggested that reduced erythropoietic activity and inflammation stimulated 
hepcidin production. We conclude that high concentrations of hepcidin explain the observed 
disturbances in host iron homeostasis associated with malaria and may contribute to malarial 
anemia and an impaired erythropoietic response to iron supplementation.
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INTRODUCTION
Iron deficiency and malaria are among the most common causes of anemia in African children, 
and the 2 conditions frequently coexist and interact in a way that is currently poorly under­
stood [1, 2]. Recently, the importance of unraveling the complex interaction between malaria 
and iron metabolism was highlighted by an iron supplementation trial performed in Pemba 
Island, Tanzania; in this trial, routine iron and folic acid supplementation resulted in an increased 
incidence of severe adverse events among iron-replete children in an area where malaria was 
hyperendemic [3]. To date, studies of iron and malaria have been hampered by insufficient in­
sight into the mechanism underlying disturbances in iron homeostasis induced by Plasmodium 
falciparum malaria [4]. The recently discovered peptide hormone hepcidin is, however, a new 
tool that may contribute to better understanding of the changes in host iron homeostasis in 
malarial infection.
Hepcidin controls extracellular iron concentration and distribution of iron in tissue by bind­
ing and subsequent degradation of the sole transmembrane iron exporter ferroportin [5, 6]. 
High concentrations of hepcidin restrict intestinal absorption of iron and the release of iron 
from macrophages and hepatocytes, resulting in low plasma concentrations of iron and limited 
availability of iron for erythropoiesis. In febrile P. falciparum malaria, hepcidin production may 
be upregulated by inflammatory cytokines [7-9] and bone marrow suppression [10, 11], where­
as hypoxia and anemia may downregulate production [12]. Increased hepcidin concentrations 
could induce or worsen malaria-associated anemia, and, by causing iron-restricted erythropoi­
esis, they might impair the recovery of hemoglobin (Hb) levels after antimalarial treatment. In 
addition, the efficacy of iron supplementation therapy may be impaired by high concentrations 
of hepcidin. Finally, hepcidin concentrations may influence susceptibility to malaria and other 
infections by regulating the supply of iron to microorganisms [13].
Recently, our group of investigators developed urine and serum assays for the measure­
ment of hepcidin concentrations by use of mass spectrometry [14-16], and subsequent studies 
showed a strong correlation between the hepcidin concentrations measured by both assays 
[15]. With the use of a recent quantitative update of the urinary hepcidin assay, the aim of our 
present study was to investigate the effect of febrile P. falciparum malaria and its treatment on 
iron homeostasis in anemic Tanzanian children. In addition, determination of the indicators of 
iron status, inflammation, and erythropoietic activity enabled us to explore the putative regula­
tory pathways of hepcidin expression in malaria. The urine assay was chosen (1) to minimize the 
volume of blood collected from young children and (2) because urinary levels of hepcidin are 
less affected by a diurnal variation [15]. Anemic children were included in the study because 
disturbances in iron homeostasis might have especially severe consequences in this group.
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PATIENTS AND METHODS
Patients and study design.
The patients recruited for the present study were a subgroup of children enrolled in a 1-year 
study investigating the causes of acute illness in children (age, 2 months to 13 years) who had 
a current or recent history of fever and were admitted to a district hospital in an area of intense 
P. falciparum transmission in Northeast Tanzania (the SFI [Severe Febrile Illness] Study). Children 
enrolled in the study underwent a standard examination; they then had blood samples drawn 
for culture, HIV testing, and slide examination for malaria and were provided routine clinical care 
according to hospital and national guidelines. Children were eligible to participate in the hepci­
din study if they were febrile at admission (axillary temperature, >37.5°C), had a positive result 
of blood slide examination for P. falciparum (i.e., with detection of at least 125 parasites/200 
white blood cells [WBCs]), a negative HIV test result, a negative blood culture result, anemia 
(Hb level, <10 g/dL), and no history of iron therapy in the preceding 3 weeks. Serum and urine 
samples obtained from these children at admission were stored at 80°C, pending laboratory 
analysis with additional serum and urine samples obtained at 48 h and at 4 weeks after admis­
sion; the samples obtained at week 4 were available for only a minority of children, because of 
logistical constraints. At the time of discharge from the hospital, all children were prescribed a 
2-week course of iron supplementation (with the dose determined according to body weight, 
as per Tanzanian guidelines).
At the follow-up visit at week 4, a short questionnaire documented the intake of iron supple­
mentation after discharge and any current illness. The child's temperature and Hb level were 
determined, and a thick blood smear was obtained to check for Plasmodium parasitemia. The 
urinary concentration of hepcidin in the sample obtained at week 4 was determined for those 
children without current or recent (within <48 h) fever and with a negative result of blood smear 
examination for the presence of asexual P. falciparum parasites. Urine samples were collected 
from 11 A.M. to6 P.M., to minimize the effect of circadian variation in hepcidin secretion [15]. 
For children from whom no sample could be obtained before 6 P.M., urine was collected the 
following morning.
Laboratory analyses.
Thick and thin blood smears were stained with Giemsa and were examined independently by 2 
experienced microscopists. A third microscopist reviewed the slides in case of discordant results. 
The number of parasites was quantified against 200 WBCs, and parasite density was calculated 
under the assumption that the WBC count was 8000 WBCs/ L. Blood cultures were performed us­
ing BacT/Alert PF bottles and the BacT/Alert 3D automated blood culture system (bioMérieux). 
The Capillus rapid assay test (Trinity Biotech) was used for detection of HIV-1/HIV-2 antibodies. A 
full blood count was determined using a hematologic analyzer (Beckman Coulter) at admission;
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the Hb level at week 4 was determined using Hemocue. Lactate levels in capillary blood were 
determined using a Lactate Pro analyzer (Arkay).
The concentrations of serum iron and total iron-binding capacity (TIBC) were determined 
using a colorimetric method; the serum C-reactive protein (CRP) level was determined using 
immunologic agglutination detection, and the urinary concentration of creatinine was deter­
mined using enzymatic colorimetric detection, with the use of an Abbott Aeroset analyzer (Ab­
bott Laboratories). The serum transferrin saturation was calculated as a percentage of the total 
iron concentration in serum divided by the TIBC. The serum concentration of ferritin was mea­
sured using an immunometric assay with the use of an Immulite 2500 (Diagnostic Products). 
The serum concentration of soluble transferrin receptor (sTfR) was measured immunonephelo- 
metrically on a BN II System (Dade Behring). Serum concentrations of interleukin (IL)-1 receptor 
antagonist (IL-1Ra), IL-6, IL-10, and tumor necrosis factor (TNF)-a were analyzed in one batch 
with the use of a multiplex assay (Luminex). The lower limits of detection for CRP, IL-1Ra, IL-6, 
IL-10, and TNF-a were 5 mg/L, 40 pg/mL, 7 pg/mL, 7 pg/mL, and 18 pg/mL, respectively. For all 
analyses, the value of the lower limit of detection was used in samples with values below the 
limit of detection.
Urinary concentrations of hepcidin were measured using surface-enhanced laser desorp- 
tion/ionization-time-of-flight mass spectrometry, as reported elsewhere [15, 16]. A custom- 
made synthetic hepcidin-24 peptide (Peptide International) was used as an internal reference 
standard. The urine concentrations of hepcidin were normalized to urine creatinine values and 
were expressed as the number of nanomoles per millimoles of creatinine.
Statistical analyses.
Data are the median value (interquartile range), unless otherwise stated. Changes in serial labo­
ratory parameter concentrations noted at the 3 time points when each patient was evaluated 
were examined with linear mixed models. The association between urinary concentrations of 
hepcidin and concentrations of other laboratory parameters was assessed using Spearman's 
correlation coefficient. Predictors of urinary concentrations of hepcidin were assessed in a mul­
tivariate linear regression model with log-transformed data, because the distributions of these 
variables were skewed. Biologically plausible variables reported to affect hepcidin concentra­
tions were entered in a multivariate linear regression model with backward stepwise elimination 
of nonsignificant (P < .1) factors, regardless of their univariate status. These variables were the 
Hb level, parasite density, the serum concentration of ferritin (as a measurement of iron seques­
tration in macrophages, inflammation, and iron stores in the body), sTfR (as a measurement of 
erythropoietic activity and iron demand in the erythron [17]), and IL-6 (as a marker of inflam­
mation). IL-6 was specifically chosen because this proinflammatory cytokine has predominantly 
been implicated in stimulation of hepcidin production [7, 9]. All analyses were performed using 
SPSS software for Windows (version 15.0; SPSS).
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Ethics.
Written, informed consent was obtained for all children. The ethics committees of the National 
Institute for Medical Research, Tanzania, and the London School of Hygiene and Tropical Medi­
cine approved the study.
RESULTS
Characteristics at baseline.
From September 2006 through January 2007, a total of 104 children were enrolled in the study. 
Patient characteristics and laboratory parameters at baseline, with reference values as reported 
by the assay's manufacturers or as reported in the literature, are shown in table 1. Urinary con­
centrations of hepcidin were very high and associated with the presence of hypoferremia, as 
was indicated by low serum iron concentrations and low transferrin saturations. In contrast, se­
rum concentrations of the iron storage protein ferritin and the acute-phase protein CRP were 
high. The median sTfR concentration was slightly above the upper reference limit for adults.
Temporal changes in urinary concentrations of hepcidin and in related laboratory 
parameters after antimalarial treatment.
Urine and blood samples obtained on day 2 after treatment were collected from 53 of 104 pa­
tients; 46 of these53 patients returned for the follow-up visit at week 4. Ten of these 46 patients 
were excluded because they had a positive result of blood slide examination for malaria or had 
signs of a systemic infection at week 4. For the remaining 36 patients, the course of urinary con­
centrations of hepcidin after the start of antimalarial treatment and the temporal associations 
with concentrations of iron status indicators, sTfR, and inflammatory markers were determined. 
There were no significant differences in characteristics at baseline between these 36 children 
and the children for whom only a sample obtained at baseline was available (data not shown). A 
blood transfusion had been given to 6 (16.7%) of 36 children during hospitalization, and all chil­
dren were reported by mothers or guardians to have used iron supplements after discharge. The 
median Hb level increased from 7.5 g/dL (range, 6.1 - 8.7 g/dL) at admission to 10.2 g/dL (range, 
8.9 - 11.5 g/dL) at week 4, with 25 (69.4%) of 36 children remaining anemic (Hb level, <11.0 g/dL).
Figure 1 shows the course of urinary concentrations of hepcidin, iron status indicators, and 
sTfR. Urinary concentrations of hepcidin decreased rapidly after the start of antimalarial treat­
ment, from a median level of 229.0 nmol/mmol creatinine (range, 125.8 - 330.2 nmol/mmol cre­
atinine) at baseline to 34.7 nmol/mmol creatinine (range, 10.2 - 93.9 nmol/mmol creatinine) 
and 9.8 nmol/mmol creatinine (range 2.5 - 19.3 nmol/mmol creatinine) at day 2 and week 4, re­
spectively. This rapid decrease in urinary concentrations of hepcidin was associated with a con-
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Table 1. Clinical and laboratory characteristics of the study population on admission.
Characteristic n Values Reference values
Age, months 104 22.2 (12.9 - 32.6) NA
Sex (% male : %  female) 104 57.7:42.3 NA
Days ill upon presentation, no. 103 3.0 (2.0 - 4.0) NA
Parasite density, parasites/pL 104 49,166 (27,724 - 73,581) NA
Hyperparasitemia*, no. of patients (%) 10/104 (10.4) NA
Hemoglobin level, g/dL 104 7.8 (6.2 - 9.0) 11.0 - 16.0
Hemoglobin level < 5 g/dL, no. of patients (%) 15/104 (14.4) NA
Mean cell volume, fL 101 74.0 (66.9 - 77.8) 75.0 - 91.0
Mean cell hemoglobin, pg 101 23.3 (21.4 - 25.5) 26.0 - 34.0
Mean cell hemoglobin concentration, g/dL 101 31.8 (30.8 - 33.1) 31.5 - 36.0
Red cell distribution width, % 101 17.7 (15.3 - 19.4) 11.0 - 15.0
White blood cell count, x109/L 101 8.4 (5.8 - 11.2) 4.0 - 11.0
Platelet count, x109/L 101 101.0 (67.5 - 150.0) 150.0 - 400.0
Urinary hepcidin concentration, nmol/mmol 
creatinine 104 177.5 (91.9 - 376.4) 0.01-5.5*
Serum iron concentration, pmol/L 96 2.0 (2.0 - 3.8) 10.0 - 25.0
Serum total iron binding capacity, pmol/L 97 56.0 (50.0 - 64.0) 45.0 - 75.0
Transferrin saturation, % 96 3.9 (2.7 - 6.5) 30.0 - 60.0
Serum ferritin concentration, pg/L 91 383.0 (238.0 - 711.0) 12.0 - 250.0
Serum soluble transferrin receptor concentration, 
mg/L 89 2.2 (1.8 - 3.0) 0.76 - 1.76*
Serum C-reactive protein concentration, mg/L 97 194.0 (108.0 - 237.5) <10.0
Capillary blood lactate concentration, mmol/L 101 2.8 (2.0 - 4.3) 2.5 - 4.0
Data are median (interquartile range) unless otherwise specified and reference values are as recom­
mended by assay's manufacturer or as reported in the literature. NA indicates not applicable
* >100000 parasites/|il_
* Values represent the range of the values obtained in July 2007 for 8 healthy Caucasian adults (4 men 
and 4 women) at 5 time points during the day (from 7 AM to 4 PM); mean is 2.20; SD is 2.37
* Reference intervals for adults. No age-specific reference intervals provided by manufacturer. Previ­
ous studies have demonstrated a strong age-related decrease in soluble transferrin receptor levels 
with the highest reference intervals found in infants [18, 19].
current increase in the serum concentration of iron and transferrin saturation, whereas marked 
changes in concentrations of serum ferritin, TIBC, and sTfR were apparent only at week 4.
As shown in figure 2, changes in the concentrations of CRP, the proinflammatory cytokines 
IL-1Ra, IL-6, and TNF-a, and the anti-inflammatory cytokine IL-10 paralleled changes in urinary 
concentrations of hepcidin. Concentrations of all inflammatory markers were high at baseline, 
but they decreased rapidly after initiation of antimalarial treatment. TNF-a was only detectable
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Figure 1. Box-whisker plots of temporal changes in concentrations of hepcidin in urine, soluble trans­
ferrin receptor, and iron status indicators noted in patients with febrile Plasmodium falciparum malaria 
at baseline, as well as on day 2 and at 4 weeks after initiation of antimalarial treatment. Boxes span the 
interquartile range, and lines denote the location of the first quartile, the median, and the third quar­
tile. Whiskers extend to the last data point within 1.5 times the interquartile range in either direction. 
Outliers are indicated by open circles and denote patients for whom values were between 1.5 and 3 
box-lengths from the first and third quartiles. Extremes, denoting patients for whom values were >3 
box-lengths from the first and third quartiles, are not shown in the figure. P values were determined 
using linear mixed models.
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Baseline Day 2 Week 4 
n = 29 n = 33 n = 33 
Figure 2. Box-whisker plots of temporal changes in concentrations of C-reactive protein and inflam­
matory cytokines noted in patients with febrile Plasmodium falciparum malaria at baseline, as well as 
on day 2 and at 4 weeks after initiation of antimalarial treatment. Boxes span the interquartile range, 
and lines denote the location of the first quartile, the median, and the third quartile. Whiskers extend 
to the last data point within 1.5 times the interquartile range in either direction. Outliers are indicated 
by open circles and denote patients for whom values were between 1.5 and 3 box-lengths from the 
first and third quartiles. Extremes, denoting patients for whom values were >3 box-lengths from first 
and third quartiles, are not shown in the figure. P values were determined using linear mixed models. 
CRP, C-reactive protein; IL, interleukin; IL-1Ra, IL-1 receptor antagonist.
in serum at baseline. Concentrations of IL-1Ra, IL-6, and IL-10 at week 4 were very low and were 
below the detection limit of the assay in 6%, 26%, and 38% of samples, respectively.
Association between urinary concentrations of hepcidin and selected laboratory 
parameters.
Spearman's correlations between selected laboratory parameters and urinary concentrations 
of hepcidin at baseline and at week 4 are shown in table 2. There was a positive correlation of 
urinary concentrations of hepcidin with Hb concentrations, as well as with concentrations of
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the cytokines IL-6, IL-10, and TNF-a. Hepcidin concentrations were inversely associated with ex­
tracellular iron concentrations, as was reflected by the strong negative Spearman's correlations 
with serum iron concentration, transferrin saturation, and TIBC. There also was a negative cor­
relation between urinary concentrations of hepcidin and sTfR concentrations. Spearman's cor­
relations determined at week 4 had changed considerably, compared with correlations noted 
at baseline. The strength of the correlation between the urinary concentration of hepcidin and 
the serum concentration of ferritin was notably stronger, whereas the strong inverse correlation 
between serum iron, transferrin saturation, and sTfR noted at baseline had weakened.
Predictors of urinary concentrations of hepcidin.
Predictors of urinary concentrations of hepcidin at baseline and week 4 were investigated in a 
multivariate linear regression model with backward stepwise elimination of nonsignificant (P 
< .1) factors (table 3). Parasite density and concentrations of Hb, serum ferritin, sTfR, and IL-6 
were included in the initial model as putative indicators or mediators of the various regulatory 
pathways of hepcidin production. At baseline, Hb concentrations and parasite density were pos­
itively associated with urinary concentrations of hepcidin, whereas sTfR concentrations were 
negatively associated. In accordance with Spearman's correlation analysis, serum concentra­
tions of ferritin were not significantly associated with urinary concentrations of hepcidin in the 
multivariate model. In contrast to Spearman's correlation analysis, IL-6 was eliminated from the 
model, and inclusion of one of the other inflammatory cytokines (IL-1Ra, IL-10, or TNF-a) or CRP 
in the initial model (instead of IL-6) also resulted in their elimination (data not shown). Pairwise 
comparison revealed significant Spearman's correlations between IL-6 concentrations and other 
variables in the model: parasite density (r = 0.398; P < .001), ferritin concentration (r = 0.333; P < 
.001), and sTfR concentration (r = 0.386; P < .001). At week 4 after treatment initiation, the serum 
concentration of ferritin was the sole independent variable associated with the urinary concen­
tration of hepcidin.
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DISCUSSION
In the present study, we showed that urine concentrations of the iron-regulatory hormone hep­
cidin were strongly elevated in anemic children with febrile P. falciparum infection, and they 
were associated with iron maldistribution, as was indicated by observations of hypoferremia 
and high serum concentrations of ferritin. Antimalarial treatment resulted in a rapid decrease in 
urinary concentrations of hepcidin and reversal of the hypoferremia. The latter outcome prob­
ably resulted from a restored functional capacity of the iron transporter ferroportin to export 
sequestered iron from macrophages, enterocytes, and hepatocytes.
These findings provide a mechanistic explanation for the observed disturbances in iron ho­
meostasis in patients with malaria, and hepcidin may prove to be a new tool with which to quan­
tify and determine the duration of these disturbances. In addition, as discussed in the following 
paragraphs, induction of hepcidin expression during malaria may: (1) prove to be a new and 
important pathogenic factor in malarial anemia and in the impaired recovery of Hb levels after 
antimalarial treatment, (2) reduce the erythropoietic response to iron supplementation, and (3) 
protect against proliferation of malaria parasites and explain the high incidence of infections 
with intracellular bacteria in patients with malaria.
Increased hepcidin production may contribute to the pathogenesis of malarial anemia by 
limiting the availability of iron for erythropoiesis and, possibly, also by directly inhibiting ery- 
throid progenitor proliferation and survival [20, 21]. Proinflammatory cytokines also exert a di­
rect [21, 22] and indirect suppressive effect on the bone marrow through a decrease in eryth­
ropoietin production or erythroblast receptivity to erythropoietin [23, 24]. Because Hb levels 
invariably decrease during episodes of malaria, it is crucial that, as soon as the infection is under 
control, concentrations of both hepcidin and proinflammatory cytokines decrease rapidly so 
the bone marrow can regain its activity. Failure to do so may result in severe anemia as a result 
of ongoing bone marrow suppression. In our patients, urinary hepcidin and pro-inflammatory 
cytokine concentrations decreased rapidly after initiation of antimalarial treatment, suggesting 
that bone marrow suppression in patients with febrile malaria is rapidly reversible after initia­
tion of efficacious antimalarial therapy. Indeed, previous studies noted a reticulocyte response 
within 3-5 days after the start of antimalarial treatment [25, 26]. In the present study, Hb concen­
trations increased markedly by week 4 after treatment initiation, although an Hb level >11 g/dL 
was noted in only a minority (30.6%) of children.
Our current findings may also contribute to a more rational use of iron supplementation 
for children with malaria anemia. High hepcidin concentrations will compromise intestinal iron 
absorption, and the nonabsorbed iron might cause gastrointestinal complaints. The initial iron 
supply for erythropoiesis after antimalarial treatment might also predominantly be derived 
from the release of sequestered iron. Our current findings suggest that, in patients with febrile 
ma- laria, iron therapy might only be effective until after the completion of antimalarial treat­
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ment, when hepcidin concentrations have decreased. Recently, using stable isotope iron incor­
poration studies, Doherty et al. [27] observed reduced iron incorporation in children with post­
malaria anemia, and they suggested that the early need for erythropoietic iron is met by iron 
recycling rather than by iron absorption from the intestine.
Like all living organisms, microorganisms (including P. falciparum) require iron for vital cell 
functions [13, 28]. The importance of iron in malaria is supported by the antimalarial effect of 
iron chelators [29] and by a recent trial showing an increased risk of death and of hospital ad­
mission among iron-replete children receiving iron and folic acid supplementation in an area of 
endemicity for malaria [3]. Malaria parasites may use several sources of iron, including a labile 
intra-erythrocytic iron pool, heme iron from Hb breakdown [30], and extracellular iron [31, 32]. 
We speculate that high hepcidin concentrations might inhibit multiplication of malaria parasites 
by depriving the parasites from the iron supply of the host. However, in contrast to a potential 
protective effect against malaria, sequestration of iron in macrophages may prove to be a risk 
factor for intracellular bacterial infections. Hepcidin-induced down-regulation of ferroportin ex-
Table 2. Spearman's rank correlation coefficients of urinary hepcidin concentrations with hema­
tological, iron status, erythropoietic activity and inflammatory indicators at baseline and week 4.
Baseline Week 4
Factor n R p n R p
Parasite density 104 0.183 0.063 NA NA NA
Hemoglobin concentration 104 0.202 0.039 34 -0.203 0.242
Serum transferrin saturation 96 -0.227 0.026 33 -0.100 0.547
Serum iron concentration 96 -0.326 0.001 33 -0.183 0.301
Total iron binding capacity 97 -0.251 0.013 33 -0.21S 0.215
Serum ferritin concentration 91 0.067 0.527 34 0.372 0.028
Serum soluble transferrin receptor 
concentration 88 -0.286 0.007 33 -0.132 0.456
Serum C-reactive protein concentration 97 0.119 0.245 34* 0.252 0.145
Serum interleukin-6 concentration 83 0.286 0.008 33* 0.209 0.11S
Serum interleukin-1 receptor antagonist 
concentration 82 0.193 0.080 33* 0.275 0.058
Serum interleukin-10 concentration 83 0.256 0.019 33* -0.060 0.372
Serum tumor necrosis factor-a 
concentration* 83 0.255 0.019
NA indicates not applicable
* Concentrations for C-reactive protein, Interleukin (IL)-6, IL-1receptor antagonist and IL-10 at week 4 
below the assay's lower detection limit in 59%, 26%, 6% and 38% respectively. The value of the lower 
detection limit was used for analyses in these cases.
* No Spearman's correlation calculated for week 4, because TNF-a concentration only above assay's 
lower detection limit in one sample.
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pression was recently reported to enhance the growth of Salmonella enterica [33], as well as that 
of other intracellular bacteria [34], in macrophages in vitro, and this finding may explain the 
observed association between malaria and non-serotype Typhi Salmonella infections [35-37].
Regulatory pathways of hepcidin production in febrile malaria were explored by Spearman's 
correlation analysis and multivariate linear regression analysis. Several putative upstream and 
interlinked pathways have been identified to date [38], including regulation by erythropoietic 
activity or anemia/hypoxia [10-12, 39], iron store-related [7, 40] and holotransferrin [41] regula­
tion, and inflammation-related regulation [7, 8].
Suppressed erythropoietic activity (as reflected by low sTfR concentrations) was associated 
with higher hepcidin concentrations at baseline. Use of sTfR for the evaluation of erythropoietic 
activity has been reviewed elsewhere [17]. At baseline, sTfR concentrations were in the upper 
limit of the range considered normal for adults, but these concentrations might have been inap­
propriately low, considering the degree of anemia and the effect of age, whereby the highest 
sTfR concentrations are found in infants [18, 19]. Suppressed erythropoiesis with reticulocytope- 
nia is a well-known characteristic of febrile malaria [42], and the negative association between 
concentrations of hepcidin and sTfR in the present study is in line with the findings of recent
Table 3. Backward stepwise multivariate linear regression analysis of putative predictors (log- 
transformed) of urinary hepcidin levels (log-transformed) at baseline and week 4 post-admission.
Full model Final model
Factor B 95% CI ß B 95% CI ß
Baseline
Hemoglobin, g/dL 1.078 -0.176 to 2.332 0.215 1.169 0.111 to 2.227 0.234
Parasite density, parasites/pL 0.331 -0.120 to 0.783 0.168 0.392 -0.020 to 0.805 0.198
Soluble transferrin receptor, 
mg/L
-0.761 -1.586 to 0.064 -0.227 -0.862 -1.571 to -0.153 -0.257
Serum ferritin, pg/L 0.014 -0.353 to 0.382 0.010
Interleukin-6, pg/L 0.068 -0.140 to 0.277 0.085
Week 4
Serum ferritin, pg/L 0.438 -0.125 to 1.002 0.296 0.511 -0.017 to 1.039 0.345
Hemoglobin, g/dL -0.925 -4.050 to 2.200 -0.118
Soluble transferrin receptor, 
mg/L
-1.021 -3.183 to 1.141 0.185
Interleukin-6, pg/L 0.741 -0.362 to 1.844 0.263
Full model with all entered variables and final model after elimination of non-significant (p<0.1) vari­
ables are shown. Data are expressed as unstandardized coefficients (B) with 95% confidence intervals 
(95% CI) and standardized coefficients (P). In this model, a log10 increase in hemoglobin concentra­
tion was associated with an estimated 1.078 increase in log10 urinary hepcidin concentration. Toler­
ance values (1/variance inflation factor) were between 0.959 and 0.983 in the final model at baseline, 
indicating that multicollinearity did not have a major influence on the final model.
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studies in mice, which have shown increased hepcidin production after bone marrow suppres­
sion by irradiation or cytotoxic chemotherapy [10, 11].
IL-6 has previously been demonstrated to stimulate expression of hepcidin [7-9]. IL-6 con­
centrations correlated significantly with hepcidin concentrations in the present study, and the 
kinetics of hepcidin and inflammatory cytokine concentrations showed a strong resemblance. 
However, IL-6 was eliminated as an independent predictor in the multivariate linear regression 
model. The fact that inflammation was also represented by other variables in the multivariate 
model - as reflected by significant Spearman's correlations between IL-6 and these other vari­
ables - may explain the elimination of IL-6.
There was also a trend for a positive association between parasite densities and hepcidin 
concentrations. Higher parasite densities were associated with higher IL-6 concentrations, al­
though a direct effect on hepatic and/or macrophage hepcidin production by malaria parasites 
or their products (e.g., hemozoin or glycosylphosphatidylinositol) cannot be excluded.
Finally, our findings of a positive correlation between Hb and hepcidin on one hand and a 
negative correlation between the erythropoietic marker sTfR and hepcidin on the other hand 
may seem contradictory, because bone marrow activity might be expected to determine Hb 
levels. However, in patients with acute malaria, Hb levels may be more influenced by the extent 
of hemolysis and the duration of malaria than by the degree of bone marrow suppression, es­
pecially given the long half-life of erythrocytes. Instead, the positive association between Hb 
and hepcidin levels in our patients with anemia probably resulted from the suppressive effects 
of anemia and secondary hypoxia on hepcidin expression, as a result of the cellular excretion of 
soluble hemojuvelin that acts as a negative regulator of hepcidin [12, 43]. Figure 3 summarizes 
the putative regulatory pathways of hepcidin production in children with febrile P. falciparum 
malaria at the time of admission to the hospital. At week 4, after receipt of successful antimalar- 
ial treatment, hepcidin concentrations appeared to be most strongly associated with iron status 
(as reflected by serum concentrations of ferritin).
To our knowledge, only one other study has measured hepcidin concentrations in patients 
with malaria. Howard et al. [45] reported semiquantitative urinary concentrations of hepcidin 
noted in a cross-sectional study of patients presenting for evaluation of possible P. falciparum 
malaria in Ghana. They found that patients with malaria had higher hepcidin concentrations 
than did healthy volunteers in other studies. However, neither iron status indicators, inflamma­
tory markers, nor longitudinal data were reported in the study from Ghana. In addition, reports 
of hepcidin concentrations in individuals with other infectious diseases are sparse. We previous­
ly reported urinary concentrations of hepcidin in healthy volunteers injected with lipopolysac- 
charide [9], and the urinary concentrations of hepcidin found in the current study were several 
fold higher.
The present study was performed in a lowland region of Tanzania characterized by intense P 
falciparum transmission and a high prevalence of asymptomatic parasite carriage. To minimize 
the chance of enrolling children with causes of fever other than P. falciparum malaria, we used
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Figure 3. Putative regulation of hepcidin production in febrile P. falciparum malaria.
Figure 3. Putative regulation of hepcidin production in patients with febrile Plasmodium falciparum 
malaria. The combined effects of several interlinked regulatory pathways may determine hepcidin 
concentrations in patients with febrile P. falciparum malaria. In the present study, serum concentra­
tions of soluble transferrin receptor (as a putative marker for erythropoietic activity), the hemoglobin 
concentration, and parasite density were associated with urinary concentrations of hepcidin in a mul­
tivariate linear regression model. Proinflammatory cytokines have also previously been reported to 
directly up-regulate hepcidin production [7, 8], and significant associations between concentrations 
of proinflammatory cytokines and urinary concentrations of hepcidin were found in univariate analy­
ses - but not in multivariate analyses - in the present study. Cytokines and parasite products might 
also indirectly up-regulate hepcidin production through a suppressive effect on erythropoiesis [42]. 
Reduced erythropoietic activity may increase hepcidin production by a mechanism that is still not 
fully elucidated. So far, hypoxia inducible factor-1a [12], soluble hemojuvelin [43], and growth differ­
entiation factor 15 [44] have been reported to be potentially involved in pathways connecting bone 
marrow activity to hepcidin production. In addition, the contribution of macrophage hepcidin pro­
duction to circulating hepcidin concentrations also requires additional study. High hepcidin concen­
trations in febrile malaria reduce extracellular iron, thereby limiting iron availability for erythropoiesis. 
However, by withholding parasites from the iron supply of the host, it might also impair multiplication 
of malaria parasites. Finally, iron trapping inside macrophages might increase susceptibility to intra­
cellular bacterial infections.
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stringent case definitions of febrile malaria with a high cutoff for parasite density that has been 
shown to be appropriate for this region [46]; we also performed blood culture and HIV testing 
for all children. The influence of diurnal variation in hepcidin concentrations on our results was 
probably limited, because reported diurnal fluctuations in urinary concentrations of hepcidin 
[15] were negligible, compared with the very high urinary concentrations of hepcidin found in 
our patients.
In summary, we showed that hepcidin concentrations were strongly elevated in febrile P 
falciparum malaria, probably as a result of suppressed erythropoietic activity, inflammation, 
and, perhaps, also by a direct stimulatory effect of malaria parasites and their products. Malaria- 
induced hepcidin expression provides a mechanistic explanation for the observed maldistribu­
tion of iron in patients with malaria, and we hypothesize that it may contribute to the high inci­
dence of infections with intracellular bacteria in regions where malaria is endemic. Our results 
might provide leads for the introduction of novel diagnostic biomarkers of iron homeostasis 
and the design of novel therapeutic interventions.
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SUMMARY
The correct selection of individuals who will benefit from iron supplements in malaria-endemic 
regions requires improved insight in the effects of malaria on host iron homeostasis and in­
novative biomarkers. We assessed sequential changes in serum hepcidin and in traditional bio­
chemical iron status indicators during an experimental Plasmodium falciparum malaria infection 
with five adult volunteers. The haemoglobin content of reticulocytes (Ret-He) and of mature red 
blood cells (RBC-He) represented iron incorporation into haemoglobin. Low-density parasitemia 
and its treatment induced a mild increase in interleukin (IL)-6 and serum hepcidin concentra­
tions. Despite this only mild increase, a marked hypoferraemia with a strong increase in serum 
ferritin concentrations developed, which was associated with a sharp fall in Ret-He, while RBC- 
He remained unchanged. The ratio of soluble transferrin receptor (sTfR) to log ferritin concentra­
tions decreased to an average nadir of 63% of the baseline value. We concluded that even mild 
increases in serum hepcidin and IL-6 concentrations result in a disturbed host iron homeostasis. 
Serum hepcidin, Ret-He and Delta-He (Ret-He minus RBC-He) are promising biomarkers to select 
those individuals who will benefit from iron supplements in malaria endemic regions, while the 
sTfR/log ferritin ratio should be used with caution to assess iron status during malaria.
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INTRODUCTION
Iron deficiency is common in children in malaria-endemic regions and associated with signifi­
cant adverse effects on child health. Iron supplementation to iron deficient children is therefore 
considered an important public health intervention [1]. The immediate goal of iron supple­
mentation is to increase iron incorporation in haem. In inflammatory states, however, distinct 
changes in iron homeostasis occur, which are mediated by the iron-regulatory hormone hep- 
cidin. Inflammatory cytokines increase the expression of hepcidin [2, 3], leading to a decreased 
absorption of iron from the intestine and a diversion of iron from the circulation into storage 
sites, such as the reticuloendothelial system (RES) and the liver [4].
In malaria-endemic regions, complex interactions exist between the host's iron status, the 
malaria parasite and the immune system [5] - as recently highlighted by a large iron supplemen­
tation trial in Pemba, Tanzania, in which universal iron supplementation resulted in increased 
morbidity and mortality in iron-replete children [6]. In response to this trial, a WHO Expert Con­
sultation advised against universal iron supplementation in malaria endemic regions without 
prior screening of individuals for iron deficiency [7]. Such a strategy, however, requires (i) the 
availability of reliable and field-friendly iron status indicators, and (ii) improved insight on the 
effects of malaria parasitemia on host iron homeostasis. Traditional biochemical iron indicators 
(e.g. serum iron, ferritin, transferrin saturation) are only of limited use because of the distorting 
effects of inflammation on their interpretation. In recent years, the use of the ratio of soluble 
transferrin receptor to log ferritin concentrations (sTfR/log ferritin index) has been advocated 
by some investigators to assess iron status [8]. However, this index may also have its limitations, 
since the parameters of this index are influenced by erythropoietic activity and inflammation, 
respectively [9, 10].
The past decade has seen considerable progress in our understanding of the regulation of 
iron homeostasis and the development of new biomarkers, e.g. the discovery of hepcidin [11]. 
In recent years, our group has developed sensitive and accurate serum and urine assays for the 
determination of hepcidin [12]. In addition, innovative reticulocyte and erythrocyte cellular in­
dices have become available on automated haematology analyzers, which provide a direct as­
sessment of iron availability for erythropoietic progenitor cells. The reticulocyte haemoglobin 
content (provided as Ret-He on Sysmex analyzers and as CHr on ADVIA analyzers from Siemens) 
is a measure for iron incorporation in haem over the previous 2-4 days [13, 14]. In contrast, given 
the life span of erythrocytes of 100-120 days, the haemoglobin content of mature red blood cells 
(RBC-He on Sysmex analyzers and CH on Bayer analyzers) provides information on iron avail­
ability over a longer time [14]. The Delta- He (RET- He minus RBC- He) provides the difference in 
hemogobinization between reticulocytes and erythrocytes.
Recently, we have shown that urinary hepcidin concentrations are strongly elevated in 
anaemic Tanzanian children with febrile P. falciparum malaria, suggesting that malaria-associ­
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ated inflammation may negatively affect the erythropoietic response to iron supplements [15]. 
However, low density parasitemia, often associated with no or only mild inflammation, is also 
highly prevalent in many malaria-endemic regions. To date, it is unknown to which extent the in­
corporation of iron in haem and the expression of hepcidin are affected under these conditions.
In addition, observational studies with naturally infected malaria patients may suffer from 
various constraints, e.g. absence of baseline data, influence of nutritional status, haemoglobin- 
opathies and (chronic) co-infections. These constraints do not apply to the experimental human 
malaria model in which healthy volunteers are infected with P. falciparum and are intensively 
followed in time [16]. Therefore, using this experimental model, we studied how changes in 
interleukin (IL)-6 and hepcidin concentrations relate to changes in iron homeostasis, including 
iron incorporation into haemoglobin. In addition, we explored the effects of early P. falciparum 
malaria on the sTfR/log ferritin index.
VOLUNTEERS AND METHODS
Study volunteers, experimental malaria infection and blood samples
Experimental human malaria infections are invaluable for testing the efficacy of candidate ma­
laria vaccines. In addition, they are a well established model for studying pathogenic mecha­
nisms in early malaria. By use of a stringent protocol, experimental human malarial infections 
have been proven to be reproducible and generally well tolerated [16, 17]. The present study 
contains data from eleven healthy and malaria naive volunteers, all belonging to the control 
groups of two intervention studies that were conducted in 2007 and 2008, respectively. The 
primary objectives of these studies were the assessment of the protective efficacy of repetitive 
exposure to live malaria sporozoites under chloroquine prophylaxis and the assessment of the 
efficacy of a candidate malaria vaccine, respectively. The current study on iron homeostasis was 
among the predefined exploratory objectives. Only controls from these interventions were in­
cluded to avoid a confounding effect of the intervention.
The volunteers were infected with P. falciparum parasites as previously described [16]. Brief­
ly, volunteers were infected by 5 P. falciparum infected mosquitoes and followed by thick blood 
smears and assessment of malaria symptoms three times daily until start of antimalarial treat­
ment. Antimalarial treatment was started upon microscopic detection of parasites in a thick 
blood smear and consisted of a standard, 6 dose curative regimen of artemether/lumefantrine 
80/480 mg (Riamet®), given at 0, 8, 24, 36, 48 and 60 hours. To assess a potential independent 
effect of artemether/lumefantrine on iron metabolism, serum_hepcidin and iron parameters 
were also measured at the start of artemether/lumefantrine treatment and two days later in five 
volunteers, who had not developed parasitemia during the first intervention study. According 
to the study protocol, antimalarial treatment was started at day 21 post-parasite inoculation in 
these volunteers with a persistent negative malaria thick blood.
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Serial blood samples were collected in the morning between 08:00 and 10:00 AM in Vacu- 
tainer® EDTA-IKj and SST plain tubes (Becton Dickinson, Rutherford, NJ, USA). Serum and plasma 
were stored at -80°C awaiting laboratory analyses. Hemocytometry was performed at parasite 
inoculation (baseline), daily from day 5 after parasite inoculation until 3 days after start of an­
timalarial treatment, at day 7 after start of antimalarial treatment and at 3 weeks after parasite 
inoculation. Concentrations of serum hepcidin and of iron status indicators were determined in 
serum collected at baseline, at the start of antimalarial treatment, 2 days before and after start 
of antimalarial treatment, and at week 3 and 5 following parasite inoculation. The Institutional 
Review Board of the Radboud University Nijmegen Medical Centre and the Dutch Central Com­
mittee on Research involving Human Subjects) approved the study protocols (CMO 2006/207 
and NL14715.000.06, respectively), including this supplementary iron study. All volunteers gave 
written informed consent.
Laboratory analyses
Hemocytometry was performed on the automated haematology analyzer Sysmex XE-5000 (Sys­
mex Corporation, Kobe, Japan) within four hours after blood collection. Reticulocyte measure­
ments are performed on the reticulocyte channel after addition of polymethine dye specific 
for RNA within reticulocytes. The RET-Y and RBC-Y are values for the mean forward light scatter 
histogram of the reticulocyte and mature erythrocyte population, and these can be mathemati­
cally transformed into Ret-He and RBC-He, respectively, which are both expressed in femtomol
[18]. The Delta-He is defined as Ret-He minus RBC-He. The %Hypo-He indicates the percentage of 
erythrocytes with a haemoglobin content lower than two times the standard deviation of mean 
from the reference interval, while the %MicroR is the percentage erythrocytes smaller than two 
times the standard deviation of mean from the reference interval.
Serum hepcidin concentrations were determined by SELDI-TOF mass spectrometry, using 
an assay that was developed by our group as recently described [12]. In brief, serum hepcidin 
concentrations were measured by use of weak cation exchange chromatography prior to mass 
spectrometry, and by use of normal phase chips (NP20; Bio-Rad Laboratories). The hepcidin-25 
analogue hepcidin-24 (Peptide International Inc., Louisville, KY, USA) was used as an internal 
standard. Serum total iron concentration and serum total iron-binding capacity (TIBC) were de­
termined by a colorimetric method using an Abbott Aeroset analyser (Abbott Laboratories, Il­
linois, IL, USA). Serum transferrin saturation was calculated as a percentage of serum total iron 
divided by TIBC. Serum ferritin was measured by an immunometric assay with the use of an Im- 
mulite 2500 (Diagnostic Products Corporation, Los Angeles, CA). Serum concentration of soluble 
transferrin receptor (sTfR) was measured immunonephelometrically on a BN II System (Dade 
Behring Marburg GmbH, Marburg, Germany). Plasma concentrations of interleukin (IL)-6 were 
measured in accordance with the manufacturer's instructions with a commercial sandwich-type 
enzyme-linked immunosorbent assay (PeliKine; Sanquin, Amsterdam, The Netherlands). P. falci­
parum parasite densities were determined by QT-PCR, as described previously [19].
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Statistical analysis
Data are presented as mean with standard deviation unless otherwise stated. Changes from 
baseline in haemoglobin concentration, reticulocyte counts and cellular indices were analyzed 
with the use of a linear mixed model for repeated measures. No assumption about the shape 
of the time trend was made i.e. time point was included as a categorical variable. Correlation 
between repeated measures within subjects was assumed to only depend on the time between 
the repeated measures (Toeplitz correlation structure). Holm's method was used to adjustment 
for multiple comparisons at several time points versus baseline. All analyses were performed 
with SPSS version 16.0.
RESULTS
Characteristics of volunteers and parasitological course
The mean age of the volunteers was 23 years (range 19 to 30 years) and 9 out of 11 were female; 
baseline results of a full blood count, renal and liver function, serum electrolytes and serum 
glucose concentration were unremarkable in all volunteers. All volunteers developed parasit­
emia following exposure to P.falciparum infected mosquitoes. Antimalarial treatment with a 
standard course of artemether/lumefantrine was started after a median time of 10.3 days (range 
7.0 to 12.3) - immediately upon microscopic detection of P. falciparum parasites in a thick blood 
smear. The median parasite density, determined by QT-PCR, at the start of treatment was 16 937 
parasites/ml (range 4 491 - 108 871 parasites/ml of blood). Three days after the initiation of 
treatment, all volunteers had cleared parasitemia (as determined by microscopy). There were no 
substantial differences between the control groups of the two intervention studies in terms of 
baseline characteristics and the clinical and parasitological course (data not shown).
Evolution of serum hepcidin and biochemical iron indicator concentrations
Serum for measurement of hepcidin and iron status indicators was available in the 5 volun­
teers belonging to the first intervention study (4 females, 1 male). The course of serum hepcidin 
and iron status indicators during the malarial infection is shown in Fig 1. All 4 females had low 
baseline hepcidin and ferritin (<45 |ag/l) concentrations, suggesting low body iron stores. Para­
sitemia and release of parasite products in the bloodstream upon start of artemether/lumefan­
trine treatment induced a rise in serum hepcidin concentrations in 4 of 5 volunteers, and this 
was associated with a decline in serum iron concentrations and transferrin saturation, and a rise 
in serum ferritin concentrations. These changes in concentrations of serum hepcidin paralleled 
the changes in IL-6 concentrations (Fig. 2A). In one female volunteer with low baseline body iron 
stores (serum ferritin 17 |jg/L) and with only a small increase in circulating IL-6 concentrations, 
serum hepcidin concentrations remained below the assays' lowest detection limits throughout 
the study. Finally, we determined the effects of malaria on the sTfR/log ferritin index. As shown
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Figure 1. Time course of (A) serum hepcidin, (B) serum iron, (C) transferrin saturation and (D) serum 
ferritin concentrations in five healthy volunteers, who were experimentally infected with P. falciparum. 
Depicted are data before parasite inoculation (baseline), at the start of antimalarial treatment (T), 
2 d before and after treatment start (T-2 and T+2, respectively) and at week 3 and 5 post-parasite 
inoculation. The median time of start of antimalarial treatment was at day 1G-3 post-parasite inocula­
tion. Mean (SD) and reference ranges of morning concentrations of serum hepcidin in 24 healthy 
Dutch male and female volunteers: 2-8 (1-7) nmol/l and G5-82 nmol/l, respectively. Reference values 
for concentrations of serum iron: 1G-25 pmol/l; serum transferrin saturation: 3G-6G%; serum ferritin: 
12-25G ng/l.
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Figure 2. Time course of (A) plasma interleukin (IL)-6 concentrations and of (B) ratio of serum soluble 
transferrin receptor (sTfR) with the log of serum ferritin in five healthy volunteers, who were experi­
mentally infected with P. falciparum. Depicted are data before parasite inoculation (baseline); from 
2 d before the start of artemether/lumefantrine treatment (T-2) until 3 d after start of this treatment 
(T+3); at 7 d after start of this treatment (T+7); and at week 3 and 5 post-parasite inoculation. The me­
dian time of start of antimalarial treatment was at day 1G-3 post-parasite inoculation.
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Table 1. Serum concentrations of hepcidin, iron parameters and C-reactive protein in five volun­
teers without parasitemia at the start and at day 2 of artemether/lumefantrine treatment.
Serum concentration of Before treatment mean (range)
Day 2 of treatment 
mean (range)
Hepcidin (nM) G.9 (<G.5 - 2.7) G.7 (<G.5 - 1.3)
Iron (pmol/L) 1G (7 - 17) 1G (6 - 14)
Transferrin saturation (%) 16 (9 - 27) 16 (8 - 25)
Ferritin (pg/L) 26 (6-83) 5G (9-15G)
C-reactive protein (mg/L) <5 <5
in Fig 2B, the index decreased substantially in 4 of 5 volunteers reaching an average nadir of 63% 
(range 49% to 91%) of baseline.
In order to assess the independent effect of artemether/lumefantrine on iron homeostasis, 
we measured serum hepcidin, iron parameters and C-reactive protein at the start of a standard 
treatment with artemether/lumefantrine and two days thereafter in 5 volunteers without ma­
laria parasitemia. Except for a small increase in serum ferritin concentrations, no change in con­
centrations of serum hepcidin or of the other iron parameters was found (table 1).
Evolution of reticulocyte and erythrocyte cellular indices
The evolution of haemoglobin concentrations and reticulocyte counts over the course of the 
malaria infection with corresponding reticulocyte and erythrocyte indices are shown in Fig 3. 
Parasitemia and its treatment resulted in a transient drop in circulating reticulocytes to an aver­
age nadir of 73% of baseline on the third day after start of treatment, followed by a compen­
satory reticulocytosis. Haemoglobin concentrations hardly changed during the infection. The 
mean Delta-He (Ret-He minus RBC-He) at baseline was 0.184 (0.041) fmol. While RBC-He remained 
stable during the infection, a sharp decline in Ret-He content was observed. At day 2 and 3 post 
treatment, levels of the Ret-He content were even lower than the corresponding RBC-He content 
in 10 of 11 volunteers, resulting in a negative mean Delta-He value at day 3 post treatment of 
-0.134 (0.114) fmol. In contrast, MCV values declined only marginally, while MCH values did not 
change substantially. This was in line with the slight increase in %MicroR (the percentage of 
'small' erythrocytes) and the unchanged %Hypo-He (the percentage of erythrocytes with 'low' 
haemoglobin content) observed during the infection.
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d d 
Figure 3. Time course of (A) haemoglobin concentration and reticulocyte counts, (B) reticulocyte (Ret- 
He) and red blood cell hemoglobin (RBC-He) content, (C) mean cell volume (MCV) and mean cell he­
moglobin (MCH) and (D) percentage microcytic (MicroR) and hypochromic red blood cells (Hypo-He) 
during an experimental P. falciparum infection. Data presented are mean ± SD of 11 volunteers (on 
day 7 post-treatment initiation only data from seven volunteers were available). Depicted are data 
before parasite inoculation (baseline), the period between 3 d (T-3) before start of antimalarial treat­
ment (T) until 3 d thereafter (T+3) and at week 3 post-parasite inoculation. The median time of start of 
antimalaria treatment was at day 10-2 post-parasite inoculation. *P < 0-05; **P < 0-005 compared with 
corresponding baseline value, determined by linear mixed model for repeated measures.
DISCUSSION
This study suggests that pronounced disturbances in host iron homeostasis can already be 
observed in the earliest phases of malaria, despite an only modest increase in serum hepci­
din and IL-6 concentrations. The disturbances in iron homeostasis involved the development 
of hypoferremia, a strong rise in serum ferritin concentrations and impaired iron incorporation 
in haemoglobin. The latter was suggested by a sharp decline in Ret-He, a measure for iron in­
corporation in haem over the past 2-4 days, and by a negative Delta- He, which indicates poorer 
haemogobinization of reticulocytes than of mature erythrocytes.
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We have previously reported that urine hepcidin concentrations were strongly increased in 
anaemic Tanzanian children with febrile malaria and high parasite densities [15] and in healthy 
volunteers during human experimental endotoxemia [20]. The inflammatory cytokine IL-6 is a 
well known inducer of hepcidin expression [3] and IL-6 concentrations found in these previous 
studies were high with average values of 1100 and 7500 pg/ml, respectively. In the volunteers 
with low-density parasitemia in our present study, however, IL-6 concentrations were only mild­
ly elevated (range 3 to 72 pg/ml). This suggests that the bioavailability of iron may also be im­
paired in patients with asymptomatic P. falciparum or P. vivax parasitemia, conditions character­
ized by a protracted course with limited parasite densities and a limited inflammatory response
[21]. Moreover, the pronounced decline in RET-He also suggests that the erythropoietic response 
to iron supplements may substantially be decreased during episodes of even only mild inflam­
mation and we therefore suggest to withhold iron supplements from malaria patients until after 
completion of antimalarial treatment.
Our model of experimental malaria infection enabled us to longitudinally assess the effect of 
an acute malaria infection on concentrations of iron status indicators. The limitations of serum 
iron, transferrin saturation and serum ferritin in the estimation of iron status in inflammatory 
conditions are well known [22]. In recent years, the sTfR/log ferritin index has been advocated 
by some authors as a useful marker for diagnosis of iron deficiency in the presence of inflam­
mation [8], because sTfR is thought to be less affected by inflammation [10, 23]. So far, there are 
only sparse data on the diagnostic performance of this index in malaria endemic regions. In our 
healthy volunteers, of who 4 out of 11 had low body iron stores at baseline, the sTfR/log ferritin 
index decreased substantially during parasitemia, which was largely due to an increase in serum 
ferritin. This illustrates the limitations of the index in malaria patients: serum ferritin concentra­
tions increase under influence of erythrophagocytosis of infected and non-infected red blood 
cells, iron retention in the RES and increased cytokine-induced synthesis, while erythropoietic 
activity and iron availability influence sTfR concentrations [10]. Both suppressed erythropoietic 
activity and erythroid hyperplasia with dyserythropoiesis have been reported in malaria [24] 
and this variation in erythropoietic activity can explain the seemingly inconsistent reports of 
both increased [25, 26] and decreased [27, 28] sTfR concentrations in malaria patients. Until 
more data are available, we suggest that the sTfR/log ferritin index should be used with caution 
for the diagnosis of iron deficiency in malaria endemic regions [29].
Instead, reticulocyte and erythrocyte cellular indices allow the direct assessment of iron 
availability for haemoglobin and these indices may provide an easy tool to select subjects who 
will benefit from iron supplements. Previous studies in children and adults have shown that 
the reticulocyte haemoglobin content outperformed ferritin, MCV and zinc protoporphyrin 
in detecting iron deficiency [30] and it may provide an early measure of the response to iron 
therapy [31]. The combined measurement of Ret-He with RBC-He may yield additional valuable 
information. Under normal conditions, levels of the Ret-He content are higher than levels of the 
RBC-He content owing to the progressive decline in erythrocyte cell volume and haemoglobin
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as erythrocytes mature. Acute inflammation rapidly induces functional iron deficiency with a 
drop in Ret-He and Delta-He, while RBC-He initially remains unchanged due to the long half life 
of erythrocytes. In contrast, absolute iron deficiency results in a more gradual decrease in both 
Ret-H and RBC-H content, owing to the chronic course of this condition, and an often normale e
Delta-He. In chronic inflammatory states (anaemia of chronic inflammation), levels of both the 
Ret-He and RBC-He content may also decrease, although levels within the reference limits are 
also observed in this condition [32, 33].
Although not yet widely available, measurement of these hematologic indices in addition to 
the standard haemoglobin concentration may prove useful as an inexpensive and rapid screen­
ing test to select those who may benefit from iron therapy in malaria endemic regions (Table 
2). However, adequate reference intervals should first be identified for people living in malaria- 
endemic regions. In addition, differentiating between iron deficiency and anaemia of inflam­
mation with or without coexisting iron deficiency may remain challenging, because all these 
conditions can be associated with reduced levels of the Ret-H and RBC-H content. Several strat-e e
egies can be adopted in this case. First, the Ret-He response to a short trial of oral iron can be de­
termined. In iron deficiency anaemia, the Ret-He is expected to rise substantially within several 
days [34], while no or only a limited effect is expected in inflammatory states. Second, serum 
hepcidin would theoretically be a valuable biomarker for assessment of the expected efficacy 
of iron supplementation therapy, but current assays are still not widely available. Finally, addi­
tional biochemical parameters, such as serum ferritin or an inflammatory marker (e.g. C-reactive 
protein) can be measured. A low Ret-He level in combination with increased concentrations of 
serum ferritin and C-reactive protein suggests functional iron deficiency. However, the obvious 
advantage of the first strategy over the last two is that Ret-He can be measured from the same 
blood tube as the haemoglobin concentration, and that it does not involve time consuming and 
expensive additional laboratory tests.
The small sample size is a limitation of our study and this may complicate extrapolation of 
our findings. However, the model of experimental human malaria infections with young, healthy 
adults has a good reproducibility and small sample sizes are often sufficient for conclusions to 
be drawn. The changes in cellular indices and in iron parameters occurred mainly after start of 
antimalarial treatment. The fact that parasite densities are very low at the start of treatment 
explains why these phenomena may be absent before the start of antimalarial treatment. Upon 
initiation of antimalarials, malaria products are released rapidly into the bloodstream and this 
process accounts for the development of fever and other characteristic symptoms and signs 
of malaria. In one female volunteer, a decrease in serum iron, transferrin saturation and serum 
ferritin was already observed before hepcidin or IL-6 had increased, which was probably related 
to a progressive decline in iron stores by the daily blood drawing. However, the RET-He only 
started to decrease in this volunteer until after antimalarial treatment was initiated, suggesting 
that functionally important iron deficiency only developed after the rise in serum hepcidin con-
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centrations. Finally, in volunteers without parasitemia, artemether/lumefantrine did not have a 
substantial independent effect on iron homeostasis.
In conclusion, we have shown that marked disturbances in iron handling and iron incorpo­
ration in heme developed in volunteers during experimental P. falciparum malaria, while serum 
hepcidin and IL-6 concentrations were only slightly increased. Compared with conventional bio­
chemical iron status indicators, serum hepcidin and the new hematologic indices Ret-He, RBC-He 
and Delta-He may be valuable biomarkers to select those who will benefit from iron supple­
ments.
Table 2. Putative diagnostic utility of Ret-He, RBC-He and serum hepcidin in selection of individuals 
who may benefit from iron supplementation therapy.
Ret-He RBC-He Hepcidin Interpretation Iron therapy
N N N Iron sufficient erythropoiesis No
i i / i i i / i i Absolute iron deficiency* Yes
1 N !
Acute functional iron deficiency (e.g. 
acute inflammation)
No
i i / i i i / i !
Absolute iron deficiency with 
coexisting inflammation*
No
N/i N/i !
Chronic functional iron deficiency* 
(e.g. anaemia of chronic disease)
No
i i i Thalassemiat No
N i i / i i Recent start iron therapy in IDA NA
Based in part on previous studies in patients with absolute iron deficiency [31, 32], anaemia of chronic 
disease [32, 33] and thalassemia [32, 35].
* Absolute iron deficiency may be differentiated from absolute iron deficiency with concurrent inflam­
mation or from chronic functional iron deficiency by: (a) Ret-He response to a trial of supplemental 
iron, (b) serum hepcidin concentration, or (c) simultaneous measurement of Ret-He/ RBC-He with a 
biochemical marker for iron status (e.g. serum ferritin) and/or inflammatory marker (e.g. C-reactive 
protein)
t  Additional cellular indices can help to distinguish thalassaemia from iron deficiency, e.g. the ratio of 
the proportion microcytic to hypochromic red blood cells [36]
Ret-He, reticulocyte hemoglobin content; RBC-He, red blood cell hemoglobin content; N, normal; IDA, 
iron deficieny anaemia; NA, not applicable.
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Comment to: Severe anemia in Malawian children.
De Mast Q, Swinkels DW, van der Ven AJ.
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The conclusion by Calis et al.[1] that iron deficiency was not a prominent cause of severe ane­
mia in Malawian children would have been more convincing if the results of bone marrow iron 
staining in the case patients had been reported. Analysis of the amount of stainable iron in bone 
marrow aspirates is considered to be the most valuable tool for assessing whether sufficient 
iron is available for erythropoiesis. Furthermore, the accuracy of the ratio of soluble transfer­
ring receptor (TfR) to log ferritin for diagnosing iron deficiency may have been hampered by 
the high prevalence of viral, bacterial, and parasitic infections in the case patients. TfR levels 
are predominantly determined by erythropoietic activity [2] and suppressed erythropoiesis is a 
common observation in infections, such as malaria and human immunodeficiency virus infec­
tion [3]. Moreover, inflammation increases ferritin levels independently of body iron stores [4].
(1) Calis JC, Phiri KS, Faragher EB, et al. Severe anemia in Malawian children. N Engl J Med 2008; 
358:888-99.
(2) Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin 
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(3) Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 
1790:682-93
(4) Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99:3505-16.
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SUMMARY
Background: Asymptomatic Plasmodium spp. infections and anemia are highly prevalent condi­
tions in tropical regions. We studied whether asymptomatic parasitemia induces hepcidin- and/ 
or cytokine-mediated iron maldistribution and anemia.
Design and Methods: A group of 1197 Indonesian schoolchildren, aged 5-15 years, was screened 
by microscopy for the presence of parasitemia. Concentrations of hemoglobin, serum hepcidin 
and parameters of iron status and inflammation were determined at baseline and 4 weeks after 
antimalarial treatment.
Results: Asymptomatic P. falciparum and P. vivax parasitemia were detected in 73 (6.1%) and 18 
(1.5%) children, respectively, of whom 84% and 83% had a C-reactive protein concentration be­
low 5 mg/L. Children with P. falciparum or P. vivax parasitemia had significantly lower hemoglo­
bin concentrations than 17 aparasitemic controls (12.6 and 12.2 g/dL versus 14.4 g/dL; P<0.01), 
together with significantly higher serum hepcidin concentrations (5.2 and 5.6 nM versus 3.1 nM; 
P<0.05). The latter was associated with signs of iron maldistribution with higher ferritin concen­
trations and lower values of serum iron concentration, transferrin saturation and erythrocyte 
mean cell volume. Concentrations of growth differentiation factor 15 were similar across groups. 
Antimalarial treatment partly reversed these abnormalities and led to a significant increase in 
hemoglobin concentration.
Conclusions: Asymptomatic malarial parasitemia is associated with increased hepcidin concen­
trations and anemia, in the absence of a manifest acute phase response. Prolonged iron mal­
distribution may be an underestimated cause of anemia. Screening for parasitemia should be 
performed before starting iron supplementation, as iron therapy may be less effective and even 
hazardous in these circumstances.
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INTRODUCTION
Infectious diseases induce alterations in the distribution of iron in the human body. Recent find­
ings have shown that many of these alterations are attributable to the actions of the hormone 
hepcidin [1]. Hepcidin inhibits the absorption of iron through enterocytes and impairs iron re­
lease by macrophages through degradation of ferroportin, the only iron exporter. Pro-inflam­
matory cytokines stimulate hepcidin expression, which leads to hypoferremia and increased 
iron storage in the reticuloendothelial system, both typical features of the anemia of chronic 
disease [2].
Recent advances in the understanding of iron homeostasis and the development of reliable 
hepcidin assays offer new opportunities to improve iron supplementation practices in regions 
in which malaria is endemic. Iron deficiency is a common condition in malaria-endemic regions 
and its complications are not restricted to anemia, but include impaired growth, cognitive de­
velopment and physical capacity [3]. Iron supplementation and iron fortification of foods have, 
therefore, been considered important public health interventions [4], but there is currently 
growing concern about the safety of iron supplementation in people exposed to malaria, as iron 
may increase malaria-associated morbidity and mortality [5, 6].
So far, studies on iron homeostasis and malaria have largely been restricted to symptom­
atic P. falciparum malaria. However, asymptomatic P. falciparum parasitemia, i.e. the presence of 
parasitemia in the absence of fever or malaria-related symptoms, is also an extremely common 
and chronic condition among (semi-)immune persons in malaria areas, with prevalence rates 
exceeding 50% in some areas [7, 8]. Moreover, up to half of all malaria cases out-side Africa 
are caused by P. vivax, which is characterized by a more indolent and chronic course than P 
falciparum, although it may also ultimately result in severe anemia [9, 10]. Previously, our group 
studied hepcidin expression in anemic Tanzanian children with febrile P. falciparum malaria with 
high parasite densities and in malaria-naïve Dutch volunteers who were experimentally infected 
with P. falciparum [11, 12]. Hepcidin concentrations were increased in both groups and associ­
ated with profound disturbances in iron homeostasis, suggesting that iron supplements should 
be withheld during symptomatic P. falciparum malaria. To our knowledge, no data are yet avail­
able on the effects of asymptomatic P. falciparum or P. vivax parasitemia on hepcidin expres­
sion. Due to the chronic and relapsing nature of both conditions, disturbances in the uptake, 
recycling and utilization of iron could play an important and so far under-recognized role in the 
pathogenesis of anemia in tropical areas and reduce the hemoglobin response to iron supple­
ments and iron fortified foods.
The aim of the present study was, therefore, to determine whether asymptomatic parasit­
emia induces disturbances in iron homeostasis. Concentrations of serum hepcidin and a range 
of hematologic, inflammatory and serum iron parameters were studied in schoolchildren with 
asymptomatic P. falciparum or P. vivax parasitemia on the Indonesian island Sumba, before and
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after antimalarial treatment. Serum concentrations of soluble transferrin receptor (sTfR) were 
used as a parameter of erythropoietic activity and functional iron status. The levels of a recently 
discovered negative regulator of hepcidin expression, growth differentiation factor 15 (GDF15), 
a molecule expressed by erythroid precursor cells, were also measured [13]. Finally, we deter­
mined the influence of the inherited red cell disorder Southeast Asian ovalocytosis on iron ho­
meostasis in our study population. Southeast Asian ovalocytosis is highly prevalent on Sumba 
(estimated prevalence 10% [14]) and may affect iron homeostasis, as reported for other red cell 
disorders [15].
DESIGN AND METHODS
Study site
This study was conducted in the Kodi region of West Sumba District, East Nusa Tenggara Prov­
ince, Indonesia, an area with perennial P. falciparum and P. vivax transmission, stable enough to 
induce clinical immunity [16].
Study design
This study used archived material collected during in vivo drug sensitivity tests in the Southwest 
Sumba District, East Nusa Tenggara Province, Indonesia. Overall, 1197 children aged 5 through 
15 years from seven elementary schools were screened for the presence of parasitemia by mi­
croscopic examination of thick and thin malaria smears. All malaria smears were read the same 
day. The study team returned the following morning and those children with asymptomatic 
parasitemia were enrolled after written informed consent from parents or guardians and con­
sent from the child. Asymptomatic parasitemia was defined as asexual P. falciparum or P. vivax 
parasitemia in the absence of fever (temperature <37.9°C) and of clinical signs or symptoms 
suggestive of malaria or another infectious disease. Seventeen healthy children with negative 
malaria smears were enrolled as a control group. A history was taken and a short physical ex­
amination performed according to a predefined checklist before 3 mL of venous blood were 
drawn into a serum and EDTA tube. Smear-positive children were treated with a 3-day regimen 
of artesunate-amodiaquine (P. falciparum) or a combination regimen of 3 and 7 days of chloro- 
quine and primaquine (P. vivax), according to guidelines from the Indonesian Ministry of Health. 
Finally, seven subjects with clinical P. falciparum (n=4) or P. vivax(n=3) malaria who presented to 
the local hospital were enrolled as a positive control group.
To evaluate the effect of treatment of asymptomatic parasitemia, a follow-up visit was con­
ducted 4 weeks after antimalarial treatment. The same study procedures were performed as 
during enrollment. The study was carried out with ethical approval from the Eijkman Institute 
for Molecular Biology Research Ethics Committees (Jakarta, Indonesia).
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Laboratory methods
Thick and thin blood smears were stained with Giemsa and examined by a certified microscopist 
using 1000x oil immersion light microscopy. Parasite density was quantified against 200 white 
blood cells and converted to parasites per microliter of blood using the measured leukocyte 
count. The blood smear was also used to assess the presence of ovalocytes, which strongly sug­
gests the presence of Southeast Asian ovalocytosis, a disease that results from a 27-bp deletion 
in the band 3 gene [17]. Presence of ovalocytes in blood smears from Sumbanese was highly 
predictive for the presence of the band 3 gene mutation (Dr. Syafruddin, unpublished data). A 
full blood count was determined by a standard hematology analyzer (Arcus, Diatron, Vienna, 
Austria).
Serum hepcidin was measured using a combination of weak cation exchange chromatog­
raphy and time-of-flight mass spectrometry (TOF MS). An internal standard (synthetic hepci- 
din-24; Peptide International Inc.) was used for quantification [18, 19]. Peptide spectra were gen­
erated on a Microflex LT matrix-enhanced laser desorption/ionization TOF MS platform (Bruker 
Daltonics). Serum hepcidin-25 concentrations were expressed in nanomoles. The lower limit of 
detection of this method was 0.5 nM; average coefficients of variation were 2.7% (intra-run) 
and 6.5% (inter-run). The median reference level of serum hepcidin-25 concentrations in healthy 
Dutch adults is 4.2 nM, while the range is 0.5-13.9 nM [20].
Serum concentrations of total iron, total iron-binding capacity (TIBC), ferritin, sTfR and C- 
reactive protein were determined as described previously [11, 12]. GDF15 concentrations were 
measured with DuoSet (R&D Systems, Minneapolis, MN, USA) enzyme-linked immunosorbent 
assay for human GDF15 according to the manufacturer's protocol. Serum concentrations of 
interleukin-1 receptor antagonist (IL-1ra), interleukin (IL)-6, IL-10 and tumor necrosis factor-a 
(TNF-a) were analyzed in one batch using a multiplex assay (Luminex, Austin, TX, USA) with 
lower limits of detection of 7 pg/mL (IL-1ra, IL-6 and IL-10) and 20 pg/mL (TNF-a).
Statistical analysis
Differences in characteristics and laboratory parameters between subjects in the malaria and 
control groups and among subjects before and after antimalarial treatment were analyzed by 
Student's t test and paired Student's t test, respectively. A two-sided P value of less than 0.05 
was considered to be statistically significant. All analyses were performed with the use of SPSS 
software.
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RESULTS
Characteristics
Of a total of 1197 screened schoolchildren, 73 (6.1%) had asymptomatic P. falciparum and 18 
(1.5%) asymptomatic P. vivax parasitemia. Seventeen asymptomatic children with a negative 
malaria smear were enrolled as a control group (see Table 1 for the baseline characteristics). Only 
16% and 17% of children with asymptomatic P. falciparum and P. vivax parasitemia, respectively, 
had an elevated (>5 mg/L) C-reactive protein concentration; the mean C-reactive protein con­
centration in those children was 13.7 mg/L (range, 6-39 mg/L). Serum concentrations of IL-1ra, 
IL-6, IL-10 and TNF-a were low with values above the lower detection limit in only 65%, 15%, 38% 
and 4% of baseline samples, respectively. Hemoglobin concentrations were significantly lower 
in children with either P. falciparum or P. vivax parasitemia than in controls (Figure 1). Antima- 
larial treatment resulted in a modest, though significant increase in hemoglobin concentration 
in both groups with mean concentration increasing from the baseline 12.6 g/dL to 13.4 g/dL 
(P<0.01) after treatment in the group with asymptomatic P. falciparum and from 12.2 g/dL to 
13.7 g/dL (P<0.01) in the group with asymptomatic P. vivax infection.
Table 1. Baseline characteristics of study participants
Characteristic Asymptomatic 
P. falciparum
Asymptomatic 
P. vivax
Controls
Number, no. 73 18 17
Age, mean (years; range) 10.9 (6 - 15) 11.0 (8 - 15) 10.9 (8 - 15)
Males, n (%) 39 (53) 11 (61) 10 (59)
Temperature, mean ( oC; range) 37.2 (36.7 - 37.9)* 37.2 (36.7 - 37.9)** 36.9 (36.6 - 37.4)
Parasite density, geometric mean (pL-1; 
range)
189 (34 - 11.956) 175 (51 - 2.458) NA
C-reactive protein < 5mg/L, n (%) 61 (84) 15 (83) 9 (100)'
IL-1ra, median (pg/mL; IQR)2 29 (14 - 61) 14 (9 - 45) ND
Ovalocytes in blood smear, no. (%) 15 (21%) 1 (6%) ND
Hemoglobin, mean (g/L; 95% CI) 12.6 (12.2 - 12.9)* 12.2 (11.6 - 12.9)* 14.4 (13.7 - 15.1)
WBC, mean (x109/L; 95% CI) 9.8 (9.2 - 10.5) 9.4 (7.8 - 11.0) 9.3 (8.0 - 10.6)
Platelet count, mean (x109/L; 95% CI) 289 (266 - 313)** 235 (184 - 285)* 360 (310 - 411)
NA, not applicable; ND, not determined; IL-1ra, interleukin-1 receptor antagonist; IQR, interquartile 
range; CI, confidence interval; WBC, white blood cell count. 1C-reactive protein concentrations avail­
able for 9 of 17 controls; 2IL-1ra concentrations above lower detection limit in 66% and 56% of sub­
jects in the P. falciparum and P. vivax group, respectively. * p < 0.01, ** p < 0.05 compared with controls, 
calculated by Student's t test.
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Serum hepcidin and parameters of iron status and inflammation
Baseline and week 4 serum concentrations of hepcidin and IL-1ra and values of the iron sta­
tus parameters are presented in Figure 2 and Table 2. Children with asymptomatic P. falciparum 
or P. vivax parasitemia had significantly higher baseline hepcidin concentrations than those of 
the control children, together with higher serum ferritin concentrations and lower values of 
serum iron, transferrin saturation, TIBC, mean corpuscular volume and mean cell hemoglobin. 
Antimalarial treatment resulted in small but significant decreases in serum concentrations of 
hepcidin and ferritin in both groups with asymptomatic parasitemia. Hepcidin concentrations 
decreased by a median of 22% and 40% in the P. falciparum and P. vivax group, whereas fer­
ritin concentrations decreased by a median of 14% and 30%, respectively. This decrease was 
associated with small increases in TIBC (P. falciparum group), mean corpuscular volume (P. vivax 
group) and mean cell hemoglobin (both groups), while the transferrin saturation and serum 
iron remained unchanged. There was no change in IL-1ra concentrations at week 4. However, 
C-reactive protein concentrations normalized to values below 5 mg/L in 12 of 15 children with 
elevated C-reactive protein concentrations before antimalarial treatment, while IL-10 concentra­
tions became undetectable in 10 of 35 children with detectable IL-10 concentrations at baseline. 
The effect of antimalarial treatment on IL-6 and TNF-a concentrations could not be determined 
as serum concentrations of the baseline samples were below the lower detection limit in the 
vast majority of children.
Soluble transferrin receptor and growth differentiation factor 15 concentrations
Erythropoietic activity was evaluated by assessment of serum concentrations of sTfR and GDF15. 
Both asymptomatic P. falciparum and P. vivax malaria were associated with markedly elevated 
sTfR concentrations, which remained elevated at week 4 (Figure 3A). In contrast, no differences 
in GDF15 concentrations were observed between the groups (Figure 3B). Erythropoietic activity 
is a negative regulator of hepcidin expression and serum concentrations of sTfR in the children 
with asymptomatic parasitemia were indeed inversely correlated with serum hepcidin concen­
trations (Pearson's R=-0.33; P=0.002). Since no data on GDF15 have previously been reported
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Figure 1. Hemoglobin concentrations in children 
with asymptomatic P. falciparum parasitemia 
(n=73), asymptomatic P. vivax parasitemia (n=18) 
and controls (n=17). Data depicted are before and 
4 weeks after start of antimalarial treatment; the 
line represents the mean. P-values determined by 
Student's t test and paired t test.
weekO week 4 weekO week 4 weekO
Asymptomatic Asymptomatic Controls 
P. falciparum P. vivax
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P. falciparum P. vivax
Asymptomatic Asymptomatic Controls 
P. falciparum P. vivax
Figure 2. Serum concentrations of hepcidin (panel 
A), ferritin (panel B) and transferrin saturation (pan­
el C) in children with asymptomatic P. falciparum 
parasitemia (n=73), asymptomatic P. vivax parasit­
emia (n=18) and controls (n=17). Data depicted 
are before and 4 weeks after start of antimalarial 
treatment; the line represents the mean. P-values 
determined by Student's t test and paired t test.
in malaria patients, we also determined concentrations of this protein in seven patients who 
presented with febrile, symptomatic P. falciparum (n=4) or P. vivax (n=3) malaria to the regional 
hospital. Symptomatic malaria was associated with lower sTfR concentrations (mean 1.3 mg/L; 
range, 1.0-2.2 mg/L) and higher GDF15 concentrations (mean 2467 pg/mL; range, 940-4500 pg/ 
mL) when compared with asymptomatic parasitemia. Although GDF15 has been reported to 
down-regulate hepcidin expression, inflammation was dominant as serum hepcidin concentra­
tions were markedly elevated (mean 24.3 nM; range 6.8-37.9 nM) in the presence of high serum 
concentrations of CRP (mean 83 mg/L; range 14-211 mg/L) and ferritin (mean 713 |jg/L; range, 
97-1387 |-ig/L) and low serum iron concentrations (mean 3.1 ^mol/L; range, 2.0 - 6.0 ^mol/L).
64
Hepcidin and iron parameters in asymptomatic malaria
Ovalocytosis
Ovalocytes were seen in the blood smear in 15 of 73 (21%) children with asymptomatic P. falci­
parum parasitemia (Table 1), a finding suggestive of Southeast Asian ovalocytosis. There were 
no significant differences in demographic or clinical characteristics between children with and 
without ovalocytes (data not shown). No significant differences in iron parameters were ob­
served between the two groups at baseline, except for higher value of mean corpuscular vol­
ume and mean cell hemoglobin (Table 3). By week 4, however, children with ovalocytosis had 
a slightly higher sTfR concentration, together with lower serum concentrations of hepcidin, se­
rum iron, ferritin and transferrin saturation (Table 3). In addition, while anti-malarial treatment 
induced a significant rise in hemoglobin concentration in the group without ovalocytosis, there 
was no change in hemoglobin or serum ferritin concentrations in the group with ovalocytosis.
DISCUSSION
The present study shows that serum hepcidin concentrations are increased in children with 
asymptomatic P. falciparum and P. vivax parasitemia in the absence of a marked acute phase 
response. These higher hepcidin concentrations were accompanied by findings suggestive of 
iron maldistribution, i.e. higher serum ferritin concentrations and lower values of serum transfer­
rin saturation, serum iron concentration and mean corpuscular volume. Antimalarial treatment 
partly reversed these abnormalities and resulted in a significant increase in hemoglobin concen­
tration and significant decreases in serum concentrations of hepcidin and ferritin.
Are these mildly elevated hepcidin concentrations functionally important, i.e. do they re­
duce the availability of iron for erythropoiesis? We recently showed in an experimental human 
malaria model that even a mild increase in serum hepcidin, to concentrations in the range of 
those observed in the current study, induces hypoferremia and a steep fall in the hemoglobin 
content of reticulocytes, which is suggestive of impaired iron incorporation in hemoglobin [12]. 
Moreover, the lower values of hemoglobin, mean corpuscular volume, serum iron concentra­
tion and transferrin saturation in children with asymptomatic parasitemia also support the pres­
ence of functional iron deficiency. Since asymptomatic P. falciparum and P. vivax parasitemia are 
chronic and relapsing conditions, a possible delocalization of iron with iron retention in mono­
cytes/ macrophages may theoretically increase the risk of anemia and of infections with intracel­
lular bacteria (e.g. Salmonella and Mycobacteria spp.), which are extremely common in regions in 
which malaria is endemic. We, therefore, suggest screening individual children in malaria areas 
for the presence of malaria when iron therapy is considered and including malaria screening 
and treatment as an integral part of universal iron supplementation programs. In addition, as 
recently proposed by Theurl et al. and by our group, hepcidin is a promising new parameter for 
the selection of individuals who will benefit from iron therapy [11, 12, 21].
65
Chapter 4
Table 2. Serum hepcidin and iron parameters (mean with 95% confidence interval) at baseline and 
4 weeks after antimalarial treatment
Characteristic Asymptomatic 
P. falciparum
Asymptomatic 
P. vivax
Controls
Serum hepcidin (nM)
week 0 5.2 (4.4-6.1)** 5.6 (3.8-7.4)** 3.1 (1.7-4.6)
week 4 4.1 (3.5-4.8)11 3.0 (1.7-4.3) 1
Serum ferritin (pg/L)
week 0 75 (60-96)* 101 (72-130)* 47 (35-59)
week 4 59 (49-70) 1 65 (48-82) 1
Serum TS (%)
week 0 14.3 (12.8- 15.9)** 14.3 (11.2-17.4)** 19.2 (13.5-24.9)
week 4 14.6 (13.2-16.1) 13.7 (11.0-16.4)
Serum iron (pmol/L)
week 0 8.6 (7.8-9.4)* 8.9 (7.1-10.7)** 13.3 (8.4-18.3)
week 4 9.3 (8.4-10.2) 8.9 (7.2-10.7)
Serum TIBC (pmol/L)
week 0 62 (60-64) 63 (59-68) 69 (60-77)
week 4 65 (63-67)l 65 (48-82)
MCV (fL)
week 0 81.4 (79.8-83.0)** 78.6 (74.8-82.3) 83.7 (78.1-89.3)
week 4 81.3 (79.7-82.9) 79.5 (75.3-83.8)#
MCH (pg)
week 0 26.7 (26,0-27,3)* 25,6 (23,9-27,4)* 29.8 (27.3-32.3)
week 4 26.9 (26.2-27.3)11 26.3 (24.3-28.2)#
IL-1ra (pg/mL)1
week 0 29 (14-61) 14 (9-45) ND
week 4 25 (14-53) 14 (7-29)
TS, transferrin saturation; TIBC, total iron binding capacity; MCV, mean cell volume; MCH, mean cell 
hemoglobin; IL-1ra, interleukin-1 receptor antagonist; ND, not determined. 'Data represent median 
and interquartile range. Values above the lower detection limit in 66% and 56% of week 0 samples 
in the falciparum and vivax groups, respectively. * p<0.01, ** p<0.05 vs. controls by Student's t test. * 
p<0.01, ** p<0.05 vs. corresponding week 0 values by paired t test.
The exact cause of the up-regulated hepcidin production in asymptomatic malaria remains 
speculative. Previous studies found only little inflammation in patients with asymptomatic 
parasitemia, which is in line with the low circulating concentrations of C-reactive protein and 
inflammatory cytokines in our present study [22]. Therefore, even though an effect of mild in­
flammation cannot be fully excluded, other mechanisms should be considered. Recent work by 
Armitage et al. showed that P. falciparum-parasitized erythrocytes directly up-regulate hepcidin 
production by peripheral blood mononuclear cells via pattern recognition receptors [23]. Our 
earlier observations, in children with febrile malaria, that IL-6 concentrations were independent 
of urine hepcidin concentrations in multivariate regression analysis are also consistent with the 
existence of such an IL-6-independent pathway in malaria [11].
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Figure 3. Serum concentrations of soluble transferrin receptor (panel A) and growth differentiation 
factor 15 (GDF15; panel B) in children with asymptomatic P. falciparum parasitemia (n=73), asymp­
tomatic P. vivax parasitemia (n=18) and controls (n=17). Data depicted are before and 4 weeks after 
start of antimalarial treatment; the line represents the mean. P-values determined by Student's t test 
and paired t test.
Erythropoietic activity is also increasingly recognized as a central regulator of hepcidin 
production [24]. Although the precise pathways are yet to be elucidated, two novel erythroid 
regulators, TWSG1 (twisted gastrulation homolog 1) and GDF15, were recently shown to down- 
regulate hepcidin expression [13, 25]. GDF15 is a molecule expressed by erythroid precursors 
and increased GDF15 concentrations have been found in patients with thalassemia major and 
other conditions with ineffective erythropoiesis [13, 26, 27]. Although earlier bone marrow stud­
ies in subjects with low density P. falciparum and with P. vivax malaria were suggestive of ineffec­
tive erythropoiesis, the normal GDF15 concentrations in our present study do not support this 
[28-30]. Instead, as also previously reported by Verhoef et al. [31], the elevated sTfR concentra­
tions, a parameter thought to correlate well with erythroid mass [32], suggests that erythro­
poiesis is effectively increased in asymptomatic parasitemia. Increased erythropoietic activity 
compensating for increased red cell destruction may negate some of the hepcidin-stimulatory 
effects of malaria antigen or inflammation. In contrast, erythropoiesis is usually suppressed in 
symptomatic malaria, as reflected by the low sTfR concentrations together with elevated GDF15 
concentrations in the seven patients with febrile malaria in our study [33].
Southeast Asian ovalocytosis is a common inheritable red blood cell disorder on the island 
of Sumba. It results from a 27-base pair deletion in the band 3 gene, which leads to rigid and 
oval-shaped red blood cells. In our study, the presence of ovalocytes in the blood smear, a find­
ing highly suggestive of Southeast Asian ovalocytosis [17], was related to higher sTfR concentra­
tions and normal GDF15 concentrations. A reduced life span of ovalocytes with a compensatory 
increase in erythropoiesis may account for this finding and may also explain why antimalarial 
treatment resulted in a greater decrease in serum hepcidin concentrations. By contrast, no 
changes in hemoglobin and ferritin concentrations were observed in the ovalocytosis group, 
a finding not readily explained though possibly related to ongoing low-grade hemolysis and
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Table 3. Hematologic and iron parameters (mean with 95% confidence interval) in children with 
and without ovalocytosis
Characteristic Ovalocytosis (n=15) No ovalocytosis (n=58) P value
Hemoglobin (g/dL)
week 0 12.7 (12.1-13.4) 12.5 (12.1-12.9) 0.58
week 4 12.8 (12.2-13.4) 13.6 (13.3-13.9)* 0.034
Serum hepcidin (nM)
week 0 4.6 (2.6-6.5) 5.4 (4.5-6.3) 0.41
week 4 2.8(1.5-4.1)** 4.5 (3.7-5.2) 0.042
Serum sTfR (mg/L)
week 0 2.8 (2.4-3.2) 2.4 (2.2-2.6) 0.09
week 4 2.8 (2.4-3.2) 2.4 (2.2-2.5) 0.046
Serum GDF15 (pg/ml)
week 0 430 (362-499) 441 (413-469) 0.73
week 4 414 (355-472) 436 (409-463) 0.46
Serum ferritin (pg/L)
week 0 79 (50-108) 74 (55-94) 0.82
week 4 80 (38-121) 54 (46-63)* 0.047
Serum iron (pmol/L)
week 0 9.4 (7.4-11.4) 8.4 (7.6-9.3) 0.34
week 4 11.4 (9.0-13.9) 8.8 (7.8-9.7) 0.017
Serum transferrin saturation (%)
week 0 17.9 (13.8-22.0) 14.2 (12.4-16.1) 0.79
week 4 14.8 (11.8-17.7) 13.8 (12.3-15.3) 0.021
MCV (fL)
week 0 84.2 (81.7-86.7) 80.7 (78.9-82.6) 0.054
week 4 83.9 (81.5-86.2) 80.6 (78.7-82.5) 0.031
MCH (pg)
week 0 27.6 (26.5-28.8) 26.4 (25.6-27.2) 0.058
week 4 28.0 (26.9-29.1) ** 26.6 (25.8-27.5) 0.059
Data from baseline and week 4 after start of a three day antimalarial treatment. sTfR, soluble transfer­
rin saturation. GDF15, growth differentiation factor-15; MCV, mean cell volume; MCH, mean cell he­
moglobin. P values in last column depict difference between ovalocytosis and no ovalocytosis group, 
calculated with Student's t test. *p<0.01, **p<0.05 vs. corresponding week 0 values within groups by 
paired t test.
erythrophagocytosis of the rigid ovalocytes. Finally, thalassemia may also influence iron homeo­
stasis, but this hemoglobinopathy seemed rare in our study population because less than 7% of 
children had microcytosis (<70 fL), a finding that is considered typical of thalassemia. Moreover, 
none of these children with microcytosis also had strongly elevated concentrations of sTfR and 
GDF15, which are usually present in thalassemia intermedia or major [13].
In conclusion, asymptomatic P. falciparum and P. vivax parasitemia were associated with low­
ered hemoglobin concentrations and increased serum hepcidin concentrations in the absence 
of marked inflammation. Antimalarial treatment resulted in a decrease in serum hepcidin con­
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centrations and an increase in hemoglobin concentrations, although a causal relationship be­
tween these findings is unproven. We speculate that asymptomatic parasitemia with impaired 
iron handling may be an underestimated cause of anemia in tropical countries. We suggest that 
universal iron supplementation programs should not be implemented without proper screen­
ing for parasitemia and functional iron deficiency. Hepcidin may prove a useful screening tool 
for this purpose.
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SUMMARY
In malaria endemic areas, iron deficiency and placental Plasmodium falciparum infection com­
monly co-exist. In primigravidae and their newborns, hepcidin and other iron parameters were 
evaluated in groups, classified according to placental P. falciparum and maternal anemia status. 
Mothers had relatively high hepcidin levels considering their low iron status. In cord blood, lev­
els of hepcidin, hemoglobin and other iron parameters were also similar for groups. We con­
clude that maternal hepcidin is not significantly altered as a function of placental infection and/ 
or anemia. Importantly, fetal hemoglobin and iron status were also unaffected, regardless of the 
presence of placental infection or maternal anemia.
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INTRODUCTION
Pregnancy malaria is a significant public health problem, since it is consistently associated with 
maternal morbidity and poor birth outcome [1-3]. Iron deficiency is also highly prevalent in ma­
laria endemic areas and, apart from Plasmodium falciparum infection, it is another well-known 
risk factor for maternal anemia and perinatal complications [4, 5]. Therefore, iron supplementa­
tion is considered a logical public health intervention. However, not all studies of iron supple­
mentation in malaria endemic regions have shown favorable results [6, 7]. The iron regulatory 
hormone hepcidin has been reported to inhibit the intestinal iron uptake and the release of 
iron from macrophages by degrading the sole cellular iron export protein ferroportin [8, 9]. In­
flammatory stimuli, including those associated with P. falciparum infection, increase hepcidin 
production, resulting in low plasma iron levels and reduced bone marrow iron supply [10-12].
During blood stage malaria infection, P. falciparum-infected erythrocytes can bind chondroi- 
tin sulphate A on syncytiotrophoblasts, leading to their accumulation in placental intervillous 
spaces. Syncytiotrophoblasts express iron regulatory proteins including ferroportin, which is re­
sponsible for iron release into the fetal circulation [13]. In addition, animal studies revealed that 
hepcidin and iron levels in the fetal liver may also regulate maternal-fetal iron transport [14-16].
We aimed to study maternal and fetal hepcidin and other iron parameters to improve our 
understanding of human placental iron transport. Therefore, we retrospectively assessed plas­
ma concentrations of these indices in primigravidae as a function of placental P. falciparum in­
fection and maternal anemia, and in corresponding cord-blood samples.
MATERIALS AND METHODS
Study population and design
Archived samples from malaria pregnancy study, carried out in an area of Gabon characterized 
by stable meso- to hyperendemic malaria transmission were used for this study [17]. Paired ma­
ternal and umbilical cord blood samples were obtained at time of parturition from pregnant 
women attending the Albert Schweitzer Hospital in Lambarene, Gabon from July 2000 to Feb­
ruary 2004. Medical records of the mothers were examined to determine whether malaria epi­
sodes were detected and appropriately treated during pregnancy. Age at delivery, number of 
previous pregnancies, and the child's birth weight and length were recorded. Antenatal univer­
sal iron supplementation during pregnancy was local practice (following the WHO recommen­
dation for all pregnant women, 60 mg iron daily); therapy compliance was not recorded [18].
Samples from primigravidae without peripheral parasitemia (determined by microscopy) 
who gave birth to singleton live births and who had no signs or symptoms of systemic infection 
were included. Primigravid women were selected for this study, since they are more susceptible 
to P. falciparum infection than multigravidae and have a higher risk of adverse outcome [1]. Fur­
75
Chapter 5
ther sample selection was performed on the basis of placental infection status, defined as the 
presence of P. falciparum parasites in giemsa stained placental blood impression smears, and on 
the presence or absence of maternal anemia, defined as a hemoglobin concentration below 10 
g/dL. This selection procedure resulted in four groups: (1) no placental malaria and no anemia;
(2) no placental malaria and anemia; (3) placental malaria and no anemia, and (4) placental ma­
laria and anemia. Sample size was determined by the availability of paired maternal and umbili­
cal cord samples that matched the selection criteria.
Informed consent, including approval for future measurements was obtained from mothers 
before inclusion. Ethical clearance for the study was given by the Ethics Committee of the Inter­
national Foundation of the Albert Schweitzer Hospital in Lambarene.
Laboratory analysis
Giemsa stained thick and thin smears of both maternal and cord blood, and impression smears 
of placental blood, were assessed microscopically for the presence of P. falciparum parasites. 
Hemoglobin concentrations were determined by a standard hematology analyzer. Blood sam­
ples were stored at - 80 °C for further analysis. Plasma concentrations of iron, total iron-binding 
capacity (TIBC), ferritin, soluble transferrin receptor (sTfR) and C-reactive protein (CRP) were 
determined as described previously [10]. Plasma hepcidin-25 measurements were performed 
in 2009 by a combination of weak cation exchange chromatography and time-of-flight mass 
spectrometry (TOF MS). An internal standard (synthetic hepcidin-24; Peptide International Inc.) 
was used for quantification (www.hepcidinanalysis.com) [19]. Peptide spectra were generated 
on a Microflex LT matrix-enhanced laser desorption/ionisation TOF MS platform (Bruker Dalton- 
ics). Plasma hepcidin-25 concentrations were expressed as nmol/L. The lower limit of detection 
of this method was 0.5 nmol/L; average coefficients of variation were 2.7% (intra-run) and 6.5% 
(inter-run). The median reference level of plasma hepcidin-25 is 4.2 nmol/L, with a range of 0.5 
- 13.9 nmol/L [20].
The reliability of the archived samples for the present study was assessed by mass profiling 
of 8 paired cord and maternal samples. We found the peptide spectra to be similar to that of 
freshly frozen sera. More specifically, degradation products as observed in sera that had been 
inadequately stored for a prolonged period of time were absent throughout the peptide pro­
file (i.e at m/z 5000-6000 and m/z 7000-8500), providing confidence in the good quality of the 
samples.
Statistical analysis
Data are expressed as median values with interquartile range (IQR). Differences among groups 
were tested by Kruskall-Wallis tests. Differences between two groups were assessed by Mann­
Whitney tests. Missing values were assumed to be at random. CRP concentrations < 5 mg/L 
were included in the analyses as CRP concentrations of 5 mg/L. Significance was defined as
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two-tailed (P < 0.05). The statistical software packages SPSS 16.0 (SPSS Inc., Chicago, IL) and 
GraphPad Prism 4.00 (GraphPad Software Inc., San Diego, CA) were used for all data analyses.
RESULTS
Study group characteristics
A total number of 69 primigravidae were stratified in four groups according to placental P. fal­
ciparum infection status and hemoglobin level. The characteristics of the study population are 
shown in Table 1. Median hemoglobin concentrations were 12.8 g/dL (IQR = 11.6-13.4) and 8.2 
g/dL (IQR = 7.5-8.8) in non-anemic and anemic mothers, respectively. There were no differences 
in the four study groups in either white blood count or platelet numbers. CRP concentrations 
were elevated in most women, with the highest values in those with placental infections. The
Table 1. Clinical data and iron status indices in pregnant women
Characteristic
Placental malaria Placenta malaria +
P *anemia- (n=21)* anemia+ (n=18) anemia- (n=16) anemia+ (n = 14)
Age, years 18.0 (17.0-19.0) 17.0 (16.0-19.3) 17.0 (16.0-18.0) 17.0 (16.8-19.3) .43
Hemoglobin, g/dL 13.2 (11.9-13.8) 8.2 (7.6-8.5) 12.2* (11.2-13.2) 8.3 (6.6-9.3) .00
Cell counts, 109/L
WBC 11.0 (9.2-18.0) 10.5 (9.2-13.0) 11.0 (9.2-13.8) 10.0 (7.6-12.0) .72
Platelets 185 (142-245) 207 (130-163) 152 (109-191) 190 (126-259) .21
CRP, mg/L 12.0 (5.0-31.0) 17.5 (6.0-43.3) 25.0* (11.0-47.3) 32.0§ (17.8-67.5) .43
CRP <10, n (%) 10 (47.6) 8* (44.4) 4§ (25.0) 2* (14.3) .005
Iron parameters
Hepcidin, nmol/L 4.2 (1.6-8.0) 2.8 (0.5-13.1) 4.2 (2.0-8.1) 3.2 (0.9-5.0) .70
Iron, pmol/L 9.0 (8.0-12.5) 8.0 (4.8-15.3) 8.0 (6.0-12.0) 7.5 (4.8-13.8) .55
TIBC, pmol/L 80.0 (73.5-89.5) 83.0 (73.3-102) 86.0 (73.0-104) 80.0 (59.5-85.3) .25
TS, % 11.2 (7.9-18.3) 9.4 (5.9-20.5) 8.1 (5.9-16.5) 9.6 (6.6-19.4) .55
Ferritin, pg/L 30.0 (16.0-45.0) 29.0 (11.0-147) 44.0 (19.3-121) 86.0 (20.5-220) .37
sTfR, mg/L 1.4 (1.2-2.1) 2.3* (1.4-3.6) 2.0 (1.5-2.4) 1.6 (1.5-2.3) .09
WBC, white blood cell count; CRP, C- reactive protein; TIBC, total iron-binding capacity;
TS, transferrin saturation; sTfR, soluble transferrin receptor.
* Data are presented as median with interquartile range; anemia was defined as hemoglobin concen­
tration below 10 g/dL.
tValues represent differences among the four groups by Kruskall-Wallis test.
+ P < 0.05 compared with the group of mothers without placental malaria infection and without ane­
mia (by Mann-Whitney test).
§ P < 0.01 compared with the group of mothers without placental malaria infection and without ane­
mia (by Mann-Whitney test).
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percentage of low birth weight, i.e. a birth weight below 2.5 kg, was relatively high in all sub­
groups (range = 18.8-35.7%). Despite a trend for lower birth weight in the groups with anemia, 
there was no significant difference in birth weight among the groups.
Maternal hepcidin and iron parameters
Maternal plasma hepcidin concentrations were similar across the groups (P=0.70, Figure 1). 
There was also no significant difference in plasma iron concentration, transferrin saturation, TIBC 
and ferritin concentration (Table 1). However, serum ferritin concentrations were higher in the 
group of women with placenta malaria as a whole compared with women without placenta 
malaria. Anemic women without placental malaria also had higher sTfR concentrations than 
those without anemia.
Cord blood parameters
Cord parameters were independent of hemoglobin and malaria status of the mother (Table 2). 
Concentrations of hemoglobin, hepcidin and other iron status indices were similar across the 
four groups. CRP concentrations were not elevated in all groups and there was neither anemia 
nor signs of iron deficiency, i.e. hypoferremia, high TIBC or low plasma ferritin concentrations.
DISCUSSION
In the current study, the effects of placental P. falciparum infection and anemia on hepcidin and 
iron parameters in mothers and their offspring were assessed, and some important findings 
are hereby reported. First, we show that primigravid women with or without placental infec­
tion and with or without anemia have relatively low ferritin concentrations, low plasma iron 
concentrations and low transferrin saturation as well as high TIBC concentrations, suggesting 
some degree of iron deficiency. We refrained from assessing iron deficiency by previously used 
formulas (e.g. the sTfR to log ferritin ratio) as they have not been standardized nor validated for 
our study population [21]. In pregnancy, iron deficiency resulting from a physiologic increase 
in erythroid iron demand is indeed a common finding. Moreover, nutritional iron deficiency is 
also highly prevalent in malaria endemic regions, even despite implementation of active iron 
supplementation programs [22].
Second, we found that maternal plasma hepcidin concentrations were not altered by pla­
cental infection and that hepcidin concentrations were relatively high, considering the pres­
ence of iron deficiency. The expression of hepcidin is principally regulated by a combination 
of factors: hypoxia, increased erythropoietic activity and iron deficiency suppress hepcidin 
expression, while inflammatory cytokines (especially interleukin-6) stimulate the production 
of hepcidin [23]. The relatively high hepcidin concentrations in the group of anemic mothers 
without placental malaria are, therefore, remarkable. The slightly elevated CRP values in some
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Figure 1. Plasma concentrations of hepcidin stratified for anemia and placental infection status. Data 
are depicted for maternal and cord blood; the line represents the median value. □ = no placental 
malaria and no anemia; O = no placental malaria with anemia;
• = placental malaria and no anemia; T=  placental malaria with anemia.
women in this group may be explained by the normal increase in CRP measurements in the third 
trimester and at parturition, and mild inflammation could have contributed to these relatively 
high hepcidin levels [24]. It should be noted that only subjects with a parasite-negative periph­
eral blood smear were included in this study to diminish the potentially confounding effects of 
higher-grade systemic (inflammatory) infection. Parasitemia in pregnant women is associated 
with higher inflammatory markers and possibly higher urinary hepcidin concentrations [25, 26]. 
Very high hepcidin concentrations were measured in African children with clinical malaria while 
slightly raised hepcidin levels were found in those with low density parasitemia [10, 11].
Third, we found a trend for lower sTfR concentrations in anemic women with placental infec­
tion compared with mothers without infection. Because sTfR is a marker for erythropoietic activ­
ity, this may suggest that placental parasitemia is associated with reduced erythroid progenitor 
proliferation [21].
The functional consequences of these findings are uncertain, although one might speculate 
that the effectiveness of iron supplementation in the study participants may be reduced by the 
relatively high hepcidin concentrations. However, iron retained in the erythrocyte precursor by 
hepcidin degradation of ferroportin, may well compensate for this decreased iron supply and/ 
or at least partly, protect against anemia [27].
Finally, we found no effect of placental infection or maternal anemia on cord-blood con­
centrations of hemoglobin, CRP, hepcidin and other iron parameters. This is in agreement with 
a study conducted in Malawi which also found no significant effect of peripheral or placental P. 
falciparum infection on cord blood concentrations of hemoglobin, CRP, sTfR and only a slightly 
effect on ferritin [28]. Moreover, among Nigerian women, placental infection was strongly as­
sociated with maternal anemia, but not with the mean hematocrit in their newborns [29]. Inter­
estingly, although the clinical implications are still to be elucidated, placental hepcidin mRNA 
expression was increased in P. falciparum infected placentas and was negatively correlated with
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Table 2. Clinical data and cord blood iron status indices in newborns
Characteristic
Placental malaria- Placenta malaria+
P tanemia- (n=21)* anemia+ (n=18) anemia-(n=16) anemia+ (n=14)
Birth weight, kg 2.8 (2.5-3.0) 2.6 (2.4-2.8) 2.9 (2.6-3.2) 2.7 (2.1-3.0) .32
LBW*, n (%) 4 (19.0) 5 (27.8) 3 (18.8) 5§ (35.7) .65
Birth length, cm 50.0 (48.5-50.0) 49.0 (48.0-50.0) 50.0 (49.0-50.0) 48.01 (46.5-49.3) .09
Hemoglobin, g/dL 15.1 (13.8-16.0) 14.2 (13.0-15.2) 13.91 (12.5-14.7) 14.6 (12.9-15.6) .21
Cell counts, 109/L
WBC 12.8 (10.0-15.1) 11.6 (8.3-14.2) 12.4 (9.6-14.4) 10.1 (8.4-13.3) .94
Platelets 299 (246-364) 296 (202-367) 265 (218-319) 273 (231-301) .58
CRP <5 mg/L, n (%) 20 (95.2) 16 (94.1) 15 (93.7) 14 (100.0) .79
Iron parameters
Hepcidin, nmol/L 4.5 (2.8-6.8) 5.5 (2.4-9.5) 3.7 (3.0-6.9) 4.4 (1.8-6.5) .33
Iron, pmol/L 22.0 (19.5-28.0) 20.0 (14.0-27.0) 19.01 (18.0-21.0) 17.01 (13.0-22.0) .14
TIBC, pmol/L 41.0 (37.0-46.5) 43.0 (36.0-52.5) 46.0 ( 35.8-47.8) 33.5 (59.5-85.3) .39
TS, % 57.1 (45.5-70.9) 45.5 (32.7-59.4) 42.91 (35.1-60.0) 61.0 (39.0-69.6) .64
Ferritin, pg/L 122 (97.0-290) 146 (84.0-217) 161 (131-224) 137 (89.3-193) .72
sTfR, mg/L 2.3 (1.9-2.8) 2.3 (1.9-3.7) 2.4 (1.8-2.8) 1.8 (1.6-3.1) .44
WBC, white blood cell count; CRP, C- reactive protein; TIBC, total iron-binding capacity;
TS, transferrin saturation; sTfR, soluble transferrin receptor; LBW, low birth weight.
* Data are presented as median with interquartile range; anemia defined as hemoglobin concentra­
tion below 10 g/dL.
t  Values represent differences among the four groups by Kruskall-Wallis test.
* Low birth weight defined as a weight below 2.5 kg.
§ P < 0.05 compared with the group of mothers with anemia but without placental malaria (by Mann­
Whitney test).
1 P < 0.01 compared with the group of mothers without placental malaria infection and without ane­
mia (by Mann-Whitney test).
birth weight, but not associated with maternal anemia [30]. In the present study, the relation­
ship between low birth weight and placental infection was absent, which may be attributed to 
the low birth weights of newborns of non- diseased mothers.
Our study is limited by its retrospective character, the absence of long-term data, the lack 
of information on premature delivery, its relatively small sample size, and the usage of archived 
samples. Concerning the latter, both the normal MS profiles of all serum samples without signs 
of degradation products as well as the broad range in concentrations of the laboratory mark­
ers observed provided confidence in the reliability of the data obtained. The study is, however, 
unique in the selection of primigravidae and cord-blood samples with either placental P. falci­
parum infection, anemia, or both in combination with the exclusion of peripheral parasitemia.
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In conclusion, neither placental infection nor maternal anemia was related to maternal and 
cord hepcidin concentrations and iron status. Our data also suggest that iron metabolism is 
biased to maintaining the fetal iron supply, even in the presence of maternal anemia and iron 
deficiency. Here, the fetus seems to be the winner in the maternal-fetal conflict, deriving its 
nutrients independently from maternal iron and placental malaria infection [31]. Whether the 
effectiveness of iron supplementation of pregnant women in the third trimester is impaired by 
the moderately elevated hepcidin concentrations needs to be determined in future studies.
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A decrease of plasma macrophage migration inhibitory 
factor concentration is associated with lower numbers 
of circulating lymphocytes in experimental Plasmodium 
falciparum malaria.
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SUMMARY
Macrophage migration inhibitory factor [MIF] has recently been implicated in the pathogenesis 
of malarial anemia. However, field studies have reported contradictory results on circulating MIF 
concentrations in patients with clinically overt Plasmodium falciparum malaria. We determined 
plasma MIF levels over time in 10 healthy volunteers during experimental P. falciparum infection. 
Under fully controlled conditions, MIF levels decreased significantly during early blood-stage 
infection and reached a nadir at day 8 post-infection. A decrease in the number of circulating 
lymphocytes, which are an important source of MIF production, paralleled the decrease in MIF 
levels. Monocyte/macrophage counts remained unchanged. At MIF nadir, the anti-inflammato­
ry cytokine interleukin [IL]-10, which is an inhibitor of T-cell MIF production, was detectable in 
only 2 of 10 volunteers. Plasma concentrations of the pro-inflammatory cytokines IL-8 and IL-ip 
were only marginally elevated. We conclude that circulating MIF levels decrease early in blood- 
stage malaria as a result of the decline in circulating lymphocytes.
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INTRODUCTION
Plasmodium falciparum malaria is a leading cause of mortality and morbidity in tropical regions 
with an estimated number of deaths of over 1 million each year [1]. Infection with P. falciparum 
provokes a complex immune response in which the cytokine network plays a central role. A 
strong pro-inflammatory immune response is required for containment of the infection, but 
may also contribute to the pathology of malaria itself. In this respect, pro-inflammatory cyto­
kines have been implicated in the pathogenesis of severe malarial anemia and cerebral malaria
[2]. Proper regulation of the pro- and anti-inflammatory immune responses in malaria is there­
fore of the utmost importance.
In recent years, macrophage migration inhibitory factor (MIF) protein has increasingly been 
recognized as a critical regulator of both innate and adaptive immune responses [3]. Several 
cell types, most notably immune cells and cells of the anterior pituitary gland, secrete MIF in 
response to various stimuli, ranging from endotoxin and Gram-positive exotoxins to inflamma­
tory cytokines and glucocorticoids [3]. Among its diverse actions, MIF mediates the initiation 
and progression of the pro-inflammatory immune response by increasing the secretion of pro- 
inflammatory cytokines while counteracting anti-inflammatory effects of glucocorticoids [4]. 
High MIF secretion has been described in a number of inflammatory, autoimmune and infec­
tious diseases.
MIF has also been implicated in the pathogenesis of several parasitic infections [5, 6]. How­
ever, its role in malaria pathogenesis is still largely unresolved. An inhibitory effect of MIF on 
haematopoiesis has been reported recently, providing a direct link between MIF secretion and 
the pathogenesis of malarial anemia [7]. However, while elevated MIF levels have consistently 
been reported in sepsis and other infectious diseases, data on circulating levels in malaria have 
been conflicting. Field studies in anemic children with clinically overt malaria have shown both 
increased and decreased levels [7-9]. Several confounding factors that are inherent to field stud­
ies, for example, differences in the study population, may have been responsible for these con­
flicting results. In our experimental human P. falciparum malaria model [10], in which volunteers 
are studied prospectively and serve as their own control, the effect of potential confounding 
factors is minimized. In addition, this model allows the study of MIF release in the early stages 
of malaria, that is, in the liver stage that immediately follows the inoculation of parasites by 
mosquitoes and during which parasites multiply in hepatocytes and in the subsequent blood 
stage during which parasites develop and multiply in red blood cells. Given its role as a pivotal 
regulator of immune responses, MIF may especially be of importance in these earliest stages 
of the infection. Therefore, we determined plasma MIF levels over time in healthy volunteers 
that were experimentally infected with P. falciparum and compared levels with lymphocyte and 
monocyte/macrophage numbers, which are important sources of MIF production. Furthermore,
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we determined pro- and anti-inflammatory cytokines as these may be involved in the induction 
and inhibition of MIF secretion, respectively.
MATERIALS AND METHODS
Study subjects, blood samples and experimental malaria infection
The experimental human malaria infection was carried out to study the pathophysiology and 
immunology of early malaria. The current study was one of the objectives of the infection. Ten 
healthy volunteers were infected with P. falciparum parasites as previously described [10]. In 
short, Anopheles stephensi mosquitoes were infected with the NF54 strain of P. falciparum. Vol­
unteers were infected by five P. falciparum infected mosquitoes and followed by thick blood 
smears and assessment of malaria symptoms twice daily from day 4 to day 6 post-infection 
and three times daily from day 6 until initiation of antimalarial treatment. Serial blood samples 
were collected once daily in EDTA-K3 tubes [Becton Dickinson, Rutherford, NJ] at baseline and 
from day 4 post-infection until 3 days after start of antimalarial treatment. Blood samples were 
collected within an as short as possible time of tourniquet application to avoid hemolysis. The 
blood was immediately stored on ice until centrifugation. Plasma was then stored at -80oC. 
Upon microscopic detection of parasites in a thick blood smear, treatment with a standard, six 
dose curative regimen of artemether/lumefantrine was initiated immediately. The Institutional 
Review Board of the Radboud University, Nijmegen Medical Centre approved the protocol [CMO 
2004/129] and volunteers gave written informed consent.
Laboratory investigations
Determination of parasitemia: Three times daily real-time quantitative nucleic acid sequence- 
based amplification [QT-NASBA], as described by Schneider et al. [11] was used for retrospective 
determination of parasitemia. Sensitivity of this NASBA is 20 parasites/mL, which is roughly a 
1000 times more sensitive than standard microscopy.
Plasma MIF, and pro- and anti-inflammatory cytokines: Plasma MIF-concentrations were deter­
mined with an enzyme-linked immunosorbent assay [ELISA], using the 4-span approach, as de­
scribed previously [12]. Interleukin [IL]-1P concentrations were determined with specific radio­
immunoassays as described previously [13]. IL-8 and IL-10 concentrations were measured by 
commercially available ELISA [Pelikine Compact; CLB; Amsterdam, Netherlands]. IL-1P, IL-8 and 
IL-10 levels were determined at MIF nadir.
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Hematological determination: Hemoglobin level, white blood cell counts and differential counts 
were determined on a routine cell counter [Sysmex XE 2100] at baseline and daily from day 4 
post-infection onwards.
Statistical analyses
Data were expressed as means with corresponding 95% confidence intervals [CIs] or standard 
deviations [SDs]. For data with a skewed distribution, medians with ranges or interquartile 
ranges [IQRs] were calculated. Differences in serial MIF levels between two time-points were 
examined by paired t-tests. Correlations between separate variables were examined by Pearson 
correlation analysis. A P-value of < 0-05 indicated a significant difference. Statistical analyses 
were performed with GraphPad Prism software [version 4-0].
RESULTS
Baseline characteristics of volunteers and clinical course
All volunteers were completely healthy and malaria naive. The mean age was 21-5 years (range 
18-23 years) and 7 out of 10 volunteers were female. Results of baseline hematology and chemi­
cal laboratory tests were unremarkable in all volunteers. Baseline mean (range) hematology val­
ues were: hemoglobin level 14 g/dL (range 12-7-15-5 g/dL), platelet number 262 x 109/L (range 
179-340 x 109/L) and leukocyte number 6-2 x 109/L (range 3-2-9-7 x 109/L) with a normal dif­
ferential count in all. Following exposure to P. falciparum infected mosquitoes, all volunteers 
developed parasitemia.
The QT-NASBA became positive after a median time of 7-2 days (range 6-5-9-0 days) post­
infection, indicating onset of blood-stage infection. Antimalarial treatment was started after a 
median time of 10-2 days (range 7^ 3-11-3) - immediately upon microscopic detection of P. fal­
ciparum parasites in a thick blood smear. Median parasite density at treatment initiation was 30 
713 parasites/mL (IQR 5440-243 052 parasites/mL) as determined by QT-NASBA.
Plasma MIF-levels decrease early during infection
Figure 1a shows the time course of the mean plasma MIF levels of the 10 volunteers from base­
line until day 12 post-infection. The mean MIF level decreased significantly during the early 
blood-infection and reached its nadir at day 8 post-infection. The mean ± SD MIF level at day 8 
post-infection was 24-3 ± 6-9 ng/mL as compared to a mean ± SD baseline level of 37-4 ± 10^ 8 
ng/mL (P = 0-0075; paired t-test). Parasitemia was present in 9 of 10 volunteers at this time point, 
as indicated by a positive QT-NASBA. As shown in Figure 1b, plasma MIF levels decreased from 
baseline to day 8 post-infection in each volunteer. In three volunteers, the MIF nadir was not 
reached at day 8 post-infection, but at day 6, day 9 and day 10 post-infection, respectively. From 
day 8 post-infection onwards, there was a gradual increase in the mean MIF level. Antimalarial
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P<  0.05
Days post-infection Days post-infection
Figure 1 (a) Time course of mean (± standard deviation) plasma MIF-levels of 10 volunteers (* data 
from nine volunteers) during experimental P. falciparum infection. Statistical significance determined 
by paired t test. (b) Individual MIF levels of the 10 volunteers at three time points: baseline, day 8 
post-infection and day 10 post-infection. MIF levels in all volunteers decreased over the course of the 
infection.
treatment, which was started in our volunteers between 7-3 and 11-3 days post-infection, de­
pendent on blood slide positivity, did not result in a strong increase in MIF levels. The mean ± 
SD MIF level at treatment start was 27-9 ± 6-0 ng/mL and this increased to 31-1 ± 9-0 ng/mL after 
2 days of treatment (P = 0-32; paired f-test). The log parasite density at the start of antimalarial 
treatment did not correlate with the MIF levels at that moment (Pearson r = 0-18; P = 0-62).
Decrease in circulating MIF parallels to decrease in lymphocytes
Immune cells, most notably T-cells and monocytes/macrophages, are an important source of 
MIF production in vivo [3, 14]. Therefore, a decrease in the number of these cells might account 
for the decrease in circulating MIF. As shown in Figure 2, the lymphocyte number decreased 
early during the course of the infection and this decrease paralleled the decline in MIF levels. Al­
though the kinetics of MIF levels strongly resembled those of the lymphocyte count, our sample 
size was too small to draw any firm statistical conclusions on the correlation between these 
two variables. Monocyte/ macrophage numbers remained unchanged during the course of the 
infection, as did hemoglobin levels (data not shown).
No increased levels of pro- and anti-inflammatory cytokines at MIF nadir
We have reported previously that pro- and anti-inflammatory cytokines increase early during 
experimental P. falciparum malaria [15]. Pro-inflammatory cytokines may be involved in MIF se­
cretion, while the anti-inflammatory cytokine IL-10 was shown to inhibit MIF synthesis in vitro
[16]. Therefore, we determined plasma concentrations of IL-10 and of the pro-inflammatory cy­
tokines IL-1P and IL-8 in the volunteers at day 8 post-infection. Plasma IL-10 and IL-1P concen­
trations were undetectable in 8 of 10 volunteers. In the two volunteers with detectable levels, 
plasma IL-10 levels were 28 and 121 pg/mL, and plasma IL-1P levels were 360 and 26 pg/mL
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Figure 2 Time course of lymphocyte count (solid line) 
and monocyte/macrophage count (dashed line) during 
experimental P. falciparum infection. Data presented are 
mean numbers (± standard deviation) of 10 volunteers.
(IL-10 and IL-1P reference values in healthy volunteers are below 5 pg/mL) and IL-8 levels were 
only marginally elevated with a median (IQR) level of 13 pg/mL (8-5-24-5 pg/mL; reference value 
in healthy volunteers is below 10 pg/mL). Finally, fever (body temperature > 38-0°C) was present 
in 4 of 10 volunteers.
DISCUSSION
The present study shows that plasma MIF levels decrease early during blood-stage infection in 
experimental P. falciparum malaria. Moreover, this decrease parallels a decline in circulating lym­
phocytes. As activated T-cells are a main source of circulating MIF [14], the decline in the num­
ber of circulating lymphocytes may explain our current findings. Peripheral T-lymphocytopenia 
is a common finding in acute malaria and has been reported to resolve within 72 h after the 
initiation of antimalarial treatment [17, 18]. Reallocation of activated T-cells to tissues during 
the acute malaria infection, followed by re-emergence of these cells into the circulating blood 
compartment upon cure, is the most likely explanation for this phenomenon [19, 20]. The exact 
destination of activated lymphocytes in human malaria is still unknown. In murine malaria, lym­
phocytes were shown to migrate to organs like liver and lungs [21]. Fas-induced apoptosis of 
T-cells may also be involved in the development of lymphopenia [22, 23], although an increase 
in plasma MIF levels would be expected in this case due to the release of high amounts of pre­
formed, intracellular MIF.
Reduced MIF production by leukocytes may have contributed to the observed fall in MIF 
levels in our volunteers as well. Acquisition of hemozoin (malaria pigment) by monocytes was 
recently proposed to inhibit peripheral blood MIF production [9]. However, only small amounts 
of hemozoin were probably produced at the submicroscopic parasite densities found in our 
volunteers. The anti-inflammatory cytokine IL-10 has also been implicated in suppression of MIF 
production by activated T-cells [16]. At day 8 post-infection (nadir of mean MIF level), however, 
only 2 out of 10 volunteers had detectable plasma IL-10 concentrations. Therefore, it is unlikely 
that reduced MIF production by leukocytes - as a result of hemozoin or IL-10 - contributed 
significantly to the decreased MIF concentrations in our volunteers. Finally, the pituitary gland
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releases MIF and reduced pituitary secretion might occur in early malaria. However, data pro­
vided by Isidori et al. [24] argue against a role of the pituitary gland as a major contributor to 
circulating MIF.
Several field studies have previously reported conflicting data on circulating MIF levels in 
more advanced stages of malaria. The first report on plasma MIF levels in P. falciparum malaria 
was in women with placental malaria. Compared to peripheral plasma and umbilical cord plas­
ma, intervillous blood MIF levels were significantly elevated [25, 26]. However, no difference in 
peripheral plasma MIF levels was found between women with and without placental malaria. In 
20 anemic Zambian children with acute malaria, however, McDevitt et al. [7] found an increase in 
plasma MIF levels, compared to uninfected hospital controls. In contrast, a small study by Awan- 
dare et al. [8] showed a reduction in both plasma MIF levels and peripheral blood mononuclear 
cell MIF transcripts in anemic Gabonese children with acute P. falciparum malaria. In a larger 
subsequent study with 357 children in Kenya, the same authors reported that plasma MIF levels 
declined progressively with increasing severity of anemia and that elevated levels of hemozoin- 
containing monocytes were associated with decreased MIF production [9]. A functional pro­
moter polymorphism in the MIF gene was, however, not associated with susceptibility to severe 
malaria anemia, although it was associated with high density parasitemia [27]. In a recent study 
in a cohort of healthy children with a history of recent malaria, children with prior mild malaria 
had higher plasma MIF levels and peripheral blood mononuclear cell MIF transcripts than chil­
dren with prior episodes of severe malaria, suggesting that higher basal MIF production might 
protect against development of severe malaria [28].
Several factors, some of them inherent to field studies, may explain the conflicting results 
on MIF levels during acute malaria in previous field studies, such as co-infections with other 
pathogens, use of different MIF-assays, timing of blood sampling and differences in study popu­
lation characteristics, for example, the severity of malaria and the degree of in vivo hemolysis. 
The latter may especially be of importance, since red blood cells contain significant quantities 
of MIF [29]. Lysis of both parasitized and non-parasitized red blood cells is an important feature 
of malaria and may prove to be an important source of circulating MIF, thereby providing a di­
rect link between the degree of malaria-induced hemolysis and inflammatory responses. In our 
experimental human malaria model, the effect of in vivo hemolysis on circulating MIF levels was 
limited, as volunteers developed only low parasitemias without a marked decrease in hemoglo­
bin levels. In addition, the effect of other potentially confounding factors was minimized by the 
fact that volunteers served as their own control.
In summary, we found a significant decrease in plasma MIF levels during early blood-stage 
infection in experimental P. falciparum malaria, which paralleled a significant decline in circulat­
ing lymphocytes and which preceded the presence of detectable concentrations of circulating 
pro- and anti-inflammatory cytokines. As T-cells are a major source of MIF production, we pro­
pose that malaria-induced reallocation of lymphocytes may be responsible for the observed 
decrease in circulating MIF during acute malaria.
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SUMMARY
Background: Premature removal of infected and uninfected red blood cells (RBC) is an impor­
tant pathogenic mechanism of malaria anemia. In order to obtain more insight in this mecha­
nism, we used a newly developed, comparative proteomics technique for a hypothesis-generat­
ing analysis of malaria-induced changes in the RBC membrane protein composition of malaria 
patients from Sumba Island in Indonesia.
Design and Methods: RBC membrane protein fractions were isolated from the blood of two 
Indonesian individuals with P. falciparum malaria and one with P. vivax malaria, and compared 
with the fractions of healthy controls. After one-dimensional gel electrophoresis, the membrane 
proteome was determined using nano-liquid chromatography followed by tandem mass spec­
trometry. Label-free peptide counting was used for semi-quantitative comparisons.
Results: Proteolysis of band 3, which is one of the major integral RBC membrane proteins, and 
increased binding of (denaturated) hemoglobin to the RBC membrane were observed in RBC 
from patients with P. falciparum malaria, but not with P. vivax malaria. Moreover, malaria anemia 
was associated with loss of cytoskeleton proteins.
Conclusions: These data suggest that especially P. falciparum malaria is associated with acceler­
ated RBC aging and provide clues to the mechanisms underlying malaria anemia.
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INTRODUCTION
Anemia is a frequent complication of malaria and responsible for a considerable part of the ma­
laria- associated morbidity and mortality. Plasmodium falciparum is responsible for most malaria 
deaths and severe illness, especially in Sub-Saharan Africa, but Plasmodium vivax may also cause 
severe anemia. Whereas P. falciparum invades red blood cells (RBC) of all ages, high parasitemias 
are rare in P. vivax malaria, probably because RBC invasion is limited to reticulocytes. The etiol­
ogy of malaria-associated anemia is multifactorial and complex [1]. Key mechanisms include 
suppressed erythropoiesis and increased clearance of infected as well as uninfected RBC. The 
latter is especially important as ten uninfected RBC (uRBC) are estimated to be removed for ev­
ery infected RBC (iRBC) [2] and especially loss of uRBC may be responsible for malaria-induced 
anemia [3].
Malaria-induced RBC membrane changes mimicking accelerated senescence have been 
suggested to account for increased removal of uRBC and iRBC [3]. A central membrane protein 
in physiologic cell aging is band 3. This protein is a major integral RBC membrane protein with 
roughly one million copies per cell. Band 3 has binding sites for other membrane proteins such 
as Rhesus proteins, cytoskeletal proteins such as ankyrin, enzymes of the glycolysis such as glyc- 
eraldehyde 3-phosphate dehydrogenase (GAPDH), and hemoglobin [4]. At the end of the RBC 
life span, binding of denatured hemoglobin to the membrane leading to or associated with pro­
teolysis and aggregation of band 3 may lead to opsonization by autologous immunoglobulins 
and complement with subsequent removal of the aged RBC [5].
Cultured P. falciparum iRBC indeed display a stage-dependent deposition of hemoglobin 
denaturation products, clustering of band 3, and deposition of IgG and complement [6, 7]. El­
evated anti-band 3 antibody titers were found in inhabitants of an area with high malaria trans­
mission, and high titers were associated with lower parasite densities and higher hemoglobin 
levels [8]. Altered band 3 may not only make iRBC more immunogenic, but also functions as a 
ligand mediating adherence to endothelial cells [9, 10]. Sequestration is considered a central 
pathogenic mechanism in malaria enabling iRBC to escape removal by the spleen.
So far, studies on changes in band 3 and other membrane proteins in malaria have mainly 
used cultured P. falciparum iRBC [6, 7, 11-13]. Malaria-induced changes in membranes of uRBC 
have largely been neglected. In recent years, new comparative proteomic techniques have be­
come available allowing a detailed quantitative characterization of the composition of the RBC 
membrane and cytoskeleton [14, 15] and we have optimized this technique to study RBC aging 
in vitro and in vivo [16]. In our present, hypothesis-generating study, we used comparative pro- 
teomics and traditional immunochemical methods to perform an in-depth analysis of the RBC 
membrane composition of two Indonesian individuals with P. falciparum malaria and one with 
P. vivax malaria. A sample from a subject with suspected Southeast Asian ovalocytosis (SAO)
99
Chapter 7
was also included, since this RBC disorder results from a deletion in band 3 [17], and offers some 
protection against cerebral malaria in children [18].
MATERIALS AND METHODS
Study participants and ethics
Blood samples were collected from two patients with febrile P. falciparum malaria and one pa­
tient with febrile P. vivax malaria presenting to the Rumah Sakit Karitas Hospital in Weetabula, 
West Sumba, East Nusa Tenggara Province, Indonesia. Their clinical characteristics are sum­
marized in Table 1. All three malaria patients had a high parasite density. One of the patients 
with falciparum malaria had anemia with moderately elevated interleukin (IL)-6 levels and a 
mild thrombocytopenia, while the other patient had no anemia with high IL-6 levels and severe 
thrombocytopenia. SAO is highly prevalent on Sumba and one afebrile individual with a low 
density P. falciparum parasitemia and ovalocytes in the blood smear suggestive for SAO was 
included. Finally, samples from three controls were also used: two from healthy Sumbanese and 
one from a healthy Dutch donor. The Eijkman Institute for Molecular Biology Research Ethics 
Committees (Jakarta, Indonesia) approved collection of blood samples for analysis of band 3 
modifications in RBC membranes.
Sample collection and storage
Thick and thin blood smears were stained with Giemsa and the number of parasites per high 
power microscopy thick film field was determined. A full blood count was determined by a stan­
dard hematology analyzer (Arcus, Diatron, Vienna, Austria). For RBC membrane analysis, three 
ml of venous blood was collected in heparin tubes (Beckton Dickinson). Tubes were centrifuged 
at 800xg for 10 minutes, and plasma and buffy coat were removed. The RBC pellet was washed 
twice with saline and stored at -20oC for several weeks before transport to a facility with a -80 
oC freezer.
Membrane isolation and analysis
RBC membranes were isolated by hypotonic lysis and washed free of loosely attached proteins 
by repeated centrifugation. All subsequent analyses were performed on five microgram of pro­
tein using the protocols and methods described before [15, 19]. Protein was measured with the 
Bio-Rad protein assay, using bovine serum albumin as a standard. After one-dimensional gel 
electrophoresis, samples were either analyzed by immunoblot [4] or submitted to in-slice tryptic 
digestion. Peptide sequencing of tryptic digests was established by nano liquid chromatogra­
phy tandem mass spectrometry using the LTQ-FT ICR (Thermo Fisher, Bremen, Germany) mass 
spectrometer essentially as described previously [16]. The acquired data was searched with the 
Mascot search engine version 2.2 against a concatenated forward and reversed version of the
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Table 1. Characteristics of patients and controls.
Code Group Age(yrs) Sex
Parasite
density*
Hb
(g/dl)
MCV
(fl)
MCH
(pg)
RDW
(%)
Platelets
(x109/l)
WBC
(x109/l)
IL-6
(pg/ml)
F1 P. falciparum 48 F ++++ 12.2 85 27.7 14.5 30 4.2 128
F2 P. falciparum 35 F ++++ 5.6 87 30.3 15.4 134 8.0 14.2
V P. vivax 2 M +++ 7.2 91 27.8 15.4 72 8.0 10.7
S Ovalocytosis/ P. falciparum 17 F + 12.0 88 29.0 13.8 263 9.2 ND
C1 Sumba control 33 F - 13.2 81 28.4 14.7 255 9.2 ND
C2
C3
Sumba control 
Dutch control
18 M - 12.4 87 27.5 13.6 287 5.6 ND
* Parasite density classified as: +, 1-10 parasites per 100 high power microscopic thick film fields; ++, 
11-100 parasites per 100 fields; +++, 1-10 parasites per 1 field; ++++, more than 10 parasites per 1 
thick film field. Hb, hemoglobin; MCV, mean cell volume; WBC, white blood cells; IL-6, interleukin-6; 
SAO, Southeast Asian ovalocytosis; ND, not determined.
P. falciparum PlasmoDB (http://plasmodb.org/plasmo/) version 5.5 supplemented with the hu­
man International Protein Index (IPI) database version 3.52 (ftp://ftp.ebi.ac.uk/pub/databases/ 
IPI/) as described [20]. Processing of the Mascot output was performed with MaxQuant [21](Cox 
J, where we accepted peptides and proteins with a false discovery rate (FDR) better than l %, 
based on the number of accepted identifications of the reversed protein sequences. For pro­
teins identified by 1 peptide, we accepted unmodified peptides with a Mascot score threshold 
of 40 that were unambiguously assigned to one protein by a Mascot peptide delta score larger 
than 10.
Samples of various origins were quantified by the label free peptide counting method em- 
PAI, that calculates protein abundancy and has been applied by us for a quantitative analysis of 
RBC membranes during storage [16].
RESULTS AND DISCUSSION
Immunoblot analysis of the different RBC membrane fractions using a monoclonal antibody 
against the N-terminal, cytoplasmic domain of band 3 showed a large variation in binding pat­
terns (Figure 1). The data indicate increased breakdown of band 3 in the membranes of the circu­
lating RBC pool from both patients with P. falciparum malaria, even though less than 5% of their 
RBC were infected. In contrast, the sample of the P. vivax patient, in which only reticulocytes are 
parasitized, showed a pattern that is routinely observed in control samples with this antibody. 
The sample of the patient with SAO and low-density P. falciparum parasitemia contained hardly 
any intact band 3 (Figure 1). Similar data were obtained with a polyclonal antiserum against the
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Figure 1: Immunoblot analysis of cytoplasmic domain of band 3 in membrane fractions from sub­
jects with P. falciparum or P. vivax malaria (F1, F2 and V), ovalocytosis (S) and healthy controls 
(C). F1: high density, febrile P. falciparum parasitemia without anemia; F2: high density, febrile P. fal­
ciparum parasitemia with anemia; V: febrile P. vivax parasitemia with anemia; S: suspected Southeast 
Asian ovalocytosis with low density P. falciparum parasitemia; C: control (see also Table 1 in Materials 
and Methods). Arrow indicates position of intact band 3 (~95 kDa)
C-terminal part of the membrane domain (data not shown), indicating that these changes in 
band 3 patterns were not caused only by changes in protein conformation.
In the subsequent proteomics analysis, we identified a total of 114 different proteins, com­
prising most major components of the RBC membrane [22]. Malaria parasite proteins were not 
identified. A summary of the quantitative data of the most relevant proteins (Table 2) shows 
three striking findings. First, all patient samples contained considerably less band 3 protein than 
healthy control RBC membranes. Second, in the samples from patients with anemia, there was 
a concomitant decrease in most cytoskeletal proteins of both the ankyrin complex and the 4.1R 
complex. In contrast, the membrane fraction of the patient with febrile P. falciparum malaria 
without anemia (F1) was enriched in spectrin and in the major components of the 4.1R complex. 
Third, there was a strong increase in the association of hemoglobin with the RBC membrane in 
the samples with increased band 3 breakdown in the immunoblot. Extremely high values were 
seen in the samples of the individual with P. falciparum anemia and with SAO; no increased he­
moglobin binding was seen in the sample of the patient with vivax malaria.
Our data do not allow us to unravel the precise sequence of events that have led to the 
observed membrane changes in these samples. Increased formation of hemichromes leading
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to proteolysis of band 3 has previously been described in cultured P. falciparum pRBC [6]. Con­
versely, alterations in band 3 structure may also induce hemoglobin binding to the membrane. 
We found a strong increase in hemoglobin association in the P. falciparum membrane samples. 
Accumulation of denatured hemoglobin during prolonged storage of RBC may induce oxidative 
modifications of cytoskeleton proteins [23]. Thus, oxidative stress may lead to dissociation of 
proteins of the cytoskeleton such as spectrin and ankyrin from the RBC membrane with ongo­
ing P. falciparum infection, associated with a high hemoglobin association and development of 
anemia. In contrast, there was hardly any change in the membrane association of protein 4.2 
and actin. This suggests that binding of the latter proteins with the lipid bilayer may be more 
direct than as a part of the anchoring complexes they participate in [24].The observed changes 
in band 3 may lead to a weakening of the binding between lipid bilayer and cytoskeleton, and 
thereby to loss of membrane by vesiculation. Indeed, enrichment of band 3 and actin with si­
multaneous loss of spectrin and ankyrin has been observed in RBC-derived vesicles of various 
sources [22, 25].
A membrane association of calpain, hsp70 and histone H4 was especially found in the sam­
ple of the individual with the febrile malaria without anemia (F1). The first two are known to be 
associated with proteolytic breakdown and altered protein conformation, respectively. The bio­
chemical cause and functional consequences of the presence of histon H4 in the RBC membrane 
are unclear, but its hemolytic activity warrants further investigation [26].
These semi-quantitative proteomics data support previous observations in vitro that P. fal­
ciparum malaria leads to accelerated aging of both iRBC and uRBC [3]. Proteolysis of band 3 and 
increased hemoglobin binding to the membrane was not observed in the sample of the person 
with P. vivax malaria, which may be due to the selective invasion of reticulocytes in this type of 
malaria. There was a clear discrepancy between the results of the semiquantitative proteomics 
and the immunoblot. The reason why the proteomics analysis showed low band 3 levels in ab­
sence of band 3 proteolysis on the immunoblot is presently unknown. Possible causes of this 
discrepancy may be the anemia of this individual, vivax malaria-related band 3 conformation 
abnormalities, unknown epitope exposure and/or resistance to trypsin breakdown.
The observed changes in the RBC membrane and cytoskeleton of RBC during P. falciparum 
malaria may contribute to the development of malaria anemia through premature recognition 
and removal of uRBC. The membrane changes may also lead to increased RBC rigidity, which 
is associated with compromised microvascular flow [27]. While it is clear that degradation of 
hemoglobin and deposition of parasite proteins on the RBC cell membrane leads to specific 
changes in iRBC [28], the mechanisms responsible for the changes in uRBC during P. falciparum 
malaria are not understood. Considerable amounts of heme, hemin and malaria heme products 
are released during P. falciparum infections, and hemin has been reported to damage RBC mem­
branes [29]. Furthermore, P. falciparum-associated increased oxidative stress may contribute to 
altered RBC structure.
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The severe proteolysis of band 3 in the sample from the individual with ovalocytosis and 
low-density parasitemia suggests that SAO RBC are extra vulnerable for the effects of malaria. 
Indeed, while SAO itself is, in general, not associated with anemia, lower hemoglobin levels and 
a lower degree of ovalocytosis were found in children with SAO during acute malaria, suggest­
ing a selective loss of ovalocytes [30].
Our study is the first to use comparative proteomics to study changes in RBC membranes 
in individuals with malaria. A limitation of this technique is that only few samples could be ana­
lyzed. In addition, the generation of large-scale label-free quantitative data with this technique 
is still in its infancy. Our study should therefore mainly been seen as a hypothesis-generating 
study that provides molecular support for the hitherto largely hypothetical assumptions that 
malaria induces marked alterations in the RBC membrane and cytoskeleton. The present data 
establishes a foundation for future studies on the underlying mechanisms and their clinical con­
sequences. Finally, there is a clear relationship between band 3-mediated RBC removal and RBC 
vesicle formation during physiological aging and pathological RBC removal [22, 31]. Thus, there 
is a need for studies on the composition of erythrocyte-derived vesicles and on the specificity 
and function of RBC-bound IgG in patients with malaria.
In conclusion, loss of uninfected RBC appears an important factor in the development of ma­
laria anemia. Our present study shows that multiple pathological alterations occur in the mem­
brane and the cytoskeleton proteins of the RBC. A better understanding of these alterations is 
needed to unravel the pathogenesis of this devastating condition and to design new therapies.
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Table 2. Comparative proteomic analysis of the RBC membrane fractions.
Control (N=3) F1 F2 S V
ankyrin complex
ankyrin 5.3 6.3 1.1 1.2 0.8
band 3 134.0 38.6 54.4 12.3 12.8
Rh 0.4 0.0 0.3 0.5 0.1
4.2 5.6 6.1 4.9 2.5 2.8
CD47 0.5 1.2 1.3 0.0 0.0
spectrin 9.9 20.2 4.9 3.1 1.2
4.1R complex
4.1R 1.6 8.6 0.6 0.3 0.7
tropomodulin 0.7 0.8 0.0 0.0 0.0
actin 1.6 1.2 1.3 1.3 1.1
adducins 0.5 1.6 0.1 0.1 0.1
dematin 0.3 1.5 0.0 0.0 0.0
p55 0.8 2.6 0.1 0.1 0.0
others
ubiquitin 0.9 0.0 1.1 1.9 0.0
calpain 0.0 0.8 0.0 0.0 0.0
immunoglobulins 0.8 2.1 0.0 0.3 0.3
histone H4 0.0 3.5 1.6 1.6 0.0
small G proteins 0.0 0.7 0.0 0.0 0.0
Hsp 70 0.0 1.9 0.0 0.0 0.0
associated
proteins
GAPDH 1.4 3.8 0.0 0.7 0.3
hemoglobin 5.1 56.2 3286.3 3185.4 3.1
stomatin 1.1 5.3 0.8 0.7 0.5
flotillin-1 0.5 2.8 0.4 0.1 0.1
flottilin-2 1.0 4.0 0.0 0.2 0.0
The concentrations of the major proteins in the membrane fractions were calculated based on the 
proteomic data, and are presented as their emPAI values (see Materials and Methods). The attribu­
tion to ankyrin or 4.1R complex is based on a recent model [24]. Rh, Rhesus protein; Glut1, glucose 
and L-dehydroascorbic acid transporter; Hsp, heat shock protein; GAPDH, glyceraldehyde 3-phoshate 
dehydrogenase.
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SUMMARY
Background. Thrombocytopenia occurs early during malarial infection, but its underlying 
mechanism is unclear. Secretion of von Willebrand factor (vWF) occurs on endothelial cell acti­
vation, and it plays an important role in platelet agglutination.
Methods. In 14 healthy human volunteers who were experimentally infected with Plasmodium 
falciparum, we studied vWF secretion and proteolysis as well as the relationship between chang­
es in circulating platelet numbers and plasma levels of vWF and activated vWF.
Results. Platelet numbers started to decrease between days 7 and 9 after infection, which cor­
responded to the earliest phase of blood-stage infection. With the decrease in platelet numbers, 
levels of vWF, vWF propeptide (markers of chronic and acute endothelial cell activation, respec­
tively), and activated vWF (exposing the glycoprotein-Iba platelet-binding domain) increased 
proportionally. A strong, reciprocal relationship was observed between platelet numbers and 
levels of both vWF and activated vWF. Activity of the vWF-cleaving protease ADAMTS13 (a disin- 
tegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) - a regulator of 
vWF activity - remained unchanged.
Conclusions. P. falciparum induces systemic acute endothelial cell activation and release of ac­
tivated vWF immediately after the onset of blood-stage infection. The resulting platelet aggluti­
nation may result in early thrombocytopenia and may play a role in the pathogenesis of malaria.
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INTRODUCTION
Clinical studies have shown the occurrence of thrombocytopenia in up to 80% of patients with 
malaria [1- 3], and platelet numbers have been negatively correlated with both parasitemia [2] 
and disease severity [4]. We have also observed a significant drop in platelet numbers in healthy 
volunteers who were experimentally infected in our clinic with Plasmodium falciparum. Remark­
ably, this decline started very early during blood-stage infection - at the time when parasite 
densities were still at a submicroscopic detection level and before symptoms of malaria were 
present. Platelets may play a significant role in the pathogenesis of malaria. Platelet accumula­
tion in the brain microvasculature has been described in children who died of cerebral malaria
[5]. Intravascular platelet agglutination with increased platelet clearance from the circulation 
can be induced by activated high-multimeric von Willebrand factor (vWF). Elevated levels of 
vWF have been reported in field studies of patients with malaria [6-8], but its role in malaria- 
induced thrombocytopenia and platelet clumping is not known.
vWF is a large, multimeric glycoprotein that functions as a carrier for factor VIII and as a 
bridging molecule for platelet adhesion and aggregation. It is predominantly produced in 
vascular endothelial cells, in which it undergoes extensive processing after synthesis, includ­
ing dimerization, multimerization, and endoproteolytic cleavage of a propeptide. Large vWF 
multimers and vWF propeptide are stored in specialized granules called Weibel-Palade bodies
[9], which are released during endothelial cell activation. Therefore, both vWF and vWF pro­
peptide serve as markers of endothelial cell activation, although vWF propeptide reflects acute 
endothelial cell perturbation because of its shorter half-life. After release from Weibel-Palade 
bodies, vWF multimers are rapidly proteolyzed to smaller and less-active forms by the plasma 
metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 
1 motif, member 13) [10]. At least some released vWF is in an activated conformation, which 
allows interaction with the platelet receptor GPIba [11]. Determination of activated vWF levels 
recently became possible with the introduction of a novel, llama-derived nanobody (AU/VWFa- 
11) that specifically recognizes the vWF GPIba -binding conformation [12]. Increased amounts 
of activated vWF were subsequently demonstrated in the plasma of patients with thrombotic 
thrombocytopenic purpura (TTP) [12]. This disease shares some similarities with malaria: intra­
vascular platelet agglutination with thrombocytopenia, non-immune hemolysis, neurological 
symptoms, and fever.
Vascular endothelial cell activation is considered a common feature of malaria and plays 
an important role in the pathogenesis of malaria by increasing sequestration of parasitized red 
blood cells in the peripheral vasculature [6, 13, 14]. We hypothesized that endothelial cell activa­
tion with subsequent release of activated vWF is an early event in malaria and is related to the 
development of early thrombocytopenia. Therefore, we studied the role played by endothelial
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cell-derived activated vWF in malaria-induced thrombocytopenia in healthy volunteers who 
were experimentally infected with P. falciparum.
SUBJECTS, MATERIALS, AND METHODS
Experimental malarial infection, study subjects, and blood sampling
Experimental human malarial infections are invaluable for phase 2a malaria-vaccine trials and 
are a powerful tool for the study of the pathophysiology and immunology of early malaria. By 
use of a stringent protocol, experimental human malarial infections have been proven to be 
reliable, safe, and generally well tolerated [15, 16]. In addition to malaria-induced thrombocyto­
penia, the current experimental infection was used to study immunological responses during 
early P. falciparum malaria. Fourteen healthy volunteers with no previous exposure to malaria 
were selected and infected with P. falciparum parasites as described elsewhere by Verhage et 
al. [16]. In short, Anopheles stephensi mosquitoes were maintained in the insectary at the animal 
house of the Radboud University Nijmegen Medical Centre and were infected with the NF54 
strain of P. falciparum. Batches with >90% infected mosquitoes were used for the experimental 
human infection. Volunteers were infected by 5 P. falciparum-infected mosquitoes and were 
followed-up via thick blood smears and assessment of malarial symptoms twice a day from day 
4 to 6 after infection. From day 6 until 3 days after initiation of antimalarial treatment, these 
assessments were done 3 times a day. Serial blood samples were collected once daily in 4-mL 
vacutainer glass tubes containing 48 |jL of EDTA-K (BD Diagnostics) at baseline, from day 4 af­
ter infection until 3 days after the start of antimalarial treatment, and on days 21 and 42 after 
infection. After centrifugation, plasma was stored at -80oC. All assays were performed on freshly 
thawed samples. Plasma from 40 healthy donors was used as a control (normal pooled plasma 
[NPP]). For the determination of ADAMTS13 activity, heparin plasma from baseline and from day 
8 after infection was used.
Treatment with a standard 6-dose curative regimen of artemether-lumefantrine was imme­
diately initiated on microscopic detection of parasites in a thick blood smear. The Institutional 
Review Board of the Radboud University Nijmegen Medical Centre approved the protocol (CMO 
2004/129), and volunteers provided written informed consent.
Quantitative nucleic acid sequence-based amplification (QT-NASBA) and vWF, vWF 
propeptide, activated vWF, and ADAMTS13 activity
Three times daily, real-time QT-NASBA, as described by Schneider et al. [17], was used for ret­
rospective determination of parasitemia. The sensitivity of this assay is 20 parasites/mL and is 
—1000 times more sensitive than standard microscopy. vWF and vWF propeptide levels were 
determined at baseline and from the last day before the onset of blood-stage infection (as as­
sessed by QT-NASBA) until 2 days after the start of antimalarial treatment. vWF levels were de-
112
von Willebrand Factor during Early Malaria
Figure 1. Kinetics of Plasmodium falciparum par­
asitemia before antimalarial treatment. Fourteen 
healthy volunteers were experimentally infected 
with P. falciparum. Data are mean ± SD values 
for parasitemia before antimalarial treatment, 
as determined by real-time quantitative nucleic 
acid sequence-based amplification. Shown in 
parentheses are the nos. of volunteers tested at 
□ays after experim ental infection the indicated time points.
termined as described elsewhere [18]. vWF propeptide levels were measured as described by 
Borchiellini et al. [19]. Levels of activated vWF were measured using the AU/VWFa-11 nanobody, 
as described by Hulstein et al. [12]. The relative amount of activated vWF was determined by cal­
culating the ratio of the absorbance slope of a plasma sample to the slope of the corresponding 
baseline sample and then correcting for the amount of vWF. ADAMTS13 activity was determined 
at baseline and on day 8 after infection by the FRETS-VWF73 assay (Peptides International) [20], 
in accordance with the manufacturer's protocol. NPP was used as a standard.
Statistical analysis
Platelet number and vWF, vWF propeptide, activated vWF, and ADAMTS13 activity were ex­
pressed as percentage of baseline values, and each participant served as his or her own control. 
Means with corresponding 95% confidence intervals (CIs) or SDs were calculated for normally 
distributed data, whereas medians with ranges were determined for data with a skewed distri­
bution. Changes in serial levels of vWF and vWF propeptide during the course of the infection 
were tested by repeated-measures analysis of variance, and the Wilcoxon matched-pairs test 
was used for activated vWF. Relationships between the separate variables were examined by 
Pearson's correlation analysis or by the nonparametric Friedman test for non-normally distribut­
ed data. The sample size allowed detection of a minimal increase in activated vWF levels of 50%, 
with a power of >80%. P< .05 was taken to indicate a significant difference. Statistical analyses 
were performed with GraphPad Prism for Windows (version 4.0; GraphPad Software).
RESULTS
Clinical course of volunteers and platelet number in time
After exposure to P. falciparum-infected mosquitoes, all 14 volunteers developed parasitemia. 
The QT-NASBA became positive after a median time of 7.0 days (range, 6.0-9.0 days) after infec­
tion and showed increasing parasitemia before the initiation of antimalarial treatment (figure 
1). Treatment was started after a median time of 9.65 days (range, 7.3-11.3 days) immediately 
on microscopic detection of P. falciparum parasites in a thick blood smear. As shown in figure 2,
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Figure 2. Kinetics of platelet nos. during early 
Plasmodium falciparum blood-stage infection. 
Fourteen healthy volunteers were experimentally 
infected with P. falciparum. Data are mean ± SD 
values for relative platelet no. (expressed as the 
percentage of the baseline value) during early 
blood-stage infection. The mean absolute platelet 
no. at baseline was 249 x 109 platelets/L (95% con­
fidence interval, 222 x 109-2 76 x 109 platelets/L). 
Changes in relative platelet nos. throughout the 
infection were significant (P < .0001, repeated- 
-1 0 1 2 3 4 5 6 measures analysis of variance). *Mean for 10 vol- 
Days after onset of blood-stage infection unteers; ** mean for 8 volunteers.
mean platelet numbers started to decrease almost immediately after the onset of blood-stage 
infection, reaching a nadir of 58.6% (95% CI, 46.8%-70.4%) of the baseline value. Successful an- 
timalarial treatment was followed by a rebound thrombocytosis, reaching a mean peak level of 
142% (95% CI, 130.2%-154.4%) of the baseline value on day 21 after infection before returning 
to normal on day 42 (data not shown). Hemoglobin levels remained unchanged throughout the 
infection (data not shown).
Time course of vWF, vW F propeptide, and activated vW F levels
Figure 3/4 shows the kinetics of plasma vWF levels during early blood-stage infection in the 14 
volunteers. Plasma vWF levels started to increase almost immediately after the onset of blood- 
stage infection, reaching a mean peak plasma level of 173% (95% CI, 116%—230%) of the base­
line value. The range of individual peak levels was 115%-385% of the baseline value. vWF pro­
peptide levels followed a similar kinetic pattern (figure 3B), with a mean peak plasma level of 
166% (95% CI, 133%-200%) of the baseline value and with individual peak levels ranging from 
129% to 340% of the baseline value.
By use of AU/VWFa-11, a recently developed nanobody that specifically recognizes the 
GPIba-binding conformation of the vWF A1 domain [12], we determined the amounts of ac­
tivated vWF present at 3 time points during the infection: (1) baseline; (2) the day of the first 
significant decrease in platelet number, defined as a decline of at least 20 x 109 platelets/L com­
pared with the previous day; and (3) the day of platelet nadir. Figure 4 shows the change in the 
amount of activated vWF in individual volunteers. On the day with the first significant decrease 
in platelet number, the median level of activated vWF was 140% (range, 59%-410%) of the base­
line value, whereas on the day of platelet nadir it was 261% (range, 57%-1370%) of the baseline 
value.
125-i
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Figure 3. Kinetics of von Willebrand factor (vWF) 
and vWF propeptide during early Plasmodium 
falciparum blood-stage infection. Fourteen 
healthy volunteers were experimentally in­
fected with P. falciparum. Data are mean ± SD 
values for relative levels (expressed as the per­
centage of the baseline value) of vWF (A) and 
vWF propeptide (B) during early blood-stage 
infection. Mean absolute baseline levels of vWF 
and vWF propeptide were 35.3 nmol/L (95% 
confidence interval [CI], 26.5-44.0 nmol/L) and 
5.8 nmol/L (95% CI, 5.1-6.6 nmol/L), respective­
ly. Changes in both vWF and vWF propeptide 
during the course of infection were significant 
(P <.0001, repeated-measures analysis of vari­
ance). *Mean for 11 volunteers.
ADAMTS13 activity
To determine whether a decrease in ADAMTS13 activity could account for the increased levels 
of activated vWF, we quantitatively measured ADAMTS13 activity at baseline and on day 8 after 
infection in the 14 volunteers. The mean ADAMTS13 activity on day 8 after infection was 99.9% 
(range, 83%-127%) of pre-infection activity (data not shown). Therefore, the elevated levels of 
activated vWF could not be explained by decreased proteolysis of large vWF multimers.
Relationship between platelet numbers, parasitemia, and levels of activated vWF.
To examine whether levels of vWF and activated vWF were related to the change in platelet 
numbers, we plotted the relative levels of these variables (expressed as a percentage of their 
corresponding baseline value) against each other. During the course of blood-stage infection, 
serial vWF levels showed a strong inverse relationship (Pearson's r = -0.62 [95% CI, -0.74 to 
-0.47]; P< .0001)) with corresponding platelet numbers on that same day (figure 5A). During 
platelet nadir, a similar strong association (Pearson's r = -0.61 [95% CI, -0.86 to -0.11]; P = .021) 
was found between relative vWF levels and corresponding platelet numbers (figure 5B). More­
over, relative levels of activated vWF were significantly related (Spearman's r = -0.75 [95% CI,
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-0.92 to -0.35]; P = .002) to platelet numbers on that day (figure 5Q. The degree of parasitemia 
(expressed as the log number of parasites per milliliter of blood) from the onset of parasitemia 
until the start of antimalarial treatment correlated weakly (Pearson's r = 0.374 [95% CI, 0.13 to 
0.58]; P = .0035) with corresponding relative vWF levels (data not shown).
DISCUSSION
In the present study, we demonstrated that vWF and vWF propeptide secretion were signifi­
cantly increased at a very early stage in P. falciparum blood-stage infection, pointing at acute 
endothelial cell activation in malaria. Increased amounts of activated vWF, exposing the GPIba- 
binding site of vWF for platelets, were observed as well. Platelet numbers and levels of both vWF 
and activated vWF showed a strong inverse correlation in our small group of volunteers. Acti­
vated vWF may therefore be an important inducer of thrombocytopenia during early malaria 
and may as such contribute to the pathogenesis of malaria.
We are the first to demonstrate increased levels of activated vWF in an infectious disease. 
Levels of activated vWF in our volunteers were comparable to levels found during TTP and dur­
ing the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome [12, 21]. These 
diseases are characterized by consumptive thrombocytopenia with intravascular platelet adhe­
sion and clumping. Our present findings of a very early decrease in platelet number, together 
with elevated levels of activated vWF, suggest that early intravascular platelet adhesion and 
clumping may also be a prominent and unique feature of malaria. Circumstantial evidence for 
this was provided by an autopsy study from Malawi that showed increased platelet accumu­
lation in the brains of children who died of cerebral malaria, compared with that in children 
who died of nonmalarial encephalopathy [5]. In addition, electron microscopy studies have also 
demonstrated platelet adherence to brain endothelial cells during both human and murine 
cerebral malaria [22, 23]. Besides causing thrombocytopenia, vWF-mediated platelet clumping 
may contribute to the pathogenesis of malaria in several ways. First, adhering and aggregating 
platelets may cause organ perfusion failure and tissue hypoxia. Second, vWF may play a role
Figure 4. Levels of activated von Willebrand factor 
(vWF) during early Plasmodium falciparum infection. 
Fourteen healthy volunteers were experimentally 
infected with P falciparum. Data are relative levels 
(expressed as the percentage of the baseline value) 
of activated vWF at 3 time points: baseline, the day 
of the first significant decrease in platelet no. (de­
fined as a decline of at least 20 x 109 platelets/L com­
pared with the previous day), and the day of platelet 
nadir. *Wilcoxon matched-pairs test.
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Figure 5. Relationship between change in platelet 
nos. and plasma levels of von Willebrand factor 
(vWF) and activated vWF. Fourteen healthy vol­
unteers were experimentally infected with Plas­
modium falciparum. A, Serial vWF levels during 
early blood-stage infection against corresponding 
platelet nos. B, vWF levels against platelet nos. on 
the day of platelet nadir. C, Activated vWF levels 
against platelet nos. on the day of platelet nadir.
in the cytoadherence of parasitized red blood cells to vascular endothelium during the early 
stages of malaria. Multiple endothelial receptors are involved in this process, most notably CD36 
and intercellular adhesion molecule-1. However, up-regulation of these endothelial receptors 
takes time, because they require de novo synthesis. In contrast, stored activated vWF can imme­
diately be secreted from endothelial cells with subsequent binding of platelets. It has recently 
been demonstrated that platelets may facilitate cytoadherence by acting as bridges between 
parasitized red blood cells and endothelial cells [24]. Last, vWF-mediated platelet adhesion may 
be important in brain microvessels that express only a little CD36 [14]. Platelets expressing high 
levels of CD36 could deliver the required CD36 in these situations.
We know of three cross-sectional studies that have previously analyzed vWF concentrations 
in patients with malaria, and all found elevated levels. In a report from 1985 [7], the inverse rela­
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tionship between vWF levels and platelet numbers was demonstrated. The authors concluded 
that thrombocytopenia during malaria is not indicative of disseminated intravascular coagula­
tion but may relate to endothelial damage. In the other 2 studies [6, 8], the relationship between 
vWF and platelet number was not reported. Therefore, previous results are in line with our find­
ings but, also because of the nature of these studies, fail to conceptualize the idea that vWF- 
mediated platelet clumping plays an important role in the development of thrombocytopenia 
and in the pathogenesis of malaria. The experimental human malarial infection model, however, 
enables comparison of the kinetics of these variables during the very early stages of malaria. 
This allows a more reliable assessment of the direct effect of P. falciparum on endothelial cells 
and platelets. In addition, several other pathogenic mechanisms for malaria-induced thrombo­
cytopenia during more advanced stages of malaria have been suggested, such as splenic se­
questration [25], oxidative stress [26], platelet apoptosis [27], and antibody- and cell-mediated 
immunity [28-30]. In our volunteers, however, platelet numbers decreased at such an early time 
point during the infection that it is highly unlikely that these mechanisms could have played 
a significant role. Activation of the coagulation system may also cause platelet consumption. 
However, the coagulation is usually only mildly activated during malaria, and disseminated in­
travascular coagulation is rare, even during severe malaria [31].
Because both vWF and vWF propeptide are predominantly synthesized in vascular endothe­
lial cells and are released on endothelial cell activation [32], the rise in circulating vWF and vWF 
propeptide levels in our volunteers, during or shortly after the release of malarial parasites from 
the liver, provides evidence for acute endothelial cell activation at this early time point. Although 
we use the term "endothelial cell activation" to describe changes in endothelial cell phenotype 
that result in vWF release, we realize that endothelial cell pathophysiology is complex and that 
changes may encompass a spectrum ranging from simple perturbation to activation and even 
endothelial cell damage. Early endothelial cell activation may be critical during the early stages 
of malaria. Sequestration of parasitized red blood cells containing the more mature stages of the 
malarial parasite is important for parasite survival. We have previously demonstrated that the 
mean asexual life cycle of malarial parasites is 43.7 h and have provided evidence that parasit­
ized red blood cells indeed adhere to vascular endothelium within 2 days after release from the 
liver [33]. In this way, early removal and destruction by the spleen is avoided. Early endothelial 
cell activation probably facilitates this sequestration by, for example, up-regulating endothelial 
adhesion molecules and vWF release.
The trigger for the early endothelial cell activation and vWF release in our volunteers is un­
clear. Inflammatory cytokines are known endothelium agonists [34] and have been shown to 
directly stimulate the release of vWF from endothelial cells or to inhibit ADAMTS13 [35]. We have 
shown in the past that levels of proinflammatory cytokines started to increase 1-2 days before 
treatment initiation during experimental malaria [36]. Alternative mechanisms may also be in­
volved in the initiation of endothelial cell activation and vWF release. A still undetermined fac­
tor released at the end of liver schizogony or, alternatively, malarial parasite products could be
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potential candidates. One of these parasite products, glycosylphosphatidylinositol anchors, has 
already been linked to endothelial cells by its potential to induce cytokine production and up- 
regulate the expression of endothelial adhesion molecules directly [37]. P. falciparum parasitized 
red blood cells also have the capacity to directly stimulate human endothelial cells [38]. How­
ever, it is important to realize that, at the time when levels of vWF and vWF propeptide started 
to rise, only a very small percentage of erythrocytes (estimated at <0.001%) were infected and 
that malarial antigen levels, including of glycosylphosphatidylinositol, were probably still low.
Plasma concentrations of vWF are influenced by blood group. Subjects with blood group O 
have ~30% lower levels of vWF than do those with blood group A, B, or AB [39]. Subjects with 
blood group O are relatively resistant against severe malaria [40]. Our hypothesis that vWF is 
involved in the pathogenesis of malaria may thus offer an additional explanation for this phe­
nomenon. In our small group of 14 volunteers, there was no significant difference in median 
vWF levels between the 7 volunteers with blood group O and the 7 with blood group non-O 
(data not shown).
In conclusion, our findings suggest that P. falciparum induces systemic acute endothelial cell 
activation and release of activated vWF immediately after the onset of the blood stage of the 
infection. The phenomenon may be responsible for the early thrombocytopenia and may play a 
role in the pathogenesis of malaria by providing a link between parasitized red blood cells and 
endothelial cells.
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SUMMARY
A deficiency in ADAMTS13 (a von Willebrand factor [VWF] cleaving protease) is associated with 
accumulation of prothrombogenic unusually large VWF multimers (UL-VWF) in plasma. We stud­
ied VWF release and proteolysis in patients with symptomatic Plasmodium falciparum or P. vivax 
malaria on the Indonesian island Sumba. Malaria patients had significantly lower platelet counts 
and higher VWF concentrations and VWF activation factors than healthy hospital staff controls. 
The latter indicates that a higher amount of circulating VWF was in a conformation enabling 
spontaneous platelet binding. In addition, ADAMTS13 activity and antigen levels were reduced 
in both malaria groups, and this was associated with the appearance of UL-VWF. The mechanism 
behind this reduction and the role in malaria pathogenesis needs to be further elucidated. In 
malaria, endothelial cell activation with increased circulating amounts of active and ultra-large 
VWF, together with reduced VWF inactivation by ADAMTS13, may result in intravascular platelet 
aggregation, thrombocytopenia, and microvascular disease.
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INTRODUCTION
Malaria remains an important cause of morbidity and mortality in the tropics with an estimated 
number of 500 million cases and 1-3 million deaths each year. Although the exact pathogen­
esis of malaria is still incompletely understood, it is well known that thrombocytopenia and 
endothelial cell activation are prominent features of clinical Plasmodium falciparum malaria and 
that platelet-endothelium interactions may play an important role in its complications, such as 
cerebral malaria [1-4].
We have previously shown in healthy volunteers participating in an experimental human 
P. falciparum infection that the decline in platelet numbers was associated with the onset of 
endothelial cell activation and with an increase in the amount of active von Willebrand factor 
(VWF)— i.e., the amount of VWF that has undergone a conformational change from a latent state 
to a state enabling spontaneous binding of platelets [5, 6]. VWF is predominantly synthesized by 
endothelial cells and stored in specialized granules, called Weibel-Palade bodies. VWF mediates 
platelet adhesion and aggregation at sites of vessel injury. Both the multimeric size and the con­
formation of VWF determine its activity, whereby ultra-large and elongated VWF multimers in­
teract best with platelets. Under normal conditions, ADAMTS-13 (a disintegrin and metallopro- 
teinase with thrombospondin-1-like domains) rapidly cleaves ultra-large and prothrombogenic 
VWF multimers (UL-VWF) [7]. UL-VWF accumulation caused by absent or markedly reduced AD- 
AMTS13 activity is characteristic for the rare microangiopathic disease thrombotic thrombocy­
topenic purpura (TTP) [8], highlighting the physiologic importance of ADAMTS13 cleavage of 
UL-VWF in humans. In recent years, an acquired ADAMTS13 deficiency has also been described 
in various other pathologic conditions [9], such as sepsis and diffuse intravascular coagulation 
[10, 11]. Mutations or polymorphisms in the ADAMTS13 gene may also account for reduced plas­
matic ADAMTS13 activity. A gene polymorphism (P475S; rs11575933) that impairs ADAMTS13 
activity is common in Japan (allelic frequency, 5.1%), but rare in China (1.7%) and Europe (0.5%) 
[12-14]. No other common functional polymorphisms have been identified thus far.
In our experimental human P. falciparum malaria model in healthy Dutch volunteers, we 
found no changes in ADAMTS13 activity levels during the pre-clinical and early clinical stages 
of malaria, when parasitemia levels were still below microscopy detection level [5]. However, we 
hypothesized that secondary ADAMTS13 deficiency may occur in later stages of clinical malaria, 
in which they may contribute to the development of thrombocytopenia and organ dysfunction, 
like in other systemic microangiopathic diseases [9]. Moreover, although thrombocytopenia and 
organ dysfunction are also observed in P. vivax malaria [15-17], no data are available on VWF 
secretion and proteolysis in P. vivax malaria, whereas this infection is highly prevalent in Asia 
and South America and is responsible for considerable morbidity and mortality [18]. Therefore, 
the aim of this study was to determine levels of VWF, active VWF, and ADAMTS13 and its relation 
with thrombocytopenia in subjects with symptomatic P. falciparum or P. vivax malaria on the
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Indonesian island Sumba. These levels were compared with those of healthy controls. Factors 
associated with ADAMTS13 activity, such as the multimeric size of VWF, the presence of AD- 
AMTS13 inhibitors, the relation with endothelial cell activation and inflammatory markers, and 
the occurrence of the P475S mutation and other mutations in the ADAMTS13 gene on Sumba 
were also studied.
MATERIALS AND METHODS
Study area, study population, and ethics
This study was conducted from April to August 2007 at the Rumah Sakit Karitas Hospital in 
Weetabula, West Sumba, East Nusa Tenggara Province, Indonesia, an area of unstable P. falci­
parum and P. vivax malaria transmission [19]. Consecutive subjects presenting to hospital with 
clinical symptoms of malaria and a P. falciparum or P. vivax parasite density of at least 2,500 and 
500 parasites/^L, respectively, were enrolled. Healthy, asymptomatic Sumbanese controls with 
a negative blood slide were recruited among hospital staff from Weetabula, which can be char­
acterized as a low malaria transmission area. In addition, a group of asymptomatic Sumbanese 
subjects with a negative malaria blood slide were selected from a remote village, located in a 
high malaria transmission area. To screen for the occurrence of common polymorphisms in the 
ADAMTS13 gene in the Sumbanese population, DNA from 71 Sumbanese individuals was used. 
This group consisted of villagers participating in a cross-section malariometric survey and of the 
above-mentioned asymptomatic Sumbanese controls and the hospital staff controls. The whole 
ADAMTS13 gene was sequenced in five subjects from this group. Healthy Dutch controls were 
recruited among laboratory staff and students. Finally, plasma from five Dutch TTP patients was 
used. Diagnostic criteria for TTP were the presence of thrombocytopenia with microangiopathic 
hemolysis and no detectable ADAMTS13 activity. This study received ethical approval for the use 
of human subjects from the Eijkman Institute for Molecular Biology Research Ethics Commit­
tees (Jakarta, Indonesia) and of the medical ethical committee of the University Medical Center 
Utrecht for use of TTP patient plasma for research purposes. All study participants - or parent or 
guardian in case of children -gave written informed consent to participate in this study.
Sample collection
Venous blood was collected before administration of antimalarial drugs and/or any other treat­
ment. Blood collected in EDTA tubes (Becton-Dickinson Vacutainer Systems, Rutherford, NJ) was 
used for determination of a full blood count; blood collected in CTAD tubes (Becton-Dickinson 
Vacutainer Systems; tubes containing citrate and the platelet stabilizing agents theophylline, 
adenosine, and dipyridamole) was used for coagulation and endothelial cell activation marker 
assays and determination of interleukin (IL)-6 concentration. Blood collected in heparin tubes 
was used for detection of anti-ADAMTS13 autoantibodies. All samples collected in the hospital
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were centrifuged at 3,500 rpm for 10 minutes and frozen at -20°C until further analysis. Double 
centrifugation to obtain platelet-poor plasma is not necessary with the CTAD system. For normal 
pooled plasma, platelet-depleted plasma of 40 healthy Dutch volunteers was pooled and stored 
in aliquots at -80°C.
Laboratory procedures
Determination of parasitemia and full blood count. Thick and thin blood smears were stained 
with Giemsa, and the number of parasites was quantified against 200 white blood cells. Parasite 
density was calculated assuming a white blood cell count of 8,000/^L. A full blood count was 
determined by a standard hematology analyzer (Arcus, Diatron, Vienna, Austria).
VWF and ADAMTS13 antigen and activity assays. VWF concentrations were determined by en­
zyme-linked immunosorbent assay (ELISA) as described previously [20]. Active VWF was deter­
mined by ELISA using a nanobody (AU/VWFa-11) that specifically recognizes the GP1b binding 
configuration of VWF, as described previously [6]. The multimeric pattern of VWF was analyzed 
using 2% agarose gel electrophoresis, followed by immunoblotting according to Raines and 
others [21]. ADAMTS13 activity was determined using the fluorescence resonance energy trans­
fer (FRETS) assay for ADAMTS13 activity (Peptides International, Lexington, KY) [22], whereby 
the ADAMTS13 activity of normal pool plasma was set at 100%, and the values obtained in study 
participant samples were expressed as percentage of normal pool plasma. ADAMTS13 activity 
was also determined by a VWF proteolysis assay as described previously [23]. Briefly, proteolysis 
of recombinant VWF (IIbQ) by study participant plasma samples was compared with normal 
pool plasma in the absence and presence of EDTA, which is known to inactivate ADAMTS13. In 
this assay, ADAMTS-13 activity is taken to be absent in case ultra-large VWF multimers remain 
visible after proteolysis. ADAMTS13 antigen levels were measured by a commercially available 
ELISA according to the instructions of the manufacturer (American Diagnostica, Stamford, CA).
ADAMTS13 inhibitors assays. Presence of ADAMTS13 inhibitors was determined by measuring 
the residual ADAMTS13 activity of normal pool plasma after incubation with plasma of study 
participants (volume ratio 1:1) at 37°C for up to 3 hours. Presence of anti-ADAMTS13 IgG anti­
bodies in plasma was measured using the Technozym inhibitor ELISA (Technoclone, Vienna, 
Austria), according to the manufacturer's instructions. In our laboratory, the upper limit of nor­
mal is a titer of 25 U/mL. A modification of this assay was used to detect the presence of IgM 
or IgA anti-ADAMTS autoantibodies. Anti-IgM and anti-IgA were added, instead of anti-IgG, as 
secondary detection antibody, and their OD values were compared with healthy hospital staff 
controls.
Mutations in theADAMTS13gene. DNA was extracted from whole blood using the Chelex-100 ion 
exchanger (BioRad Laboratories, Hercules, CA). Presence of the P475S genotype was determined
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using fluorescence-based genotyping (Assay on Demand; Applied Biosystems, Nieuwerkerk a/d 
IJssel, The Netherlands), as described in detail previouslye [24]. From five subjects, the exons of 
the ADAMTS13 gene, including part of the intronic boundaries, were amplified by PCR on an 
ICycler PCR machine (Biorad Laboratories, Veenendaal, The Netherlands). Primers and PCR con­
ditions are available on request. PCR products were purified using the High Pure PCR product 
purification kit (Roche Applied Science, Mannheim, Germany) and sequenced in both directions 
using the BigDye Terminator kit version 3 (Applied Biosystems) and a 3730 or 3100 DNA Ana­
lyzer (Applied Biosystems).
Measurement of sICAM-1 and IL-6. Concentrations of soluble intercellular adhesion molecule-1 
(sICAM-1) and IL-6 were determined by sandwich ELISA technique using anti-human sICAM-1 
(R&D DuoSet ELISA Development Systems) and antihuman IL-6 antibodies (ImmunoTools, 
Freiburg, Germany).
Statistical analysis
Data are presented as median followed by interquartile range in parentheses unless otherwise 
stated. Differences between more than two groups were assessed by Kruskal-Wallis test for 
quantitative variables with the Dunn procedure for pairwise comparisons. Mann-Whitney U test 
was used for comparisons between two groups. Relationships between laboratory parameters 
were assessed using the Pearson or Spearman correlation coefficient, depending on whether 
parameters were normally distributed. All analyses were performed with SPSS version 15.0 for 
Windows.
RESULTS
Demographic and laboratory characteristics
Characteristics of the patients presenting to hospital with P. falciparum malaria or P. vivaxmalaria 
and the healthy hospital staff controls are shown in Table 1. Two patients had severe P. falci­
parum malaria according to World Health Organization criteria (hyperparasitemia). All hospital 
staff controls were adults, whereas 52% of the malaria patients were < 18 years of age. Thrombo­
cytopenia was a common finding in both P. falciparum and P. vivax malaria patients, and platelet 
numbers were significantly lower in the malaria patients than in hospital staff controls. Levels 
of the proinflammatory cytokine IL-6 and the endothelial cell activation marker sICAM-1 were 
significantly higher in both malaria groups than in hospital staff controls. In the malaria groups, 
no significant differences were present between children and adults in platelet number or in 
concentrations of measured mediators (data not shown).
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Table 1. Demographic and laboratory characteristics of study participants.
P. falciparum malaria P. vivax malaria Hospital staff controls P
Number of subjects (N) 26 16 11
Sex (% female) 50.0 50.0 90.9
Age (years) 20.0 (3.8-37.3) 11.0 (2.1-25.3) 25.5 (21.2-30.8) 0.066*
Parasitemia (parasites/pL) 3,240 (2,420-8,200) 880 (800-1,240) 0 < 0.001 +
Hemoglobin level (g/dL) 9.3 (7.9-12.2) 11.6 (9.9-13.2) 13.2 (11.3-13.4) 0.009*+
Platelet count (x109/L) 122 (70-154) 117 (77-220) 237 (172-258) < 0.002*+§
Thrombocytopenia (%)1 69.2 50.0 9.1
White blood cell count (x109/L) 6.3 (5.0-8.0) 7.6 (6.2-8.6) 7.7 (6.6-9.4) 0.114*
Lymphocytes (x109/L) 0.9 (0.6-1.7) 1.8 (1.4-3.7) 2.1 (1.9-2.7) 0.001*+
Granulocytes (x109/L) 4.4 (3.4-6.3) 4.3 (3.4-5.8) 4.0 (3.6-5.6) 0.985*
Interleukin-6 (pg/mL) 28.1 (2.0-87.5) 9.2 (2.0-45.6) NA** 0.659+
sICAM-1 (pg/mL) 245.7 (213.7-283.4) 190.5 (141.8-402.5) 123.3 (94.6-140.4) < 0.001*+§
Data are median (interquartile range) unless otherwise specified. NA, not applicable; sICAM-1, soluble 
intercellular adhesion molecule-1.
* Differences between three groups by Kruskal-Wallis test, with post hoc testing by the Dunn proce­
dure.
t  Mann-Whitney U test.
* P < 0.05 between P. falciparum and control group.
§ P < 0.05 between P. vivax and control group.
1 Thrombocytopenia defined as platelet number < 150 x 109/L.
** Below assay's detection limit in all.
VW F antigen concentrations and VW F activation factors
VWF concentrations were highest in patients with P. falciparum malaria (Figure 1A). However, 
compared with hospital staff controls, VWF concentrations in the P. vivax group were also sig­
nificantly elevated. The mean VWF concentration in hospital staff controls was comparable to 
the concentration present in normal pool plasma obtained from healthy Dutch volunteers (10.1 
versus 12.4 |jg/mL, respectively). VWF activation factors were also significantly higher in P. falci­
parum malaria patients than in hospital staff controls (Figure 1B), indicating that their circulating 
VWF was in a more active conformation (i.e., in a conformation enabling spontaneous platelet 
binding).
ADAMTS13 activity and antigen levels
ADAMTS13 activity levels were reduced in all patients with symptomatic P. falciparum or P. vivax 
malaria with median (IQR) levels of 13.5% (9.2-23.2%) and 13.3% (9.2-19.5%), respectively (Fig­
ure 2A). Levels in healthy Sumbanese hospital staff were comparable to levels found in healthy 
Dutch volunteers, whereas Dutch TTP patients typically had no demonstrable ADAMTS13 activ-
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Figure 1. Scatter dot plots with line at median showing VWF antigen concentrations (A) and VWF 
activation factors (B) in patients with symptomatic P. falciparum malaria (N = 26), P. vivax malaria (N 
= 16), and healthy Sumbanese hospital staff controls (N = 11). Group comparisons were done using 
Kruskal-Wallis test, whereas pairwise comparisons were done using the Dunn procedure (*P < 0.05; 
**P < 0.001; nsP > 0.05).
Figure 2. Scatter dot plots with line at median showing ADAMTS13 activity (A) and ADAMTS13 anti­
gen concentrations (B) in patients with symptomatic P. falciparum malaria (N = 26), P. vivax malaria (N 
= 16), healthy Sumbanese hospital staff controls (N = 11), healthy Dutch controls (N = 9), and throm­
botic thrombocytopenic purpura (TTP) patients (N = 5). ADAMTS13 activity is expressed as percent­
age of normal pool plasma. Group comparisons were done using Kruskal-Wallis test, whereas pairwise 
comparisons were done using the Dunn procedure (*P < 0.05; **P < 0.001; nsP > 0.05).
ity. ADAMTS13 antigen concentrations were also low in nearly all malaria patients (Figure 2B), 
and concentrations correlated well with ADAMTS13 activity levels (Pearson R = 0.78; P < 0.001). 
Additionally, the findings of low plasmatic ADAMTS13 activity by the FRETS assay were con­
firmed in a proteolytic VWF multimer assay. Figure 3A shows the results of this assay for three 
patients with a moderate decrease in ADAMTS13 activity and one with severely reduced activity 
(4%). Especially in the latter, large VWF multimers remained visible after incubation of synthetic
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Figure 3. A, VWF proteolysis assay showing multi­
meric pattern of recombinant IlbQ VWF after incu­
bation with plasma from individual P. vivax and P 
falciparum patients with moderate or severely re­
duced ADAMTS13 activity in FRETS assay and with 
normal pool plasma in absence and presence of 
EDTA (inactivator of ADAMTS13 activity). Percent­
ages in parentheses indicate the ADAMTS13 activ­
ity in the plasma of the individual patients using 
FRETS assay. ADAMTS13 deficiency is shown by 
the presence of large VWF multimers. B, VWF mul- 
timer pattern in the plasma of two patients with P 
falciparum malaria with reduced ADAMTS13 activ­
ity (14% and 15%, respectively), showing presence 
of circulating ultra-large VWF multimers (multim­
ers visible above the dashed line). NPP depicts 
normal pooled plasma of healthy Dutch subjects.
VWF with patient plasma, confirming a strong reduction of plasmatic ADAMTS13 activity. Fur­
ther confirmation was obtained by analysis of the VWF multimer pattern in plasma of malaria 
patients. As shown for two patients with P. falciparum in Figure 3B, UL-VWF could be detected 
in the plasma of these patients. Finally, we determined ADAMTS13 activity and antigen levels 
in Sumbanese with a negative malaria slide, living in remote villages, and found very low AD- 
AMTS13 activity and antigen levels. Compared with the hospital staff controls, these villagers 
had significantly lower platelet counts (222 versus 331x 109/L; P = 0.012) and borderline sig­
nificantly higher VWF concentrations (15.3 versus 10.1 pg/mL; P = 0.07). However, although the 
differences in platelet number and VWF concentration might indicate that the low ADAMTS13 
levels were a true finding, we decided to exclude these samples from further analysis because 
heat inactivation of ADAMTS13 during sample collection or transport to hospital could not be 
excluded with certainty.
ADAMTS13 inhibitors and mutations in the ADAMTS13 gene
In six malaria patients with strongly reduced ADAMTS13 activity levels, we determined the pres­
ence of ADAMTS13 inhibitors and ADAMTS13 autoantibodies. There was no difference in de­
cline in residual ADAMTS13 activity between a mixture of normal pool plasma incubated with 
patient plasma and normal pool plasma alone (data not shown). In addition, no increased titers 
of ADAMTS13 autoantibodies of the IgG, IgA, or IgM class were found (data not shown). Because 
mutations in the ADAMTS13 gene may also influence ADAMTS13 activity and antigen levels 
in the Sumbanese population, we screened a group of 71 Sumbanese for the presence of the 
P475S polymorphism, which is common in Japan [12]. This mutation was, however, not found
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in any of these subjects. Subsequent sequencing of the ADAMTS13 gene of five Sumbanese 
to screen for the occurrence of other common polymorphisms yielded multiple silent exonic 
mutations in all five Sumbanese and one missense mutation in one subject (Table 2). The silent 
mutations have all been previously reported as single nucleotide polymorphisms (SNPs) [25], 
whereas the missense mutation has not been described before. However, although the silent 
mutations were highly prevalent in the remaining 66 Sumbanese, including our hospital staff 
controls with normal ADAMTS13 levels, the missense mutation was not found in others. Unfor­
tunately, no ADAMTS13 level was available for the subject with the missense mutation.
Correlations between laboratory parameters
Figure 4 depicts correlations between VWF activation factor, platelet count, and ADAMTS13 
activity and antigen concentrations in patients with P. falciparum or P. vivax infection. Higher 
VWF activation factors were associated with lower platelet counts (Figure 4A). Furthermore, AD- 
AMTS13 antigen concentrations, but not ADAMTS13 activity levels, were inversely correlated 
with VWF activation factors (Figure 4B and C). ADAMTS13 antigen and VWF antigen concentra­
tions were also inversely associated (Spearman R = -0.413; P = 0.007). Finally, there was an in­
verse correlation of IL-6 concentrations with ADAMTS13 activity levels (Spearman R = -0.417; P 
= 0.007) and with platelet count (Spearman R = -0.442; P = 0.006). No significant correlation was 
present between platelet numbers and either ADAMTS13 activity levels (Spearman R = 0.081; P 
= 0.626) or ADAMTS13 antigen concentrations (Spearman R = 0.273; P = 0.097).
DISCUSSION
In this study, we reported that symptomatic P. falciparum or P. vivax infections are associated 
with a significant increase in VWF and active VWF levels and a decrease in ADAMTS13 activity 
and antigen levels, resulting in the presence of circulating UL-VWF multimers.
Table 2. Mutations in the ADAMTS13 gene identified in five Sumbanese individuals with the preva­
lence in 66 other Sumbanese individuals
Prevalence in 66 Sumbanese individuals
Subject Exon Nucleotide Amino acid WT Het Ho
1 + 2 + 4 + 5 5 420 T > C Silent 6% 31% 63%
1 + 2 + 3 + 4 + 5 15 1716 G >A Silent 7% 36% 58%
1 + 2 + 4 + 5 19 2280C >T Silent 25% 23% 51%
4 29 4221 C > A Silent ND
3 22 2814 G >T K938N 100% 0% 0%
WT = wildtype; Het = heterozygous; Ho = homozygous; ND= not determined.
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The high VWF activation factors with circulating UL-VWF multimers indicated that an in­
creased amount of the circulating VWF was in an active platelet binding conformation, which 
was supported by our findings of an inverse correlation between platelet numbers and VWF 
activation factors. We have previously found a similar association in our experimental human P 
falciparum malaria model [5], and our current study expands these observations to naturally ac­
quired P. falciparum and P. vivax infections. Both sICAM-1 and VWF are known markers of endo­
thelial cell perturbation, and these findings therefore suggest that endothelial cell perturbation 
is not a phenomenon restricted to P. falciparum but also occurs in P. vivax malaria, an infection in 
which thrombocytopenia is also a common observation [15]. This is in line with a previous study, 
which also found an almost similar increase in sICAM-1 concentrations in patients with either P 
vivax or uncomplicated P. falciparum malaria [26]. We speculate that, in addition to providing a 
mechanistic explanation for the thrombocytopenia in P. vivax malaria, relapsing P. vivax blood 
infections, which arise from dormant liver stages, may induce repeated episodes of endothelial 
cell activation with excessive VWF release. In high-income countries, elevated VWF levels have 
been associated with adverse clinical consequences, such as increased risk for cardiovascular
Figure 4. Correlation of VWF activation factor with platelet 
count (A), ADAMTS13 activity levels (B), and ADAMTS13 
antigen concentrations (C) in patients with symptomatic 
P. falciparum (N = 26) or P. vivax (N = 16) malaria. Shown is 
the Spearman correlation coefficient.
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diseases [27]. However, the possible clinical consequences of high VWF levels and decreased 
ADAMTS13 activity need to be determined for low-income countries where malaria is endemic.
Recent evidence suggests that severe disturbances in the interplay of endothelial cells, 
platelets, VWF, and ADAMTS13 may result in secondary microangiopathy and thrombocytope­
nia-associated multi-organ failure in severely ill patients [28-30]. Our study included patients 
with symptomatic, but uncomplicated P. falciparum or P. vivax malaria. Although the occurrence 
of microvascular dysfunction was not routinely classified, the alterations in the balance between 
VWF secretion and ADAMTS13 activity in our patients probably did not seem to result in clinical­
ly relevant complications. However, at this moment, we cannot exclude with certainty that more 
severe disturbances in the VWF/ADAMTS13 system may contribute to the development of com­
plications in severe malaria, as reported for severe sepsis. Future studies are needed in patients 
with severe malaria to test this hypothesis, as well as studies determining the functional thresh­
old levels of ADAMTS13 activity below which complications may ensue. In addition, recent data 
have proposed a role for angiopoietin-2 in the pathogenesis of severe falciparum malaria [31]. 
Both angiopoietin-2 and VWF are constituents of endothelial cell Weibel-Palade bodies, high­
lighting the possible importance of Weibel-Palade body exocytosis in malaria pathogenesis.
At this time, the exact pathogenic mechanism behind the low ADAMTS13 activity levels in 
our malaria patients remains elusive. Induction of ADAMTS13 autoantibodies is the usual un­
derlying pathogenic mechanism in TTP. Malaria may also induce various autoantibodies, as 
suggested by their high prevalence in malaria-endemic regions [32]. However, inhibitor assays 
could not show the presence of inhibitors or ADAMTS13 autoantibodies in our study popula­
tion, although the used assays may not have been sufficiently sensitive to detect weak inhibi­
tors or low ADAMTS13 autoantibody titers. Alternatively, various non-immune mechanisms may 
be involved. First, consumption of ADAMTS13 is observed in situations with release of large 
amounts of VWF, as previously shown by desmopressin or endotoxin administration [33, 34], 
whereas the proinflammatory cytokine IL-6 at high concentrations can inhibit, at least partially, 
ADAMTS13 activity [35]. In our study, VWF and IL-6 concentrations indeed correlated inversely 
with ADAMTS13 antigen concentrations. Regrettably, the limited sample size of our study did 
not allow a multivariate analysis. Second, parasites express various proteases, and these might 
theoretically inactivate ADAMTS13, as has recently been shown for the bacterium Bacillus an- 
thracis [36]. ADAMTS13 activity levels were, however, equally low in patients with P. falciparum 
and P. vivax malaria, despite the parasite density being much lower in vivax malaria. Third, high 
concentrations of free hemoglobin [37], as can be found in massive intravascular hemolysis or 
in vitro hemolysis, and of the coagulation proteins plasmin and thrombin have been reported to 
reduce ADAMTS13 activity [38]. However, none of the plasma samples in our study were macro- 
scopically hemolytic and a marked procoagulant state with diffuse intravascular coagulation is 
rare in malaria [39]. Fourth, reduced ADAMTS13 synthesis by liver stellate cells and/or endothe­
lial cells may also result in ADAMTS13 deficiency. Recently, inflammatory cytokines were shown 
to reduce ADAMTS13 synthesis in vitro [40]. Finally, genetic mutations may influence ADAMTS13
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activity and antigen levels, and malaria may have resulted in selection of certain polymorphisms 
in malaria-endemic regions. However, the P475S polymorphism, which is common in Japan, was 
not found in 71 Sumbanese individuals. In addition, sequencing of the ADAMTS13 gene in a 
small number of Sumbanese subjects did show three highly prevalent SNPs, but these were also 
present in hospital staff controls with normal ADAMTS13 activity and antigen levels, suggesting 
that these SNPs are not associated with altered ADAMTS13 expression.
In conclusion, we showed that symptomatic P. falciparum and P. vivax infections are associ­
ated with endothelial cell perturbation, ADAMTS13 deficiency, and increased concentrations of 
active and ultra-large VWF. These combined mechanisms may contribute to malaria-induced 
thrombocytopenia. Future studies are needed to determine whether the disturbances in the 
interplay between endothelial cells, VWF, ADAMTS13, and platelets may also play a role in the 
complications observed in severe malaria.
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Thrombocytopenia in early malaria is associated with GP1b 
shedding in absence of systemic platelet activation and 
consumptive coagulopathy.
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SUMMARY
Thrombocytopenia develops early in malaria, but the underlying mechanisms remain incom­
pletely understood. We studied the etiology of malaria-associated thrombocytopenia in volun­
teers experimentally infected with Plasmodium falciparum malaria, in Indonesian malaria pa­
tients and in ex vivo studies. In experimental human malaria, the decrease in platelet numbers 
was associated with a concurrent rise in young platelets (immature platelet fraction) and throm- 
bopoietin. D-dimer concentrations were moderately elevated without a prolongation in APTT 
or decrease in fibrinogen. There was no increase in expression of the platelet surface markers 
CD62P, PAC-1 and CD63 and in plasma concentrations of the platelet factors P-selectin, CXCR4, 
CXCL7, RANTES and CD40L. In contrast, concentrations of soluble glycoprotein-lb (sGPlb), the 
external domain of the platelet receptor for von Willebrand factor (VWF), increased early. In­
donesian malaria patients also had elevated concentrations of sGPlb, which correlated with 
VWF concentrations. Finally, incubation of platelets with parasitized erythrocytes in vitro failed 
to induce platelet aggregation or activation. We conclude that neither a compromised platelet 
production nor platelet activation or consumptive coagulopathy are responsible for the early 
thrombocytopenia in malaria. We hypothesize that the increase in sGPlb concentrations result 
from VWF-mediated GPlb shedding; a process that may prevent excessive adhesion of platelets 
and parasitized erythrocytes.
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INTRODUCTION
Thrombocytopenia is a common finding in patients with Plasmodium falciparum and Plasmo­
dium vivax malaria. Apart from their central role in haemostasis, platelets contain a wide range 
of inflammatory, immune modulating and angiogenic factors [1]. Two recent studies have sug­
gested that platelets play a distinct role in the innate host defense in the early stages of a malaria 
infection. McMorran and co-workers showed that purified human platelets were able to kill P 
falciparum parasites within erythrocytes in an in vitro culture system, an effect that was depen­
dent on platelet activation by adenosine 5'-diphosphate [ADP] [2]. Moreover, they showed that 
platelet deficient mice were more susceptible to death during infection with the murine malaria 
species P. chabaudi. Srivastava and co-workers showed that erythrocytes infected with the mu­
rine malaria parasite P. berghei interacted with and activated platelets, which resulted in secre­
tion of CXCL4 [platelet factor 4], a platelet derived chemokine thought to be involved in the 
development of cerebral malaria [3].
So, platelet activation may be an important process in early malaria that contributes to the 
fall in platelet number and it raises concern over the use of aspirin as antipyretic in children with 
malaria [4;5]. However, to what extent platelets are activated during human malaria is uncertain. 
To our knowledge, there are no studies on platelet activation in early malaria, while the available 
data from patients with a more advanced malaria infection have been inconclusive [6; 7]. There 
are also fundamental differences in the pathogenesis of human and murine malaria and caution 
should be taken when extrapolating findings from murine malaria models to human malaria [8].
Previously, we have reported a significant decrease in circulating platelet numbers in vol­
unteers experimentally infected with P. falciparum during the earliest stages of the blood stage 
infection and we have shown that this decrease coincided with the onset of endothelial cell 
activation with release of the platelet binding protein von Willebrand factor [VWF] [9]. In the cur­
rent study, we studied the occurrence of platelet activation, coagulopathy and reduced throm- 
bopoiesis in this experimental human malaria model. Observations made in these volunteers 
were confirmed in patients with naturally acquired malaria in Indonesia and in ex vivo studies
DESIGN AND METHODS
Experimental human P. falciparum  infections
Design. Experimental human malaria infections with healthy and malaria naive volunteers are in­
valuable for testing the efficacy of candidate malaria vaccines and a well established and highly 
reproducible model for studying pathogenic mechanisms in early malaria [10; 11]. The present 
study contains data from three experimental human malaria infections, which were carried out 
in 2005, 2007 and 2008. Details on the objectives, the characteristics of the volunteers and the 
clinical and parasitologic course have been described in detail before [9; 12-14]. The primary ob­
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jective of the study in 2005 was to study immunological responses in early P. falciparum malaria 
[9; 14]; the latter two were intervention studies, assessing the protective efficacy of repetitive 
exposure to live malaria sporozoites under chloroquine prophylaxis [13] and of a candidate ma­
laria vaccine (study in 2008). The current study on platelet kinetics was among the predefined 
exploratory objectives of all three studies. Only volunteers belonging to the control groups of 
these intervention studies were included to avoid a confounding effect of the intervention.
As previously described, all volunteers were infected by 5 P. falciparum infected mosquitoes 
and followed by thick blood smears and assessment of malaria symptoms three times daily until 
start of antimalarial treatment [11]. Antimalarial treatment was started upon microscopic detec­
tion of parasites in a thick blood smear and consisted of a standard, 6 dose curative regimen of 
artemether/lumefantrine 80/480 mg (Riamet®), given at 0, 8, 24, 36, 48 and 60 hours. The pres­
ence of P. falciparum was also analyzed by PCR and this revealed that submicroscopic parasit­
emia is usually present 3 days before thick smears become positive and treatment is given. Five 
volunteers who did not develop a positive malaria blood smear and thus no thrombocytopenia 
and who received artemether-lumefantrine at day 21, according to the study protocol, were in­
cluded as controls in some experiments. The Institutional Review Board of the Radboud Univer­
sity Nijmegen Medical Centre and the Dutch Central Committee on Research involving Human 
Subjects approved the study protocols (CMO 2004/129, CMO 2006/207 and NL14715.000.06, 
respectively), including these supplementary platelet studies. All volunteers gave written in­
formed consent.
Sample collection. Venous blood was collected daily between 08:00 and 10:00 AM in EDTA and 
in CTAD plasma tubes (Beckton Dickinson Vacutainer Systems, Europe). The latter contain the 
anticoagulant sodium citrate and the platelet stabilizing agents theophylline, adenosine and 
dipyrimadol. The CTAD tubes were kept on ice pending whole blood flow cytometric analyses 
or they were immediately centrifuged at 3500 rpm for 10 minutes followed by a second high 
speed centrifugation of the plasma to obtain platelet poor plasma for measurement of platelet 
circulating plasma markers. Plasma was stored at -80 °C awaiting analyses.
Laboratory procedures. The amount of blood that could be collected daily from volunteers for re­
search purposes was limited. Therefore, platelet activation was studied by flow cytometry in 15 
volunteers in the study in 2005 and by measurement of soluble platelet products in 5 volunteers 
in 2007. Platelet kinetics and coagulation parameters were studied in 11 volunteers in the 2007 
and 2008 experimental infection.
Hemocytometry was performed on a Sysmex XE-5000 automated hematology analyzer 
(Sysmex Corporation, Kobe, Japan) within four hours after blood collection. Platelet production 
was assessed by measurement of the immature platelet fraction (IPF), a parameter for young 
platelets that was recently introduced on Sysmex analyzers [15]. Quantification of the IPF was
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performed after addition of a polymethine dye and making use of specialized software as de­
scribed in detail previously [15]. The IPF is expressed as percentage of the total platelet number.
For measuring platelet activation by flow cytometry, whole blood in CTAD tubes was fixed 
with paraformaldehyde 1%, diluted with HEPES buffer and stained for 15 minutes with satu­
rating concentrations of anti-CD41-PE, anti-CD62P-PE, PAC-1-FITC and anti-CD63-FITC. Data on 
10,000 platelets in a log side-scatter versus log CD41-PE dot plot were acquired. The mean fluo­
rescence intensity (given in arbitrary units) of each antibody was analyzed and corrected for 
non-specific binding of isotype control.
Circulating concentrations of the platelet products P-selectin, CXCL4 (platelet factor-4), 
CXCL7 (NAP-2), CCL5 (RANTES), CD40 ligand (CD40L) and soluble glycoprotein-1b (sGP1b; gly- 
cocalicin) were determined by using semiautomated ELISA on a TECAN RSP150 robot as previ­
ously reported in detail [16]. Commercially available antibody duosets Dy137, Dy795, Dy393 
and Dy278 (all R&D Systems, Wiesbaden, Germany) and antibody combination BMS239 (Bender 
Medsystems, Vienna, Austria) were used to concentrations of P-selectin, CXCL4, CXCL7, CCL5 
and CD40L, respectively. Soluble glycoprotein-1b (sGP1b; glycocalicin) was determined by ELI­
SA with an in house capture antibody (RUU-630) and a commercial detection antibody (M1852, 
Sanquin, Amsterdam, the Netherlands). Western blot analysis showed that this capture antibody 
is very specific for GP1b (data not shown). Intra- and inter-assay CV's of this assay were 4% and < 
10%, respectively. Plasma thrombopoietin (TPO) concentrations were determined by a commer­
cially available ELISA kit (R&D Systems, Wiesbaden, Germany). VWF and the VWF activation fac­
tor, which reflects the amount of VWF that is in a platelet binding conformation, was determined 
by ELISA as previously described [9]. Levels of D-dimer were measured by means of the STA 
Liatest D-Dimer and fibrinogen assay (Roche Diagnostics SpA, Mannheim, Germany). Activated 
partial thromboplastin time (APTT) was determined using a KC10A coagulometer (Amelung, 
Lemgo, Germany). Plasma (50 |jl) was incubated for 2 minutes with 50 |jl Patromtin (Behrin­
gwerke, Marburg, Germany). Coagulation was started with 50 |jl of 25 ^mol/l calcium chloride 
and the time to coagulation was measured.
Field study in Indonesia
Data obtained in the experimental human malaria studies were confirmed in patients with natu­
rally acquired P. falciparum and P. vivax malaria, who presented to the Rumah Sakit Karitas Hos­
pital in Weetabula, West Sumba, East Nusa Tenggara Province, Indonesia. Consecutive subjects 
presenting to hospital with clinical symptoms of malaria and a P. falciparum or P. vivax parasite 
density of at least 2500 and 500 parasites/ |jL, respectively, were enrolled. A group of healthy 
hospital staff was enrolled as controls. Characteristics of the malaria patients and the controls 
have been described in detail previously [17].
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Ex vivo studies
The findings from the in vivo studies were further confirmed by in vitro studies. The effect of para­
sitized red blood cells (pRBCs) and various Toll like receptors (TLR) agonists on platelet activation 
status and platelet function were examined using flow cytometry and platelet aggregometry. 
Citrated blood (final concentration citrate 11mM) from two healthy volunteers was used for all 
experiments. P. falciparum asexual stages of the NF54 strain were cultured in vitro as described 
previously [14]. Asynchronous cultures of NF54 strain parasites were harvested at a parasitemia 
of 10-20% and the mature asexual stages were purified by centrifugation on a 63% Percoll den­
sity gradient [14]. This purification step results in preparations with 80-90% parasitemia, consist­
ing of >95% schizonts/mature trophozoites. These preparations of pRBC were washed twice in 
RPMI 1640 and used fresh in stimulation assays or freeze-thawed twice to obtain parasite lysate. 
Mock-cultured uninfected erythrocytes (uRBC) were obtained similarly and served as control. 
Whole blood was also stimulated with the following TLR agonists: TLR2 with Pam3Cys (10 |g/ 
ml; InvivoGen), TLR4 with purified Escherichia coli LPS (10 ng/ml), TLR9 with CpG ODN repeat (10 
ig/ml; TIB MolBiol).
Flow cytometry. Citrate whole blood (90ml) was incubated for 30 minutes at 370 C with asyn­
chronous pRBCs (final parasitemia ~5%), synchronized mature pRBCs (final parasitemia ~0.25%), 
uRBCs, lysate of synchronized pRBCs and uRBCs (2.5x106 pRBCs) or phosphate buffered saline 
(PBS). Further platelet activation was inhibited by the fibrin polymerization inhibitor Gly-Pro- 
Arg-Pro peptide (GPRP; Biotrend Chemicals AG, Zurich, Switzerland). After adding saturating 
concentrations of antibodies, samples were incubated for 15 minutes in the dark at room tem­
perature, followed by fixing with paraformaldehyde 10% for 10 minutes. The following antibod­
ies were used: CD62P PECy5 (AK-4 clone; BD Pharmingen, San Jose, CA); CD41 ECD (P2 clone), 
CD40 PE (MAB-89 clone) and CD36 FITC (FA-6:152 clone; all from Beckman Coulter, Immunotech, 
Marseille, France); TLR2 PE (CD282, TL2.1 clone), TLR4 PECy7 (CD284, HTA125 clone; eBioscience, 
San Diego, CA) and TLR9 FITC (CD289, 5G5 clone; Hycult Biotechnology Uden, the Netherlands). 
Analyses were performed using a Beckman Coulter FC500 flow cytometer (Beckman Coulter, Mi­
ami Florida). Platelets were identified by FSC/CD41 positive staining. Isotype and fluorochrome 
matched controls as well as non-stained samples were used to adjust the detectors.
Aggregometry. Platelet aggregation was measured in an impedance dual channel aggregometer 
(Chrono-log, Model 570, Havertown, USA) and analyzed by the AggroLink software package. 
750 |l of platelet rich plasma (PRP) was pre-warmed for 5 min at 37°C in a magnetically stirred 
polycarbonate cuvette. After calibration, pRBCs or uRBCs were added (final hematocrit of 15%) 
and aggregation was monitored on two leads with ADP (22 |M ) and PBS as positive and nega­
tive control, respectively. Whole blood impedance aggregometry was chosen over optical ag­
gregometry because the preparatory steps required for the latter technique (separation of RBCs 
from the PRP by extra centrifugation steps), resulted in unwanted platelet activation.
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Statistical analysis
Data are presented as mean with standard deviation unless otherwise stated. Changes from 
baseline in serial data were analyzed with the use of a linear mixed model for repeated mea­
sures. No assumption about the shape of the time trend was made i.e. time point was included 
as a categorical variable. Correlation between repeated measures within subjects was assumed 
to only depend on the time between the repeated measures (Toeplitz correlation structure). 
Holm's method was used to adjust for multiple comparisons at several time points versus base­
line. Differences between groups were analyzed by Student's T-test. All analyses were performed 
with SPSS version 16.0.
RESULTS
Experimental human malaria infections
Platelet kinetics. Platelet kinetics were studied in 11 volunteers. Parasitemia induced an early and 
marked decrease in platelet count from a mean value of 253 x 109/L to a mean nadir value of 
113 x 109/L (range 55 - 188 x 109/L) with a concurrent decrease in circulating leukocyte numbers 
(Fig 1A-B). In the early phase of the malaria infection, the IPF remained stable with a subsequent 
rise in the first days after the positive malaria blood smear, suggesting that the thrombopoietic 
capacity of the bone marrow was not suppressed (Fig 1C). Young platelets are larger and the 
changes in the IPF paralleled changes in the mean platelet volume (MPV; Fig 1D) and the plate­
let large cell ratio (P-LCR; Fig 1E). The relative thrombocytosis at week 3 was associated with a 
low IPF and MPV. A transient increase in plasma TPO concentrations occurred during the drop 
in platelet count (Fig 1F). Platelet clumps were not observed, neither by automated hemocy- 
tometry, nor by morphological examination (data not shown). Finally, in contrast to the IPF, the 
reticulocyte fraction decreased in the first days after the thick smear became positive and the 
subsequent start of antimalarial treatment, suggesting that erythrocyte and platelet production 
are independent processes in patients with malaria (Fig 1C).
Absence of consumptive coagulopathy. Activation of the coagulation cascade was evaluated in 
the same volunteers by measurement of D-dimers, fibrinogen and the APTT. These parameters 
were measured once at day 1 after start of antimalarial treatment, i.e. at the day platelet num­
bers declined markedly. Concentrations of D-dimers were above the upper reference limit (0.5 
Hg/ml) in 9 out of 11 volunteers with a mean value of 2.6 ng/ml (range 0.2 - 7.5 ^g/ml). The 
mean fibrinogen concentration was 3.3 g/l (range 2.4 - 4.4 g/l), and none of the volunteers had 
fibrinogen concentrations below the lower limit of the reference value (2.0 - 4.0 g/l). Compared 
with the corresponding baseline values, there were no relevant changes (>5 seconds) in the 
APTT in 9 of the 11 volunteers. A prolongation in APTT of 9.3 and 19 seconds was found in the
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Figure 1. Time course of (A) platelet and (B) leukocyte counts, (C) immature platelet fraction and re­
ticulocyte fraction, (D and E) platelet indices and (F) plasma thrombopoietin concentrations in 11 
volunteers during an experimental human P. falciparum malaria infection. Data presented are mean ± 
SE at the following time points: parasite inoculation (baseline), the period between 3 days (d T-3) be­
fore thick smear positivity and subsequent start of antimalarial treatment (d T) until 3 days thereafter 
(d T+3), day 7 after start of antimalarial treatment (d T+7) and at week 3 and 4 post-parasite inocula­
tion. The median time to thick smear positivity and subsequent start of antimalarial treatment was 
10.2 days post-parasite inoculation. *p<0.05, **p<0.01 compared with corresponding baseline value, 
determined by linear mixed model for repeated measures.
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remaining 2 volunteers with the latter occurring in the volunteer with the highest D-dimers 
value (7.5 ng/ml).
Increased sGP1b concentrations in absence of systemic platelet activation. Platelet activation status 
was measured at four pre-specified time points by whole blood flow cytometry in 15 volunteers 
(Fig 2). A slightly higher PAC-1 (aIIb£3 activation marker) surface expression was found in some 
volunteers, but there was no concurrent increase in expression of the a-granule membrane pro­
tein CD62P (P-selectin) or the lysosomal marker CD63.
Since activated, adherent platelets may be missed with flow cytometry, plasma concentra­
tions of a range of platelet membrane and granule products were measured in five volunteers. 
No consistent increase occurred in plasma concentrations of soluble P-selectin, CXCL4, CXCL7 
and RANTES during parasitemia and its treatment (Fig 3A-D). Plasma CD40L concentrations were 
below the assay's lowest standard value in all samples. One volunteer had a transient increase 
in soluble P-selectin concentration, while RANTES concentrations were transiently increased in 
two others. In contrast, parasitemia and its treatment resulted in a significant increase in sGP1b 
concentrations in all volunteers from a mean concentration of 486.6 ng/ml at baseline to 704.2 
ng/ml (p=0.04) at day 2 after treatment initiation (Fig 3E). sGP1b is the extracellular domain 
of glycoprotein-1ba, the main platelet receptor for VWF. Previously, we have demonstrated a 
similar time course for VWF concentrations [9]. sGP1b concentrations depend on the circulating 
platelet mass and the relatively high sGP1b concentrations at week 3 are probably due to the 
relative thrombocytosis at that time point. The increase in sGP1b during parasitemia and treat­
ment was not a direct effect of artemether-lumefantrine on platelets, because aparasitemic vol­
unteers treated by a standard course of artemether-lumefantrine showed no increase in sGP1b 
concentrations (Fig 3F).
sGP1b in naturally acquired malaria
To confirm our findings of a malaria-associated increase in sGP1b, we compared plasma concen­
trations of this protein adjusted to the individual platelet number between patients with symp­
tomatic P. falciparum or P. vivax malaria and healthy controls on the Indonesian island Sumba. 
Patients with symptomatic P. falciparum and P. vivax malaria had significantly higher sGP1b con­
centrations per platelet than healthy controls (Fig 4A). Total sGP1b concentrations were also sig­
nificantly higher in the falciparum and vivax malaria groups than in controls with median (IQR) 
values of 1074 ng/ml (696 - 1511 ng/ml), 709 ng/ml (551 - 1061 ng/ml) and 512 ng/ml (420- 612 
ng/ml), respectively. Recently, it was reported that shear-induced interaction of platelets with 
VWF results in GPIb-ectodomain shedding [18]. In these Indonesian malaria patients, there was 
indeed a significant correlation between sGP1b concentrations per platelet and VWF concentra­
tions (Fig 4B) and VWF activation factors (Fig 4C).
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Figure 2. Time course of the mean fluorescence intensity (X-mean) of the platelet activation markers 
CD62P (P-selectin), PAC-1 (aIIb^3 activation marker) and CD63 (lysosomal marker) in 15 volunteers 
during an experimental human P. falciparum malaria infection. Antimalarial treatment was started 
after a median time of 9.7 days (range, 7.3-11.3 days) after parasite inoculation. Expression was de­
termined by whole blood flow cytometry at the following time points with the corresponding rela­
tive (percentage of baseline value) mean platelet count between parentheses: start of antimalarial 
therapy (d T) or the day thereafter (d T+1; 76%); day 2 or 3 after start of antimalarial treatment (d T+2 
or d T+3; 62%); week 3 post-parasite inoculation (140%) and week 6 post-parasite inoculation (97%). 
This latter time point corresponds with the normal, healthy situation after treatment of malaria. For 
all three markers, no significant differences between the week 6 value and the other time points were 
found by paired t test with Bonferroni correction. Only 9 blood samples were available for analysis at 
time point d T+2 or T+3.
Ex vivo studies
Flow cytometry. The effect of pRBCs on platelet phenotype was studied by measurement of the 
surface expression of various platelet receptors upon incubation of whole blood with pRBCs 
containing synchronous, mature asexual P. falciparum stages (final parasitemia of whole blood 
~0.25%), pRBCs with asynchronous P. falciparum stages (final parasitemia ~5%) or pRBC lysate. 
Neither synchronized, nor asynchronous pRBCs changed CD62P expression (Fig 1A of support­
ing information; only data for synchronous mature pRBCs shown). Lysate of pRBCs and uRBCs 
increased CD62P expression to the same degree, probably owing to the platelet activating ef­
fects of ADP and haem from erythrocytes.
Platelets express various TLRs and because P. falciparum contains TLR4 and TLR9 ligands, 
these receptors may be involved in the presumed role of platelets in the innate immune re­
sponse [19; 20]. However, there was no up- or down-regulated expression of the platelet recep­
tors CD36, CD40 and TLR2, 4 and 9 with either intact or lysed pRBCs (Fig 1B-F of supporting 
information). Finally, no change in CD62P or TLR expression was observed upon incubation of 
whole blood with the specific TLR ligands Pam3Cys (TLR2), lipopolysaccharide (TLR4) or CPG 
repeat ODN (TLR9; results not shown).
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Aggregometry. The effect of direct interaction of platelets with pRBCs on platelet aggregation 
was studied with impedance aggregometry. Incubation of pRBCs with non-synchronized asex­
ual stages (hematocrit 15%; parasitemia 15%) with PRP (ratio 1:1) did not induce any detectable 
platelet aggregation (Fig 2A of supporting information). In addition, there was no difference in
Figure 3. Time course of plasma concentrations of (A-E) platelet a-granule and membrane factors in 
5 volunteers during an experimental human P. falciparum malaria infection and (F) soluble glycopro- 
tein-1b concentrations in 5 aparasitemic volunteers at the start of a standard course of artemether- 
lumefantrin and two days thereafter. Plasma concentrations shown in panel A-E were determined at 
the following time points: parasite inoculation (baseline), the period between 2 days (d T-2) before 
start of antimalarial treatment (d T) until 3 days thereafter (d T+3) and at week 3 post-parasite inocu­
lation. The median time of start of antimalarial treatment was at day 10.2 post-parasite inoculation.
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the degree of platelet aggregation to 22 |jM ADP between PRP incubated with pRBCs or uRBCs 
(Fig 2B of supporting information).
DISCUSSION
Recent evidence from murine malaria and in vitro studies has suggested that platelets and plate­
let activation play a role in the pathogenesis of early malaria. Studies in humans are however 
sparse. From our current study, in which the decrease in platelet numbers was associated with 
an early increase in the IPF and TPO concentrations, we conclude that thrombopoiesis is not 
suppressed in early malaria, unlike the erythropoiesis. Increased peripheral platelet clearance 
thus seems responsible for the malaria-induced thrombocytopenia, a finding supported by an 
earlier scintigraphic platelet study showing a strongly reduced platelet life span in malaria pa-
Figure 4. (A) Scatter dot plot with line at mean of 
plasma concentrations of soluble glycoprotein-1b 
(sGPIb) per platelet in patients with symptomatic 
P. falciparum malaria (n=26), P. vivax malaria (n=11) 
and healthy Sumbanese controls (n=10). Mean 
platelets counts (interquartile range) in the first 3 
groups were 122 x 109/L (70 - 154 x 109/L), 117 x 
109/L (77 - 220 x 109/L) and 237 x 109/L (172 - 258 
x 109/L). Group comparisons were done using stu­
dents t test. One outlier in the falciparum group was 
excluded (sGP1b concentration of 84.7 ng/ml). (B- 
C) Correlation (Pearson r) of sGP1b concentrations 
per platelet with von Willebrand factor antigen and 
von Willebrand activation factors.
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tients [21]. Second, we demonstrate that systemic platelet activation and consumptive coagu­
lopathy are not responsible for this enhanced clearance.
Previously, in the same human malaria model, we have shown that endothelial cell activa­
tion with release of active VWF, i.e. VWF in a platelet binding conformation, is an early event in 
malaria and that VWF concentrations correlated negatively with platelet numbers [9]. Multiple 
other recent in vivo and in vitro studies have also implicated VWF release as a pathogenic mecha­
nism in malaria [17; 22-24]. Given this presumed role for VWF, the increase in plasma concentra­
tions of sGP1b is an interesting observation. sGP1b, also known as glycocalicin, is the external 
domain of the GP1b receptor, the main platelet receptor for VWF and the leukocyte integrin 
Mac-1 [25]. The external domain of the GP1b receptor can be shed from the platelet surface by 
cleavage by the metalloproteinase TNF-a-converting enzyme (TACE/ADAM17) and this leads to 
a clear attenuation of normal platelet function [26]. Recently, Cheng and co-workers reported 
data from in vitro studies in which they showed that interaction of platelets with VWF under 
flow condition induces GPIb-ectodomain shedding, a process that could be inhibited by inhibi­
tors of metalloproteases [27]. The similar kinetics of sGP1b and VWF plasma concentrations in 
experimental malaria and their positive correlation in Indonesian malaria patients support these 
recent findings by Cheng et al. This novel mechanism may not only explain the elevated sGP1b 
concentrations in absence of other signs of platelet activation in our volunteers, but may also 
prove important for the negative regulation of both excessive platelet adhesion and VWF-medi- 
ated cytoadherence of infected red blood cells - a mechanism that has recently been reported
[22]. Future studies will need to establish the functional consequences of GP1b shedding in 
malaria.
There is a paucity of data on the occurrence of platelet activation in human malaria. To our 
knowledge, no previous studies have used flow cytometry to examine platelet activation in ma­
laria patients. Our findings suggest that platelet activation does not contribute to the thrombo­
cytopenia in early malaria. We cannot exclude that some degree of platelet activation occurs in 
severe malaria, a condition associated with organ dysfunction and high mortality. No significant 
difference in absolute CXCL4 (PF4) and CXCL7 (P-TG) levels between patients with severe ma­
laria and healthy controls was found in a well performed study in Thailand, in which special 
attention was paid to prevent ex vivo platelet activation [7]. The occurrence of some low grade 
in vivo platelet activation was suggested, however, by the fact that malaria patients had a lower 
circulating platelet mass and a slightly higher CXCL4/CXCL7 ratio. Thus, while our study found 
no platelet activation in early malaria, further studies are required to clarify the role of platelet 
activation in more advanced stages of malaria. In contrast to studies in humans, marked platelet 
activation has been described in several animal models of malaria [28]. There are however im­
portant differences in the pathology of cerebral murine malaria compared with severe human 
malaria. Murine malaria is primarily an immunopathological process with marked inflammation 
and little or no sequestration of pRBCs, while endothelial activation with pRBC sequestration is
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a central feature of human malaria [8]. These fundamental differences in pathology can explain 
the discrepancy in results of platelet activation studies between human and murine malaria.
These findings in human volunteers were supported by the finding of in vitro studies, in 
which incubation of whole blood with pRBCs failed to induce direct platelet activation or plate­
let sensitization to ADP. In contrast to our results, enhanced platelet aggregation and increased 
surface expression of CD62P and PAC-1 after incubation of platelets with pRBCs were found in 
previous studies [3; 29]. Differences in the used protocols may be responsible for these conflict­
ing results. In vivo conditions were simulated as much as possible in our current study by using 
impedance aggregometry to measure aggregation of platelets after addition of RBCs, instead 
of PRP in optical aggregometry. In addition, parasite densities in the range of those normally 
found in clinical malaria infections were used, which limits the possible confounding effects of 
excessive release of free hemoglobin and ADP, both potent platelet activators, from pRBCs dur­
ing the incubation time.
In recent years, platelets were shown to express various TLRs, although their precise func­
tional importance remains elusive [19; 20]. P. falciparum contains known TLR2/4/9 ligands [30; 
31]. Incubation of whole blood with pRBCs did not change the surface expression of TLR2/4/9, 
while incubation of whole blood with specific TLR2/4/9 agonists did not upregulate CD62P ex­
pression. Two earlier studies also found no induced platelet CD62P expression after stimulation 
with TLR2 and TLR4 agonists [32; 33]. Therefore, to date, it remains uncertain whether TLRs on 
platelets play a role in malaria pathogenesis.
The contribution of activation of the coagulation cascade to the malaria-induced thrombo­
cytopenia has also been disputed in the past [34]. In our study, coagulation activation did occur, 
as indicated by the elevated D-dimer concentrations in 9 of 11 volunteers. However, a consump­
tive DIC did not develop, given the absence of a clear prolongation in the APTT in all except 
one volunteer and the high-normal fibrinogen concentrations. Earlier field studies had already 
shown that frank DIC is only rarely encountered [35]. So, coagulation activation does occur in 
early malaria, as it occurs in almost every infectious disease, but its role in the marked throm­
bocytopenia in malaria seems only minor. The same holds true for splenic pooling of platelets; 
a scintigraphy platelet study in malaria patients was consistent with diffuse platelet sequestra­
tion, instead of splenic or hepatic pooling [36], while asplenic persons also develop pronounced 
thrombocytopenia when infected with malaria [37]. Finally, immune-mediated mechanisms 
have also been implicated in the pathogenesis of malaria-associated thrombocytopenia. Anti­
platelet IgG antibody concentrations were reported to correlate with platelet number [38], al­
though this finding could not be confirmed in another study [39]. Antiphospholipid antibodies 
also occur in malaria patients. While antiplatelet antibodies may play a role in later stages of a 
malaria infection, it seems unlikely that they are responsible for the early decrease in platelet 
number while parasite densities are still extremely low. Previously, we found no induction of 
anticardiolipin antibodies in our experimental human malaria model [40].
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In conclusion, there is growing evidence that platelets play a distinct role in the pathogen­
esis of malaria during the early phases of the blood infection. Thrombocytopenia occurs in ab­
sence of platelet activation or consumptive coagulopathy. We hypothesize that the increase in 
sGP1b results from VWF-mediated GP1b shedding; a process that may prevent excessive adhe­
sion of platelets and parasitized erythrocytes.
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SUPPORTING FIGURES
Figure S1. Expression (shown as the mean fluorescence intensity) of the platelet receptors 
CD62P (P-selectin), CD36, CD40 and Toll like receptors-2/4/9 upon incubation of whole 
citrate blood with synchronized, mature parasitized red blood cells (parasitemia ~0.25%, black line) 
and uninfected red blood cells (grey line) and their lysate. Isotype fluorochrome matched platelets 
were used as a negative control (dotted line).
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Figure S2. Impedance aggregometry using platelet rich plasma (PRP) incubated with asynchronous, 
asexual parasitized red blood cells (pRBCs; parasitemia 15%; red line) or uninfected red blood cells 
(uRBCs; blue line). (A) Incubation of PRP did not result in platelet aggregation. (B) No difference in the 
degree of platelet aggregation was observed after incubation of PRP with pRBC or uRBC and subse­
quent stimulation with 22mM ADP.
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SUMMARY
A 20 year-old healthy female volunteer participated in a clinical Phase I and IIa safety and ef­
ficacy trial with candidate malaria vaccine PfLSA-3-rec adjuvanted with aluminium hydroxide. 
Eleven weeks after the third and last immunization she was experimentally infected by bites of 
Plasmodium falciparum-infected mosquitoes. When the thick blood smear became positive, at 
day 11, she was treated with artemether/lumefantrine according to protocol. On day 16 post­
infection i.e. two days after completion of treatment, she woke up with retrosternal chest pain. 
She was diagnosed as acute coronary syndrome and treated accordingly. She recovered quickly 
and her follow-up was uneventful. Whether the event was related to the study procedures such 
as the preceding vaccinations, malaria infection or antimalarial drugs remains elusive. However, 
the relation in time with the experimental malaria infection and apparent absence of an un­
derlying condition makes the infection the most probable trigger. This is in striking contrast, 
however, with the millions of malaria cases each year and the fact that such complication has 
never been reported in the literature. The rare occurrence of cardiac events with any of the pre­
ceding study procedures may even support a coincidental finding. Apart from acute coronary 
syndrome, myocarditis can be considered as a final diagnosis, but the true nature and patho­
physiological explanation of the event remain unclear.
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INTRODUCTION
Experimental human malaria infections are a well accepted method for testing efficacy of candi­
date pre-erythrocytic malaria vaccines since 1971 [1-5]. The clinical presentation of experimen­
tal human malaria infections is generally mild and associated with symptoms of uncomplicated 
malaria [1, 2]. The most commonly reported symptoms and laboratory abnormalities are head­
ache, malaise, fever, thrombocytopenia and leucopenia. With close monitoring and immediate 
administration of treatment upon detection of parasitemia, experimental human malaria infec­
tions have been considered safe and well-tolerated [1-3]. Here, a cardiac event occurring shortly 
after treatment is described in a healthy volunteer participating in a malaria vaccine phase I/IIa 
trial.
CASE PRESENTATION
A 20-year old, healthy female volunteer (medical student) participated in a double blind ran­
domized phase I conditional IIa trial with the candidate malaria vaccine PfLSA-3-rec in 2007­
2008. The volunteer's medical history was unremarkable, except for a tonsillectomy at the age of 
4 and mild atopic symptoms for which she occasionally used a nasal corticosteroid. As medica­
tion, she also used a second generation oral contraceptive. Family history revealed a myocardial 
infarction in the paternal grandfather, when 43 years old, and a positive paternal family history 
for dyslipidemia. She had never smoked or used illicit drugs. At inclusion, the blood pressure 
was 135/88 mmHg with a pulse of 64/minute and a body mass index of 20 kg/m2; the results 
of the physical examination were normal. Subsequent blood pressure measurements yielded 
values below 130/80 mmHg. ECG and laboratory tests were normal, including plasma glucose 
and lipid levels (Table 1).
The volunteer received three immunizations with 30 |jg of LSA-3 recombinant protein ad- 
juvanted with aluminium hydroxide. Immunizations were administered subcutaneously in the 
upper arm at monthly intervals. Adverse events after immunization were injection site pain, 
and headache with increasing intensity after each immunization. The headache after the third 
vaccination was severe and accompanied by photophobia; it lasted for two days and made her 
keep bed rest.
Permission from the Independent Research Committee was obtained for proceeding with 
the phase IIa part of the trial. Eleven weeks after the last immunization the volunteer was ex­
posed to the bites of five mosquitoes infected with Plasmodium falciparum (strain NF54). The 
thick blood smear became positive eleven days after exposure (44 parasites/^l, infected red 
blood cells 0.0012%) and treatment with 80/480 mg artemether/lumefantrine (Riamet") was 
immediately initiated. The dose was repeated after 8, 24, 36, 48 and 60 hours. At the time of 
treatment onset the volunteer reported headache, fatigue and myalgia. These symptoms had
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started at day eight and nine after exposure. The day after treatment onset the volunteer re­
ported intermittent fever, which had completely resolved two days later. The highest recorded 
sublingual temperature was 39.6°C. Artemether/lumefantrine was continued until day 14 and 
blood smears and PCR were negative on this day. On day 15 she experienced some shortness of 
breath when performing physical exercise, which she attributed to hay fever.
On day 16, two days after completion of treatment and with a negative blood smear, the 
volunteer woke up at 5.30 a.m. with retrosternal chest pain characteristic of angina pectoris, not 
radiating, not related to respiration or change of position. Pain was severe during 30 minutes 
and at that time accompanied by nausea. The volunteer called the study doctor who referred 
her to the cardiologist. On admission, the volunteer appeared not in acute distress, blood pres­
sure was 120/80 mmHg, pulse 75/ min, oxygen saturation 100% while breathing ambient air and 
temperature was 37.9°C. The jugular venous pressure was normal, as was the examination of the 
heart, lungs and peripheral arteries. The electrocardiogram showed 1 mm ST elevation in leads 
II, III and AVF and a negative T-wave in lead V2. A limited rise and fall of troponin I (peak 11.8 |ag/l 
on day of admission) and other cardiac enzymes, including CPK, LDH and AST was found. The 
results of laboratory investigations are presented in Table 1.
On admission, chest X-ray was normal and the echocardiogram showed mild hypokinesia 
of the inferior wall. Cardiac MRI performed four days after start of the complaints did not show 
any abnormalities. A second cardiac MRI after ten months conducted in a specialized center in 
the Netherlands showed absence of aberrant coronaries and good cardiac function with small 
patchy subepicardial staining (posterior)-laterally suggestive for myocarditis. A coronary angi­
ography was not performed.
The volunteer was admitted to the cardiac care unit with a diagnosis of acute coronary syn­
drome. Treatment consisted of nitroglycerin, metoprolol, perindopril, calcium carbasalate, clopi- 
drogel, enoxaparine and acetaminophen. Complaints completely resolved within 30 minutes 
after treatment and the further clinical course was uneventful, e.g. the patient was free of symp­
toms throughout a follow-up period of one year. After four days, the volunteer was discharged 
from the hospital in good condition. Medications were gradually discontinued after discharge; 
only calcium carbasalate was continued for six months. Given the MRI data and evolution so far 
the prognosis is currently considered good.
DISCUSSION
A case of limited myocardial necrosis occurring just after completion of anti-malarial treatment 
is reported in an experimentally infected healthy volunteer without obvious risk factors for car­
diovascular disease. A relationship between the cardiac event and the parasite challenge and/ 
or its treatment seems probable, especially because of the chronology of the event and the ab­
sence of an alternative explanation. Remarkably however, cardiac complications are extremely
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rare in malaria. To date, myocardial infarction during or after naturally acquired P. falciparum in­
fection has not been reported, neither in hundreds of millions of endemic cases, nor in hundreds 
of thousands military troops that were temporarily deployed to endemic areas [6-8]. In Sierra 
Leone, a patient was described with angina pectoris and a positive blood slide, which may have 
been an incidental finding in an highly endemic area [9]. Elevated troponins without cardiac 
complaints or ECG abnormalities are rare; an elevation just above threshold was measured in 1 
out of 161 malaria patients [10, 11]. Finally, a few cases of myocarditis have been reported and 
only during severe or fatal falciparum malaria [12-15].
Regarding a possible effect of the anti-malarial treatment, it should be noted that the car­
diac event occurred shortly after therapeutic administration of artemether/lumefantrine. There 
is no direct evidence for ischemic cardiotoxicity of this drug combination [16] and artemether, 
dihydroartemisinin and lumefantrine concentrations in the volunteer, measured in the Centre 
Hospitalier Universitaire Vaudois in Lausanne, Switzerland, were within therapeutic ranges (Ta­
ble 1). Desbutyl-lumefantrine levels were elevated according to Hatz and Lefebvre, however 
according to McGready these values are normal [17-19]. One case of coronary artery spasm was 
reported in a 17-year old male using artemether/lumefantrine, but that patient's urine was also 
tested positive for tetrahydrocannabinol, the active substance in marijuana, which may have 
contributed to this complication [20].
Since 1985, experimental human malaria infections have been conducted in three centers 
in 1367 volunteers. No cardiac complications have been reported, except a case of myocardial 
infarction in 2002 whereby a 39-year old male volunteer developed a myocardial infarction dur­
ing malaria treatment by chloroquine, two days following detection of malaria parasites in a 
blood smear [2, 21], i.e. with a similar chronology as in the above reported case. However, this 
volunteer had cardiovascular risk factors (hypercholesterolemia and smoking) and the angiog­
raphy, which was performed in this case, revealed a stenosis of one of the coronary arteries. In 
retrospect, the reality of a true parasitemia was debatable since blood samples tested by RT-PCR 
several months later proved to be negative [2].
A plausible diagnosis in the LSA-3 volunteer is an acute coronary syndrome, since limited 
myocardial necrosis was found as expressed by the small rise and fall of cardiac enzymes includ­
ing the most specific one, troponin. Also chest pain occurred that was mimicking angina pec­
toris and that disappeared after treatment with nitrates. Finally temporary changes on ECG and 
echocardiography were found, both corresponding for damage in the inferior wall. An acute 
coronary syndrome can occur in patients with normal or with abnormal coronary arteries.
An acute coronary syndrome associated with coronary atherosclerosis primarily occurs in 
patients over the age of 40. Young patients with myocardial infarction secondary to atheroscle­
rosis usually have multiple risk factors, such as dyslipidemia, hypertension, smoking, diabetes 
mellitus, obesity and a positive family history [22, 23]. In this volunteer, the only risk factors 
present is a positive family history, although not in a first degree family member. Anomalous
163
Table 1. Clinical Laboratory Findings
Haematology and 
biochemistry tests
Haemoglobin (mmol/l) 
Leukocytes (*1071)
Platelets (*1071)
Glucose (mmol/l) fasting 
Sodium (mmol/l)
Potassium (mmol/l)
Creatinin (umol/l)
Urea nitrogen (mmol/l)
Bilirubin (umol/l)
Alkaline phosphatase (U/l) 
Aspartate aminotransferase (U/l) 
Alanine aminotransferase (U/l) 
Lactate dehydrogenase (U/l) 
Gamma GT (U/l)
Creatinin Kinase (U/l)
Troponin I (ug/l)
CRP (mg/l)
Cholesterol (mmol/l) 
Triglycerides (mmol/l)
HDL cholesterol (mmol/l)
LDL cholesterol (mmol/l)
Reference
range
Screening
7.3 - 9.7 7.1
3.5-11.0 6.6
120-350 259
4.0 - 5.5 4.6
137-144 142
3.4 - 4.6 4.1
45-90 61
3.0 - 7.0
< 17 <10
< 120 55
<40 16
<45 15
<450 313
<35 13
< 170
<0.20
< 10
4.7 - 6.5
0.8 - 2.0
1.10-1.70
<3.5
Admission Adm+1 Adm+2 Adm+3 Adm+4 =
Discharge
6.9
7.9 
160
4.9 
140
3.9 
55
4.9
74
132
137
540
29
296
10.40
26
4.0
1.5
1.20
2.12
104 
134 
534
105 
2.75
7.1
3.9 
254
137
3.9 
60
3.2
111
171
562
39
<10
166
36
6.9
5.4
302
69
83
164
384
35
28
0.20
Coagulation assays
INR 0.9-1.1 1.0 1.0
Fibrinogen (mg/l) 2000-4000 4320
Factor VIII activity (%) 60-150 130%
Protein C activity (%) 70-150 100%
Free protein S antigen (%) 55-115 92%
Homocystein ([amol/I) < 13.4 9.3
Antithrombin III (%) 85-120 98%
Factor II mutation negative
Factor V (Leiden) mutation negative
von Willebrand Factor (%) 50-150 166%
ADAMTS13 activity (%) 60-140 90%
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Additional tests
Convalescent micro­
biological tests
adenovirus, RS-virus, influenza virus, mycoplasma pneumonia, 
Chlamydia, Q-fever, parainfluenza, enterovirus Negative
Auto-immune anti­
bodies
ANCA, anticardiolipin antibodies, ß2 glycoprotein antibodies, 
lupus anticoagulans, anti-heart (rat) antibodies Negative
Toxicology test tetrahydrocannabinol, amphetamine-derivatives, cocaine, diazepam, methadone, tramadol, opiates Negative
Inflammatory param­
eters Interleukin 6, Interleukin 8 < detection limit
Time after last dose 7 h15 103 h45
Artemether < detection limit < detection limit
Dihydroartemisinin 26.5 ng/ml < detection limit
Lumefantrine 4308 ng/ml and 443 ng/ml
Desbutyl-lumefantrine 40 ng/ml 18 ng/ml
coronary arteries are a rare cause of myocardial infarction in young patients [24]. There were, 
however, no indications for coronary abnormalities by cardiac MRI.
Myocardial ischemia may also occur in patients with normal coronary arteries. Patients with 
this condition are generally younger, female and have no history of angina pectoris or tradi­
tional risk factors for atherosclerosis, except smoking [25, 26]. Although the exact pathogenic 
mechanism often remains elusive, various mechanisms may contribute, e.g. coronary vaso­
spasm, arterial thrombosis and hypercoagulability, and inflammation [27].
Variant angina, also known as Prinzmetal's angina, is caused by coronary vasospasm and 
might be a possible explanation for the symptoms in this volunteer. The classic patient is a 
young woman without traditional cardiovascular risk factors, except for tobacco use [28]. In 
some patients, variant angina is a manifestation of a more general vasospastic disorder and as­
sociated with Raynaud's phenomenon and migraine [29]. Although the volunteer has no previ­
ous history of a vasospastic disorder, she experienced severe migraine-like headache with pho­
tophobia after the last immunization, which may theoretically have been caused by increased 
vasospastic sensitivity. Vasospasm may also be induced by illicit drugs, most notably cocaine, 
but also marijuana [30, 31]. The volunteer denied to have used recreational drugs and the toxi­
cology screening was negative.
Coronary thrombosis, often secondary to an inherited or acquired thrombophilia, may also 
cause a transient coronary obstruction. No inherited thrombophilia was detected in this volunteer. 
Acquired thrombophilia may result from changes in coagulation cascade, endothelial function and 
platelets. Hypercoagulability caused by auto-immune disease, e.g. the antiphopholipid syndrome, 
seems unlikely because antiphospholipid antibodies and the ANCA were negative (Table 1).
166
General discussion and Summary
Inflammation may result in a transient coagulopathy, although in this volunteer neither a 
pronounced pro-inflammatory state, nor a pronounced coagulopathy were observed [32]. The 
volunteer did use an oral contraceptive which might increase the risk for arterial thrombosis, 
although this risk is minimal in young, non-smoking women [23]. Inflammation also affects en­
dothelial cell function. Endothelial dysfunction may impair endothelium-dependent relaxation, 
induce vasoconstriction and vasospasm and promote platelet adhesion [33, 34]. Release of von 
Willebrand factor (vWF) may mediate this platelet adhesion [35]. Endothelial cell activation with 
adherence of infected erythrocytes is considered a key factor in the pathogenesis of a P. fal­
ciparum infection. Indeed, the occurrence of endothelial cell activation with release of active 
vWF has previously been demonstrated in early experimental malaria infections [36]. Increasing 
evidence suggests a potential mechanistic role for vWF in the pathogenesis of acute coronary 
syndromes [37]. However, significant rises in vWF levels have also been demonstrated in pa­
tients with naturally acquired malaria without the development of any coronary syndromes [38]. 
Nonetheless, regardless of biological explanations, various studies have found recent infections 
to be associated with acute coronary syndromes with normal coronary arteries [39].
A substantial fall in platelet numbers is observed during the P. falciparum blood stage in ex­
perimental malaria, followed by a rapid recovery and a transient relative thrombocytosis [2, 36]. 
Young platelets are considered to be more reactive and increased numbers of young platelets 
have been reported in patients with myocardial infarction [40, 41].
Finally, histamine is a strong inducer of endothelial cell activation. The volunteer has an al­
lergic diathesis and the day before the event she experienced some shortness of breath, which 
she attributed to hay fever. In the Kounis syndrome acute coronary syndromes are associated 
with mast cell activation and hypersensitivity [42, 43].
Changes in endothelial cell function, platelets and the coagulation system during experi­
mental malaria might increase the likelihood for an acute coronary syndrome. However, it 
should be noted again that these changes also occur in naturally acquired malaria infections 
in individuals living in malaria-endemic regions and in non-immune travelers - both groups in 
which acute coronary syndromes are not encountered.
Another possible diagnosis in this young female is myocarditis. Differentiation between 
acute coronary syndrome and myocarditis is difficult since many clinical and laboratory findings 
overlap. Because of the young age, the absence of clear cardiovascular risk factors and the find­
ings by cardiac MRI, myocarditis is a reasonable alternative diagnosis. A high occurrence of myo­
carditis has been found in young patients without risk factors presenting with a clinical picture 
of an acute coronary syndrome and normal coronary arteries [44]. Post-infectious myocarditis 
can be associated with cardiac events especially in combination with viral infections [45-49]. 
Convalescent titers in the patient were negative, neither confirming nor excluding viral infec­
tion. In relation to malaria few cases of myocarditis have been reported, but these reports were 
limited to patients with severe or fatal falciparum malaria [12-15]. In uncomplicated malaria with 
low parasitaemia, as was the case in this volunteer, myocarditis has never been reported. Vacci­
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nations, in particular smallpox have been associated with myocarditis, though in a small number 
of cases [49-52]. The clinical presentation of post-vaccination myocarditis may mimic that of an 
acute coronary syndrome, making the diagnosis particularly challenging [48, 53]. In this volun­
teer, the event occurred rather late at 94 days after the last LSA3 immunization, which makes 
the association less likely. In such case, a boost of anti-LSA3 antibodies by the malaria challenge 
would have been expected, which was not detected.
In conclusion, this volunteer presented with limited myocardial necrosis after an experimen­
tal human malaria infection. Multiple factors possibly contributing to the cardiac event can be 
identified, e.g. the preceding vaccinations, malaria infection or antimalarial drugs. However, the 
relation of this serious adverse event with the experimental malaria infection is probable be­
cause of its relation in time and apparent absence of underlying illness; this is in striking con­
trast, however, with the millions of malaria cases each year and the fact that such complication 
has never been reported in literature. The rare occurrence of cardiac events with any of the pre­
ceding study procedures may even support a coincidental finding. Apart from acute coronary 
syndrome, myocarditis can be considered as final diagnosis but the true nature and pathophysi­
ological explanation of the event remain unclear.
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Chapter 12
GENERAL DISCUSSION
The work described in this thesis predominantly deals with the effects of malaria on the host's 
iron metabolism (Part I) and the causes of malaria-associated thrombocytopenia (Part II). Both 
topics are being discussed in more detail below.
PART I: IRON AND MALARIA
Iron deficiency is the most prevalent micronutrient deficiency in the world and iron supple­
mentation or food fortification are considered important public health interventions [1]. Iron 
therapy in malaria endemic regions has been a much debated issue in the past years and im­
portant questions regarding the efficacy, optimum timing, potential hazards of iron therapy and 
the proper selection of individuals in need of extra iron remain unanswered. The first step in 
answering these questions is to delineate the effects of malaria on the host's iron homeostasis. 
Our general understanding of iron metabolism has evolved dramatically in the past decade with 
the discovery of the iron regulatory protein hepcidin and of specialized iron transporters like 
ferroportin.
In this thesis, we describe four studies in which we studied changes in iron homeostasis in 
the following settings: a) anemic Tanzanian children with febrile P. falciparum  malaria (chapter
2), b) healthy volunteers participating in an experimental P. falciparum  malaria infection (chap­
ter 3), c) Indonesian children with asymptomatic malaria (chapter 4), and d) women with preg­
nancy malaria and their offspring (chapter 5). The data obtained in these studies help to answer 
the following questions.
How does malaria alter the host's iron homeostasis?
Iron for erythropoiesis (20-25mg/day) is normally provided by recycling of iron by tissue mac­
rophages which are localized in the spleen, bone marrow and liver and which primarily derive 
iron from erythrophagocytosis of senescent red blood cells (RBC). Iron is liberated from heme 
by heme oxygenase and coupled to ferritin molecules or exported back to the plasma via fer­
roportin.
This homeostatic balance is disturbed in malaria, and to the greatest extent in febrile ma­
laria. Uptake of iron by macrophages increases due to: i) erythrophagocytosis of infected and 
uninfected RBC, and ii) increased uptake of transferrin and non-transferrin bound iron as a result 
of up-regulated expression of transferrin receptors (induced by anti-inflammatory cytokines, 
e.g. interleukin (IL)-10, IL-4) and of the iron divalent metal transporter 1 (DMT-1; induced by 
IFN-y). To bind the abundant (heme) iron, macrophages increase the production of ferritin under 
the influence of pro-inflammatory cytokines (e.g. TNF-a and IFN-y). At the same time, release of 
iron from macrophages decreases due to cytokine-induced inhibition of ferroportin expression
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and due to stimulated hepcidin synthesis. Hepcidin expression is stimulated by the pro-inflam­
matory cytokine IL-6 and by suppressed erythropoietic activity and results in degradation of the 
sole iron exporter ferroportin in the spleen, tissue macrophages and in the enterocytes of the 
duodenum [2]. The net result of these changes is the development of functional iron deficiency, 
i.e. low serum iron concentrations (hypoferremia) together with iron sequestration in the spleen 
and the reticuloendothelial system, and this is characteristic for the anemia of inflammation, 
also known as the anemia of chronic disease (ACD). Overexpression of hepcidin in transgenic 
mice indeed leads to the typical features of the anemia of inflammation [3]. Hepcidin can also 
directly inhibit red blood cell production during inflammation [4].
The changes in iron homeostasis in our studies were most outspoken in Tanzanian children with 
acute (febrile) P. falciparum  malaria (chapter 2). All children had high concentrations of urine 
hepcidin and pro-inflammatory cytokines (IL-6, TNF-a, IL-1), together with high ferritin concen­
trations and hypoferremia. These abnormalities were rapidly reversible upon start of antima- 
larial treatment; cytokines and hepcidin concentrations fell steeply and this was associated with 
a clear increase in serum iron levels through restored iron efflux from macrophages. Howard et 
al have also reported high urinary hepcidin concentrations in a cross-sectional study in patients 
presenting for evaluation of possible P. falciparum  malaria in Ghana [5]. Interpretation of this 
study is however difficult as only semi-quantitative hepcidin values are given without any levels 
of iron status indicators or inflammatory markers.
We also found mild disturbances in iron homeostasis in Indonesian children with asymp­
tomatic malaria, in the absence of a marked acute phase response (chapter 4). This is especially 
relevant since this chronic condition usually remains undiagnosed and untreated. Children with 
asymptomatic parasitemia had slightly higher serum hepcidin concentrations than aparasit- 
emic children, together with lower concentrations of hemoglobin and serum iron and higher 
concentrations of ferritin. This suggests that this slight increase in hepcidin is sufficient to lead to 
some degree of functional iron deficiency and iron-restricted erythropoiesis. This is supported 
by our study in experimental human malaria in which a similar slight increase in serum hepcidin 
in the volunteers was sufficient to lead to a marked reduction in the hemoglobin concentration 
in reticulocytes, suggestive for iron-restricted erythropoiesis (chapter 3).
Impaired duodenal iron absorption by elevated hepcidin expression in asymptomatic ma­
laria or recurrent episodes of febrile malaria may thus theoretically lead to absolute iron defi­
ciency. Data on this issue are however almost nonexistent. One study in northern Liberia found 
significantly lower Hb A2 values in children from a malaria-holoendemic region in comparison 
with those from a hypoendemic region; chloroquine prophylaxis significantly increased Hb A2 
values [6]. As iron deficiency is associated with lower Hb A2 values, this may indeed support 
the hypothesis that asymptomatic malaria contributes to iron deficiency. In the children with 
asymptomatic malaria from Sumba Island in Indonesia, however, absolute iron deficiency (i.e. 
low ferritin levels) seemed rare one month after treatment.
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The regulation of hepcidin expression is complex and primarily depends on the following 
factors: systemic iron availability, levels of inflammatory cytokines, and erythropoietic signals 
(reviewed in [7]). Putative erythroid regulators are growth differentiation factor 15 (GDF15) and 
twisted gastrulation homolog 1 (TWSG1), which are released by erythroid precursors and inhibit 
activation of hepcidin. So, increased erythropoietic activity decreases hepcidin levels to maxi­
mize iron absorption and utilization, while hepcidin levels are high in conditions with a sup­
pressed hematopoiesis [8]. The etiology of the very high hepcidin levels in febrile malaria most 
likely involved a combination of inflammation, suppressed erythropoiesis and possibly direct ef­
fects of parasite products [9]. A relation with erythropoietic activity was suggested by a negative 
correlation of urine hepcidin levels with sTfR, a well known indicator of erythroid mass. GDF15 
levels were high in a small group of Sumbanese with febrile malaria (chapter 4) and this may 
negate part of the malaria-stimulatory effects on hepcidin expression. The etiology of the mildly 
elevated hepcidin levels in asymptomatic parasitemia is less clear, especially because there was 
no marked acute phase response and sTfR levels were high, suggesting increased erythropoietic 
activity. Most likely, the absence of absolute iron deficiency at baseline, combined with discrete 
inflammation led to a mild stimulation of hepcidin production in these children.
Placental malaria is associated with fetal anemia and low birthweight [10] and we hypothesized 
that iron maldistribution contributes to these complications by reducing iron availability to the 
fetus. Unexpectedly, concentrations of serum hepcidin and other iron parameters were simi­
lar between primigravidae with and without placental malaria from Gabon. The pattern of iron 
parameters in most women was consistent with low absolute iron stores, which is not surpris­
ing given the physiologic increase in erythroid iron demand in pregnancy. The newborns had 
no signs of absolute or functional iron deficiency, suggesting that the adequate maternal to 
fetal iron supply is maintained as long as possible for fetal erythropoiesis and other vital de­
velopmental processes. This is an essential process, as an adequate amount of iron needs to be 
stored by the fetus during gestation (about 250 mg of iron) to avoid developing iron deficiency 
while being breastfed as breastmilk is relatively poor in iron [11]. Given the low iron stores in 
the mothers, we had expected low hepcidin levels in the mothers to allow maximal availability 
of iron for the fetus. A recent study in healthy Finnish pregnant women at term indeed found 
low circulating hepcidin concentrations [12]. The relative high hepcidin concentrations in our 
study group may therefore appear surprising and we hypothesize that these are related to cy­
tokine activation towards the end of pregnancy and during labor [13]. Women with anemia had 
lower hepcidin values despite similar CRP concentrations, suggesting that anemia dampens the 
inflammation-induced hepcidin secretion, as recently demonstrated [14].
What are the consequences for iron therapy?
It is still common practice for anemic children with febrile malaria to receive iron supplements 
together with antimalarial drugs. Hepcidin decreases the expression of duodenal ferroportin
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and thus iron absorption [15, 16] and our data suggest that the effects of oral iron in subjects 
with febrile malaria are suboptimal because of blocked duodenal iron absorption and iron re­
tention in macrophages. Our study also showed that the functional iron deficiency was rapidly 
reversible upon start of antimalarial treatment with a marked increase in serum iron by day 2 
(chapter 2). Release of sequestered iron is thus likely to cover initial erythropoietic iron needs. 
Whether iron therapy is beneficial at a later stage will depend on the absolute iron status of the 
subject, i.e. whether there is enough iron available for the hematologic recovery. Iron stores are 
difficult to assess during inflammation and the decision to start with iron should idealistically be 
guided by the results of iron status parameters determined after disappearance of inflamma­
tion. Iron status parameters are distorted by inflammation (see below) and it is not well known 
how fast hepcidin and iron parameters return to their pre-infection values after malaria. In our 
study in Tanzanian children, urine hepcidin and inflammatory markers were low in most chil­
dren at day 28 after start of antimalarial treatment; no data were available about the interval 
between day 2 and day 28. In our experimental malaria model, serum hepcidin and other iron 
status indicators had returned to baseline values by week 3 after parasite inoculation, which cor­
responds with day 10-14 after start of antimalarial treatment. Although there are obvious differ­
ences between experimental and naturally acquired malaria infections, these data suggest that 
results of iron status indications will probably adequately reflect true iron status from around 2-3 
weeks after antimalarial treatment.
Based on our findings, if empirical treatment with iron supplements is chosen, it seems wise not 
to start too early, i.e. not within one or two weeks after antimalarial treatment. Only a handful 
of clinical studies is available on the benefit of iron combined with antimalarials following acute 
malaria and results are contradictory and confusing. In one study from the Gambia, co-admin­
istration of iron (during 1 month) with antimalarials to children with malaria resulted in a better 
hematologic recovery [17]. In contrast, a study from Tanzania showed no benefit from added 
iron on hemoglobin levels in children with malarial anemia [18], while a third study showed only 
a better hematologic recovery by iron in children with a hemoglobin level below 8 g/dL [19]. 
The effectiveness of iron supplementation immediately after treatment of malaria has not been 
studied. One could reason that oral iron is not harmful when hepcidin levels are high because it 
will not be absorbed. However, non absorbed iron is associated with common side effects such 
as nausea and it may alter the composition of the gut microflora.
Changes in iron homeostasis in asymptomatic malaria may especially be relevant for univer­
sal iron supplementation or fortification programs since asymptomatic parasitemia is a chronic 
and often untreated condition. In general, as summarized in a recent Cochrane review, most 
individual studies in resource poor countries have found a positive effect of iron treatment on 
hemoglobin and on anemia prevalence and these effects seemed independent of malaria ende- 
micity [20]. Our data, however, suggest that presence of asymptomatic parasitemia may reduce
177
Chapter 12
duodenal iron absorption and leads to some degree of macrophage iron retention. High preva­
lence of asymptomatic parasitemia may thus account for the rather disappointing effects of 
iron fortification on iron status and anemia in some studies in Sub-Saharan Africa [21]. Recently, 
this notion was supported by an iron isotope study in Beninese women [22]. Asymptomatic P 
falciparum  parasitemia was associated with a =  40% decrease in dietary iron absorption in these 
women; systemic iron utilization was not affected, although the latter may have been confound­
ed by the antimalarial effects of concurrent administration of ciprofloxacin.
The subject's absolute iron status is likely to partly determine the degree of iron absorption 
during malaria parasitemia. Theurl et al. have recently shown in mice that hepcidin levels are 
considerably lower in anemia of inflammation combined with absolute iron deficiency than in 
anemia of inflammation alone [14]. This suggests that iron deficient subjects may continue to 
absorb iron despite the presence of some degree of inflammation.
Finally, several initiatives are being undertaken to develop drugs that specifically aim to inhibit 
the actions of hepcidin. Antihepcidin antibodies have already proven to be an effective treat­
ment for anemia of inflammation in a mouse model [23]. However, although these specific hep­
cidin blocking interventions may offer a new treatment for anemia of inflammation in diseases 
with chronic inflammation, e.g. rheumatoid arthritis or chronic kidney diseases, their role in ma­
laria will be limited. Treatment of parasitemia with antimalarial drugs will be a far more practical 
and cheaper method to lower hepcidin levels.
New iron status indicators
As a consequence of the results of the large trial by Sazawal et al. which showed adverse effects 
of iron and folic acid supplementation in Zanzibar in children without iron deficiency [24], the 
WHO released a new consensus statement in which universal iron supplementation is discour­
aged for children under the age of two years living in malaria-endemic areas [25]. Instead, iron 
supplements should be reserved for children with proven iron deficiency. Implementation of 
this recommendation has burdened the global health community with important practical ob­
stacles. Especially the widespread assessment of children's iron status is a challenging task, as 
available biochemical iron parameters are costly, time-consuming and often difficult to inter­
pret.
Ideally, a single parameter identifies those subjects in whom oral iron increases iron availability 
to the developing erythron. Presently, such parameter is not available due to the complex inter­
action between iron homeostasis, inflammation and erythropoiesis. Infectious diseases such as 
malaria are extremely common in many tropical regions and their high prevalence complicates 
the use of many traditional iron parameters. Serum or plasma ferritin concentrations are the 
most reliable indicator of iron stores in healthy individuals, but concentrations are increased
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in infectious diseases because ferritin is also an acute phase protein. Serum iron cannot dif­
ferentiate between absolute iron deficiency (AID) and inflammation-associated functional iron 
deficiency (IFID) because levels are low in both conditions; the transferrin saturation can either 
be normal or low during IFID. Another parameter that is increasingly being used is the concen­
tration of red cell zinc protoporphyrin (ZPP). This test relies on the fact that zinc replaces iron 
in the protophorphyrin ring when iron is unavailable, causing the concentration of ZPP to rise. 
Elevated concentrations can thus be found in both AID and IFID and this parameter can thus not 
differentiate between both conditions. The effect of zinc deficiency, which is a common micro­
nutrient deficiency in many tropical regions, on the ZPP value is also unknown.
Soluble transferrin receptor (sTfR) concentrations have been suggested to be a valuable param­
eter for distinguishing AID from IFID. sTfR originates mostly from erythroblasts and to a lesser ex­
tent from reticulocytes and sTfR concentrations correlate well with erythropoietic activity [26]. 
The cellular expression of TfR on bone marrow erythroid precursor cells increases during iron 
deficiency and sTfR concentrations are thus elevated in AID. In contrast, erythropoiesis is usually 
suppressed in inflammation and this prevents sTfR concentrations to rise [26, 27]. In practice, 
serum ferritin concentrations appear superior over sTfR to diagnose AID in absence of inflamma­
tion [28, 29] and elevated sTfR are not specific for AID as they may also be elevated in conditions 
with increased erythroid precursor cells (e.g. thalassemia). While some studies have found that 
AID could be distinguished from IFID on the basis of sTfR results [30, 31], others have failed to 
do so [32, 33].
A combination of iron parameters may better estimate iron status. Cook and colleagues showed 
that the ratio of sTfR to ferritin (or its log) provides a good estimation of total body iron in popu­
lation studies [34]. Moreover, the ratio was also shown to be a good predictor of absolute iron 
deficiency in patients with chronic inflammation, i.e. patients with chronic or recurrent infec­
tions, a chronic inflammatory illness such as rheumatoid arthritis or a nonhematologic malig­
nancy [35]. Use of this ratio to distinguish AID from anemia of chronic disease with or without 
concurrent AID has since then be promoted by several authors [36, 37]
Use of sTfR or the sTfR/ log ferritin ratio has, however, not gained wide acceptance and its use in 
malaria areas has several potential disadvantages. First, there is no international standardization 
of sTfR assays and reference values of the various assays vary widely. This is about to change 
with the introduction of a WHO reference standard reagent in 2010 [38]. Second, as mentioned 
above, sTfR originates mostly from erythroblasts and to a lesser extent from reticulocytes and 
erythropoietic activity is thus an important determinant of sTfR levels [26]. This makes use of 
sTfR problematic in malaria, as erythropoiesis is usually suppressed in acute malaria, while the 
bone marrow in asymptomatic parasitemia is characterized by erythroid hyperplasia with dys- 
erythropoiesis [39]. This variation in erythropoietic activity explains why studies have found
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both increased [40, 41] and decreased [42, 43] concentrations of sTfR in malaria. Third, serum 
ferritin concentrations may rise disproportionally during malaria because of the hyperactivated 
phagocytic system with massive erythrophagocytosis of both infected RBC and uninfected RBC 
and because of damage to hepatocytes. Liver enzyme abnormalities are frequently found in 
malaria patients and may result of sequestration of infected RBC in the liver microcirculation 
[44, 45]. Ferritin is present in high quantities in liver tissue and may thus leak into the circula­
tion. In our opinion, sTfR concentrations or the ratio should thus be used with care in malaria- 
endemic regions. This is illustrated by data from the studies described in this thesis: mean sTfR 
concentrations were markedly higher in Indonesian children with asymptomatic parasitemia 
(2.5 mg/L) compared with healthy controls (1.5 mg/L) and subjects with symptomatic malaria 
(1.3 mg/L; chapter 4). Moreover, sTfR/log ferritin index decreased substantially (to 67% of the 
baseline value) in our experimental malaria model during parasitemia, which was largely due to 
an increase in serum ferritin (chapter 3). In the anemic Tanzanian children with febrile malaria, 
sTfR-log ferritin ration increased from a mean of 1.06 to 1.79 by day 30, owing to a fall in ferritin 
concentrations combined with a rise in sTfR (chapter 2).
So, current biochemical iron status indicators are neither reliable, nor affordable or field-friendly. 
Moreover, with the possible exception of sTfR, they do not provide direct information on iron 
availability for erythropoiesis. So, there is urgent need for new functional biomarkers which pre­
dict the response to iron supplements. Two promising new biomarkers that were explored in 
this thesis are serum hepcidin and new reticulocyte parameters.
First, given its central role in homeostasis, serum hepcidin concentrations may be a valuable 
diagnostic tool to predict and monitor the need for iron supplementation. Two iron absorp­
tion studies in young females indeed showed that serum hepcidin concentrations predicted 
iron absorption, although this predictive effect was only modest [46, 47]. As already mentioned 
above, Theurl and colleagues recently showed in both humans and rats that patients with a 
combination of anemia of chronic disease (ACD) and AID had markedly lower hepcidin con­
centrations than those with ACD, together with lower duodenal ferroportin expression and in­
creased duodenal iron absorption [14]. These data suggest that serum hepcidin concentrations 
can distinguish ACD from ACD/AID. In general, individuals with low hepcidin concentrations 
are expected to respond to treatment with oral iron while those with high hepcidin levels are 
not. Hepcidin can be measured in urine and serum. The urine assay was operational before the 
serum assay and this was the reason why urine hepdidin concentrations were measured in our 
study in Tanzania (chapter 2). Interpretations of the urine concentrations in malaria patients may 
be complicated by changes in the fractional excretion of hepcidin. After filtration, hepcidin is 
almost completely reabsorbed by the proximal tubulus [48]. Tubular dysfunction is common 
in malaria infections and this may have a significant impact on urine hepcidin concentrations. 
Therefore, serum hepcidin assays are clearly preferred over urine assays.
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Many hurdles need to be taken, however, before hepcidin can be employed on a large scale. 
First, measurement of hepcidin proved technically difficult. Reliable assays based on mass spec­
trometry and immunochemical methods have only recently become available [48-50] and are 
still laborious and expensive. An easy to perform, field friendly and inexpensive method thus 
needs to be developed first. Second, there is no standardization yet of the various methods 
which makes comparison of data difficult [51]. Reference values for various populations can only 
be established after such standardization. Third, the predictive value of hepcidin for iron ab­
sorption needs to be determined in various pathological conditions (e.g. chronic inflammation, 
malaria, hemoglobinopathy).
New erythrocyte and reticulocyte parameters reported by a new generation automated hema­
tology analyzers may offer a fast and inexpensive alternative to the traditional biochemical iron 
indicators. Especially the hemoglobin content of individual reticulocytes (Ret-Hb) has showed 
promising results as an early indicator of iron deficient erythropoiesis. This parameter can be 
measured on Sysmex analyzers (abbreviated as Ret-He; Sysmex Corporation, Kobe, Japan) and 
on Siemens analysers (abbreviated as CHr; Siemens, Deerfield, IL, USA); Ret-He and the CHr have 
been shown to correlate well with each other [52]. The reticulocyte hemoglobin content is the 
product of the reticulocyte volume and hemoglobin concentration and represents an indirect 
measure of the functional iron available for erythropoiesis over the previous 2-4 days. This pa­
rameter has proven to be a useful screening tool for iron deficiency in both children [53-55], 
adults [56] and pregnant women [57] that often outperformed traditional biochemical iron pa­
rameters. Moreover, multiple studies have the usefulness of reticulocyte haemoglobin content 
in monitoring iron deficiency and the response to intravenous iron in patients on dialysis [58­
60].
So far, there are no data on the use of Ret-Hb in malaria-endemic regions and our study in ex­
perimental malaria was the first report of Ret-Hb in malaria. Use of Ret-Hb in malaria-endemic 
regions may have several possible limitations. First, the high prevalence of thalassemia may 
complicate the interpretation of Ret-Hb values, because Ret-Hb levels are usually low in this 
hemoglobinopathy due to the microcytosis. Formulas based on other erythrocyte indices, such 
as the % microcytic minus the % hypochromic cells, may differentiate thalassemia from iron 
deficiency [61].
Second, it is unclear to what extent Ret-Hb can differentiate between AID and IFID due to acute 
or chronic inflammation. Ret-Hb levels were lower in patients with AID than in patients with 
anemia of chronic disease in several studies [52, 62, 63], but there seems a considerable over­
lap in values [64, 65]. Especially in acute infections accompanied by a strong inflammatory re­
sponse, Ret-Hb levels may decrease steeply because of the hepcidin-mediated hypoferremia. 
Erythrocyte parameters that give an indication of hemoglobinization over the past 2-3 months, 
such as the hemoglobin content of mature red blood cells or the percentage hypochromic red
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blood cells, may provide additional information in these circumstances, as these are expected 
to remain largely unchanged in acute IFID. To further overcome the difficulties in differentiation 
AID from IFID, Thomas et al. have proposed a diagnostic plot in which they combine Ret-Hb 
as a parameter for hemoglobinization with the sTfR/log ferritin ratio as an indication of bone 
marrow iron stores [65]. For reasons outlined above, use of this plot has its limitations in malaria- 
endemic regions. Third, these new hematologic parameters are still only available on the latest 
generation hematology analyzers. The first step that needs to be taken before these reticulocyte 
parameters can be used in resource poor countries, is that these parameters will become avail­
able on affordable and field friendly analyzers.
In conclusion, Ret-Hb and other new hematologic parameters may be an easy, rapid and inex­
pensive tool for a first selection of subjects who may benefit from iron supplements. In those 
cases in which AID cannot be differentiated from IFID, additional biochemical parameters (e.g. 
serum ferritin, CRP or hepcidin) or the response to a short trial of oral iron can be used. Table 
1 in chapter 3 summarizes the putative diagnostic utility of Ret-Hb. Further studies in relevant 
populations in malaria-endemic regions need to be done to determine reference values and the 
ability to distinguish AID from IFID in settings of acute and chronic inflammation and in subjects 
with thalassemia.
PART II: PLATELETS AND MALARIA
Malaria-associated thrombocytopenia: pathogenesis and the role of VWF
Thrombocytopenia is a hallmark of malaria infections and correlates with the severity of infec­
tion. During experimental malaria infection, we noticed that the platelet counts dropped already 
very early after the onset of the blood-stage of the malaria infection. Using this experimental 
model, we could show that reduced thrombopoiesis, platelet activation and consumptive co­
agulopathy did not occur in early malaria. These processes are often quoted to be responsible 
for the malaria-associated thrombocytopenia, but our findings suggest that their role is limited, 
at least in early malaria.
Instead, we found that the development of thrombocytopenia coincided with an increase in von 
Willebrand factor (VWF) and its propeptide. Moreover, the circulating VWF was also hyperreac­
tive, as demonstrated by enhanced binding of the llama nanobody AU/VWFa-11, which recog­
nizes an active conformation of the VWF A1 domain capable of spontaneous platelet binding
[66]. VWF and its propeptide are both predominantly derived from endothelial cells and both 
are well known markers of endothelial cell activation. Other endothelial cell activation markers, 
ICAM-1 and angiopoietin-2, showed a similar time course as VWF in experimental human ma­
laria (unpublished data). This implies that malaria induces early endothelial cell activation with
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adhesion of platelets and leukocytes to the endothelium. Early activation of the endothelium 
is important for the malaria infections as infected RBC need to adhere to the endothelium to 
prevent clearance by the spleen.
The mechanism responsible for this early endothelial activation and VWF release is unclear. We 
have done various experiments to identify involved mechanisms (unpublished data). Incuba­
tion of human umbilical vein endothelial cells (HUVEC) with infected RBC induced a clear dose 
dependent increase with increasing parasite densities in mRNA concentrations of the endothe­
lial markers E-selectin and VCAM-1, but there was no specific effect on VWF or ICAM-1 mRNA ex­
pression. Incubation of HUVEC with infected RBC also failed to increase VWF levels to detectable 
levels in the supernatant. In contrast, sera from experimentally infected volunteers increased 
mRNA levels of VWF, ICAM-1 and E-selectin three to five fold. These preliminary data suggest 
that interaction of infected RBC with endothelial cells results in upregulation of some endothe­
lial proteins (E-selectin, VCAM-1), but not of VWF. Instead, a circulating serum factor may pri­
marily responsible for the increase in VWF and ICAM. The nature of this circulating factor is still 
unknown. Examples of factors that could be involved are infected RBC derived microparticles, 
which were recently shown to stimulate macrophages more potently than intact infected RBC
[67], other parasite products or proinflammatory cytokines. The latter seems less likely as VWF 
levels had already increased before the first measurable increase in cytokines. Further studies 
using sera from experimentally infected volunteers are underway.
Malaria as a thrombotic microangiopathic disease?
The findings from the experimental malaria infection model were subsequently explored in field 
studies in Indonesia. We (chapter 9) and others indeed found that VWF and propeptide concen­
trations are elevated in patients with naturally acquired malaria [68-71]. Unlike in the experi­
mental model, a deficiency in ADAMTS13 was found in the field study, a finding also reported 
by Larkin et al. [69] and Lowenberg et al. [70]. This circulating metalloproteinase is crucial in 
the regulation of VWF-platelet interactions. Following secretion of VWF from endothelial cells, 
long strings of VWF remain attached to the endothelium and unfold due to exposure to shear 
stress. Unfolding of VWF exposes its platelet-binding sites within the VWF A1 domains and en­
ables spontaneous platelet binding. ADAMTS13 inhibits this process by proteolysis of the ultra- 
large VWF multimers (UL-VWF). ADAMTS13-mediated proteolysis thus reduces the spontaneous 
platelet-binding capacity of VWF by removal of UL-VWF and by dissociation of VWF from the 
endothelial surface, which enables VWF to adopt a more globular conformation which prohibits 
platelet binding. ADAMTS13 deficiency in the Indonesian subjects was indeed associated with 
the occurrence of UL-VWF (chapter 9). The importance of ADAMTS13 is especially illustrated 
by the devastating microvascular thrombotic disorder, thrombotic thrombocytopenic purpura 
(TTP). A severe deficiency in ADAMTS13 is the central pathogenic mechanism in this disease, 
which is characterized by systemic occlusion of small blood vessels by platelet thrombi. Impor­
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tant clinical features of TTP resemble those of a severe malaria infection, such as fever, thrombo­
cytopenia, hemolysis and neurological symptoms (seizures). In addition, pregnancy is a known 
risk factor for TTP and for severe malaria.
As already described above, an increased amount of the circulating VWF was in an 'active' con­
formation, i.e. in an open, unfolded conformation that favors platelet binding. Increased lev­
els of active VWF have been found in various pathologic conditions with thrombocytopenia, 
e.g. malignant hypertension, HELLP syndrome and the antiphospholipid syndrome [72-75]. Al­
though the regulation of VWF-platelet interaction is still incompletely understood, the presence 
of elevated levels of active VWF in these conditions may be due to acute endothelial cell activa­
tion, high shear stress with a change in conformation of VWF from the globular, quiescent form 
into the elongated active form, and/or changes in the activity of functional VWF inhibitors [76]. 
Besides ADAMTS13, two other proteins have been identified that may prevent premature for­
mation of VWF-rich thrombi: osteoprotegerin (OPG) and beta2-glycoprotein-1 (P2-GPI). OPG is 
a Weibel-Palade body constituent, just like VWF, which binds selectively to the VWF A1 domain 
and remains associated to VWF in the circulation, suggesting that it may interfere with platelet 
binding [77]. |32-GPI also inhibits platelet binding to VWF and it may especially be important in 
the prevention of undesired platelet aggregation in conditions with increased VWF in a platelet- 
binding conformation [74]. Whether malaria is associated with changes in these natural inhibi­
tors is still unknown; studies are underway.
Inhibition on the level of the platelet may also prevent excessive VWF-platelet interaction. We 
found that malaria was associated with increased soluble levels of the external domain of the 
glycoprotein (GP)1b receptor (chapter 10). Recently, interaction of VWF with platelets was shown 
to induce shedding of GP1b from platelets [78]. This shedding of sGP1b leads to a dramatic at­
tenuation of normal platelet adhesive properties [79]. Indirect evidence for the relevance of this 
phenomenon is presented in chapter 10: sGP1b and VWF had a similar time course in experi­
mental malaria and levels of both proteins correlated well in naturally acquired malaria. The me- 
talloprotease ADAM17/TACE is responsible for shedding of GP1b [78, 79]. Studies investigating 
ADAM17/TACE activity in malaria are underway.
Taken together, endothelial cell activation with increased circulating levels of VWF in a plate­
let binding conformation and reduced proteolysis by ADAMTS13 may lead to the formation of 
platelet-rich thrombi in the microcirculation and, as such, malaria has clear features of throm­
botic microangiopathic diseases (TMA). Indeed, accumulation of platelets in the cerebral mi­
crocirculation has been observed in pediatric autopsy series [80], although fragmented red 
blood cells are not commonly seen in severe malaria. The imbalance between active VWF and 
ADAMTS13 activity levels may have two potential consequences in malaria. First, formation of 
platelet-rich thrombi in the microcirculation may contribute to the development of organ fail­
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ure. Second, it may lead to better cytoadherence of infected RBC to the endothelium. Bridges 
et al recently showed that infected RBC adhere to UL-VWF strings decorated with platelets in a 
CD36-dependent manner [81]. This mechanism is especially important in the cerebral microcir­
culation as cerebral endothelium is largely devoid of CD36.
Are these disturbances in the VWF/ADAMTS13 specific for malaria? Similar abnormalities in VWF 
and ADAMTS13 can be found in patients with severe sepsis [82-86]. Sepsis is also associated 
with thrombocytopenia and organ failure and the importance of secondary microangiopathy 
in these conditions is increasingly appreciated [86]. What makes malaria special is that endo­
thelial activation already occurs very early during the course of the infection with a still limited 
inflammatory response. In addition, while activation and dysfunction of the endothelium with 
sequestration of infected RBC are central factors in malaria, sepsis is primarily an immunopatho- 
logical process with intense inflammation and activation of platelets and coagulation. Thus, the 
observed changes in VWF so early in the course of a malaria infection in absence of an intense 
inflammatory state without platelet activation and coagulopathy seem specific for malaria and 
may be related to the need for sequestration of infected RBC.
The cause of the low ADAMTS13 was studied extensively in our study in Indonesia and so far, 
we have failed to come up with a conclusive explanation. Larkin et al found evidence for a cir­
culating ADAMTS13 inhibitor [69], while we did not. Supra-physiologic concentrations of free 
hemoglobin and interleukin-6 have been shown to inhibit ADAMTS13 activity in vivo, but in 
vivo levels in the two studies by Larkin et al and Lowenberg et al. remained well below these re­
quired levels [69, 70]. Incubation of plasma with infected RBC also failed to decrease ADAMTS13 
levels (unpublished data), suggesting that there are no specific proteases released from infected 
RBC that inhibit ADAMTS13. ADAMTS13 is predominantly produced by stellate cells in the liver, 
but (small) amounts are also present in endothelial cells. While it is unknown whether hepatic 
ADAMTS13 synthesis is reduced in malaria, we found no decrease in mRNA levels of ADAMTS13 
in HUVECs following incubation with infected RBC (unpublished data). Finally, ADAMTS13 lev­
els may decrease because of consumption by high circulating VWF levels. An acute increase 
in circulating VWF levels in volunteers through administration of desmopressin or endotoxin 
is followed by a decrease in ADAMTS13 levels [87, 88] and lower ADAMTS13 levels have been 
observed in several pathologic and physiologic conditions with high VWF levels, e.g. pregnancy 
and acute inflammatory states [89]. Presently, in our opinion, acute endothelial cell activation 
with release of VWF is the most likely explanation for ADAMTS13 consumption and subsequent 
deficiency.
Plasma exchange is mainstay of therapy for TTP and the findings above suggest that elimination 
of hyperreactive VWF and replacement of ADAMTS13 through plasma exchange may also be 
beneficial in severe malaria. There is ongoing discussion on the value of exchange transfusion as
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an adjunctive treatment of severe malaria in returning travellers. While removal of infected RBC 
is the central goal of exchange transfusion, exchange of plasma may have additional beneficial 
effects. Use of plasma exchange for cases of severe thrombocytopenia-associated organ failure 
in sepsis has also been recommended by some authors and beneficial effects are suggested 
in some case reports and small trials [90, 91]. In addition, inhibitors of VWF and synthetic AD- 
AMTS13 are under development and may possibly be useful as an adjunctive therapy.
Chronic endothelial cell activation and ADAMTS13 deficiency in low-income areas?
An interesting observation in our study on Sumba island in Indonesia was that individuals from 
remote villages with a negative blood slide for malaria had a lower platelet count, together with 
a higher level of VWF and a lower level of ADAMTS13 activity and antigen (chapter 9). These 
data are only mentioned in the discussion of that chapter because the quality of the plasma 
samples from these remote villages was not guaranteed. In the meantime, we have conducted a 
large cross sectional study in several areas in Sumba and again, individuals from remote villages 
with high malaria transmission had lower platelet numbers. These findings suggest that chronic 
endothelial cell activation with elevated VWF levels, lower platelet counts and lower ADAMTS13 
levels are not uncommon in some low-income areas. Chronic infectious diseases may be highly 
prevalent in these areas and may contribute to prolonged endothelial cell activation. Children 
with asymptomatic P. falciparum  and P. vivax malaria in Sumba indeed had significantly lower 
platelet numbers than healthy children (chapter 4, table 1). We recently completed a study in 
Sumba in which blood was collected from subjects living in areas with high, low or absent ma­
laria transmission during the wet and dry season. These studies will answer whether asymptom­
atic or submicroscopic malaria is indeed associated with elevated VWF concentrations. Non- 
infectious causes such as malnutrition may also be involved. Finally, people from Southeast Asia 
may have lower ADAMTS13 activity levels. ADAMTS13 levels were lower than expected in the 
healthy controls in the malaria study in Bangladesh with values around 60-70% of Dutch normal 
pool plasma [70]. In contrast, the healthy controls in our study in Sumba had comparable AD- 
AMTS13 activity levels to those in Dutch controls.
Chronic endothelial cell activation with elevated VWF levels is considered an important car­
diovascular risk factor in developed countries [92]. In low-income countries, communicable dis­
eases have always received most of the public health attention and vascular disease, especially 
stroke, is a neglected cause of morbidity and mortality [93]. Other cardiovascular risk factors 
than the traditional 'Western' ones (e.g. smoking, obesity and dyslipidemia) may be important 
in these regions and we hypothesize that chronic infectious diseases and poverty contribute 
to chronic endothelial cell activation and possible subsequent cerebrovascular disease. Further 
studies are underway to explore this hypothesis.
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Chapter 12
Introduction
Malaria is major health problem in many tropical countries. A malaria infection is accompanied 
by clear hematological changes of which anemia and thrombocytopenia are the most pro­
nounced. This thesis focuses on these hematological changes and is divided in two parts: Part I 
deals with malaria-associated anemia and focuses on the effect of malaria on iron homeostasis, 
the cytokine macrophage migration inhibitory factor (MIF) and on malaria-induced changes in 
the red blood cell (RBC) membrane. Part II focuses on the malaria-associated thrombocytopenia 
and the importance of endothelial cell activation.
I. MALARIA ANEMIA AND IRON HOMEOSTASIS
The etiology of malaria-associated anemia is multifactorial and complex. Key mechanisms in­
clude suppressed erythropoiesis and increased clearance of both infected and uninfected RBC. 
Iron is an essential micronutrient required for the synthesis of hemoglobin and for a range of 
other cellular functions. Malaria influences the host's iron homeostasis but the exact nature of 
this interaction remained to be clarified, largely due to limited insight in the regulation of iron 
homeostasis. This has changed with the discovery of the hormone hepcidin, which has proved 
to be the long sought central regulator of iron homeostasis. We have used hepcidin to deter­
mine the effects of malaria on iron metabolism in various clinical scenarios.
Chapter 2 describes a study in anemic Tanzanian children with febrile malaria. We found that 
febrile malaria induced a strong increase in hepcidin expression and this led to maldistribution 
of iron with iron sequestration in storage sites and low serum iron levels (hypoferremia). Hepci­
din production was stimulated by reduced erythropoietic activity and inflammation. Hepcidin 
levels fell surprisingly fast after start of antimalarial therapy and this was associated with release 
of sequestered iron in the serum. In febrile malaria, iron is thus not available for erythropoiesis 
(functional iron deficiency) and this may contribute to the development of anemia. Moreover, 
it suggests that adjunctive treatment with iron supplements early after start of antimalarials is 
not effective. In addition, we speculate that iron sequestration in the reticuloendothelial system 
may explain the well known association between malaria and intracellular bacterial infections, 
such as non-typhoidal Salmonella bacteremia.
Changes in iron homeostasis and in iron parameters during malaria were further studied in 
healthy Dutch volunteers who were experimentally infected with P. falciparum  malaria (chapter
3). In contrast to the Tanzanian children mentioned above, these volunteers only develop a mild 
illness with low parasite densities and low levels of inflammatory cytokines. While only a moder­
ate increase in serum hepcidin levels occurred during the blood stage infection, hypoferremia 
developed together with a strong increase in serum ferritin levels. This iron maldistribution had
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clear functional consequences for the incorporation of iron in the bone marrow: reticulocyte 
hemoglobin (Ret-Hb) levels, a marker for iron incorporation in the bone marrow over the past 
2-4 days, fell sharply. This study also showed that traditional iron parameters, including the ratio 
of soluble transferrin receptor (sTfR) to the log ferritin, are affected even by mild malaria. This 
limits their wide scale use as a screening test to select individuals who will benefit from oral iron 
supplements in areas with a high prevalence of malaria parasitemia. Instead, we propose that 
Ret-Hb and hepcidin are better screening tests and we have proposed a diagnostic scheme.
We further extended these findings in chapter 4, in which we show that Indonesian school­
children with asymptomatic malaria also had mild disturbances in iron homeostasis in absence 
of a marked manifest acute phase response. This is especially relevant since asymptomatic para­
sitemia is a highly prevalent chronic condition that usually remains undiagnosed and untreated. 
The discrete changes in iron homeostasis in these children may not only account for their lower 
hemoglobin levels, but it also suggests that the efficacy of universal iron supplementation pro­
grams in areas with a high prevalence of asymptomatic parasitemia is reduced.
Iron deficiency, anemia and malaria are also common complications during pregnancy. 
Pregnancy malaria is an important cause of mother and neonatal infant morbidity and mortal­
ity. In the study described in chapter 5, serum hepcidin and other iron parameters were studied 
in Gabonese primigravidae with and without placental malaria and in their offspring. The most 
interesting finding was that - while women in general had low iron stores owing to the increased 
physiological iron demand during pregnancy - newborns had no signs of absolute or functional 
iron deficiency and this was independent of the presence of placental malaria. This indicates 
that placental malaria does not stimulate hepcidin levels in the newborn and that adequate 
maternal to fetal iron supply is maintained as long as possible for fetal erythropoiesis and other 
vital developmental processes.
From the studies described above we conclude that the occurrence of functional iron de­
ficiency is not restricted to febrile malaria with manifest changes in inflammation and erytho- 
poiesis, but that it also occurs in subjects with a more chronic malaria infection in absence of a 
clear pro-inflammatory response. Pro-inflammatory cytokines (e.g. interleukin-6) can not only 
up-regulate hepcidin production directly, but also indirectly by suppressing erythropoiesis. The 
cytokine MIF has been shown to inhibit erythroid differentiation and hemoglobin production in 
synergy with TNF-a and IFN-y. However, both high and low circulating levels of MIF have been 
reported in patients with malaria. In our experimental human P. falciparum  malaria model, cir­
culating MIF levels decreased during the blood stage and its treatment (chapter 6). MIF is pre­
dominantly produced by activated T-lymphocytes and we speculate that the drop in circulating 
lymphocyte numbers is responsible for the lower MIF levels.
Finally, accelerated removal of uninfected RBC also plays a major role in the development of 
malaria anemia. Malaria-induced changes in the RBC membrane may contribute to this prema­
ture removal. In the hypothesis-generating study described in chapter 7, we used a newly de­
veloped, comparative proteomics technique to analyse the RBC composition of malaria patients
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from Sumba Island in Indonesia. Proteolysis of band 3, which is one of the major integral RBC 
membrane proteins and increased binding of (denaturated) hemoglobin to the RBC membrane 
was observed in RBC from patients with P. falciparum  malaria, but not with P. v iva xmalaria. More­
over, malaria anemia was associated with loss of cytoskeleton proteins. These data suggest that 
especially P. falciparum  malaria is associated with accelerated senescence of RBC.
II. MALARIA-ASSOCIATED THROMBOCYTOPENIA
Thrombocytopenia is a hallmark of malaria infections. Increasing evidence indicates that the 
drop in platelet number is not merely an epiphenomenon, but that platelets do play a role in the 
pathogenesis of malaria. Yet, our current understanding of the causes and consequences of the 
low platelet counts in malaria is still limited.
A central protein in platelet physiology is von Willebrand factor (VWF). This protein is syn­
thesized by endothelial cells and acts as a binding protein for platelets at sites of vascular injury. 
In a study in volunteers participating in our human P. falciparum  infection model (chapter 8), 
we showed that platelet numbers drop early during the blood stage of a malaria infection. This 
drop in platelet count coincided with an increase in VWF and its propeptide, the latter being a 
marker for acute endothelial cell activation. Moreover, the circulating VWF was hyperreactive, as 
demonstrated by enhanced binding of the llama nanobody AU/VWFa-11, which recognizes an 
active conformation of the VWF A1 domain capable of spontaneous binding platelet. These data 
suggest that the early drop in platelet count is caused by early endothelial cell activation with 
release of VWF and that malaria has clear features of thrombotic microangiopathic diseases.
A study in individuals with P. falciparum  or P. vivax malaria on the Indonesian Island Sumba 
(chapter 9), confirmed that malaria is indeed associated with high levels of hyperreactive VWF. 
A striking finding in this study was that both antigen and activity levels of ADAMTS13 were re­
duced. ADAMTS13 is a metalloprotease responsible for proteolysis of ultralarge and prothrom- 
bogenic VWF multimers (UL-VWF); UL-VWF was indeed present in the plasma of these malaria 
patients. Further analysis of the cause of the ADAMTS13 deficiency showed neither mutations in 
the ADAMTS13 gene nor the presence of ADAMTS13 inhibitors.
Other possible causes of thrombocytopenia were investigated in the study described in 
chapter 10. Reduced thrombopoiesis, platelet activation and consumptive coagulopathy did 
not occur in experimentally P. falciparum  infected volunteers and these factors thus do not ac­
count for the early malaria-associated thrombocytopenia. Incubation of platelets with parasit­
ized RBC in vitro also failed to induce platelet aggregation or activation. The most striking find­
ing in platelet-derived proteins was an increase in soluble glycoprotein-1 (sGPlb), the external 
domain of platelet receptor for VWF, in both the volunteers as in Indonesian malaria patients. 
Interaction of platelets with VWF was recently shown to induce GP1b shedding and we hypoth­
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esize that this process accounts for the increase in sGP1b levels, which may prevent excessive 
adhesion of platelets and parasitized erythrocytes.
Finally, a cardiac event occurred in one of the volunteers participating in an experimental 
malaria infection. In general, changes in platelet and/or endothelial physiology may play a role 
in cardiovascular diseases. A detailed clinical description of this case together with an analysis 
of possible causative factors is given in chapter 11.
199

Chapter 13
Nederlandse samenvatting, Dankwoord en Curriculum Vitae
Chapter 13
NEDERLANDSE SAMENVATTING
Introductie
Malaria is één van de belangrijkste infectieziekten in de tropen. Een malaria-infectie gaat vaak 
gepaard met veranderingen in het bloed waarvan bloedarmoede (anemie) en een daling in het 
aantal bloedplaatjes (thrombocytopenie) het meest opvallend zijn. In dit proefschrift beschrijf 
ik verschillende onderzoeken naar de oorzaken en gevolgen van deze hematologische verand­
eringen. Het proefschrift bestaat uit twee delen: Deel I gaat over malaria-geassocieerde anemie 
waarbij de nadruk ligt op het effect van malaria op de ijzerhuishouding van de gastheer. Deel II 
gaat over de malaria-geassocieerde thrombocytopenie en het belang van activatie van de cel­
len die de binnenzijde van bloedvaten bekleden (endotheel).
I. MALARIA-ANEMIA EN IJzERHUISHOUDING
De oorzaak van de anemie die bij een malaria-infectie ontstaat is complex. Niet alleen is er een 
toegenomen afbraak van geïnfecteerde én ongeïnfecteerde rode bloedcellen, maar ook is de 
aanmaak van rode bloedcellen in het beenmerg (erythropoiese) geremd. IJzer is een essentiële 
voedingsstof die nodig is voor de aanmaak van hemoglobine en verstoringen in de ijzerhuis­
houding kunnen dus leiden tot anemie. Het was al langer bekend dat de ijzerhuishouding bij 
malariapatiënten verstoord was, maar gedetailleerde kennis over de betrokken mechanismen 
ontbrak. De recente ontdekking van het eiwit hepcidine -  dat de centrale regulator van de ijz­
erhuishouding bij mensen blijkt te zijn -  bood nieuwe mogelijkheden om dit verder te onder­
zoeken. Hepcidine wordt onder andere vrijgemaakt tijdens ontsteking en zorgt voor remming 
van de ijzeropname in de darm en opslag van ijzer in witte bloedcellen en in de lever. Het gevolg 
is een daling van het ijzergehalte in het bloed, waardoor in het beenmerg minder ijzer in he­
moglobine kan worden ingebouwd. Bij anemie wordt de afgifte van hepcidine juist geremd. 
De ontwikkeling van gevoelige bloed- en urinetesten voor hepcidine in Nijmegen maakte het 
mogelijk in detail de effecten van malaria op de ijzerhuishouding van mensen te bestuderen.
Hoofdstuk 2 beschrijft een studie bij Tanzaniaanse kinderen met een acute, ernstige malaria- 
infectie met daarbij een anemie. Ondanks de anemie hadden deze kinderen een sterk verhoogd 
hepcidine. Na start van antimalariabehandeling daalde het hepcidine verrassend snel en dit 
ging gepaard met het vrijmaken van opgeslagen ijzer. Bij acute malaria is ijzer dus niet beschik­
baar voor de aanmaak van rode bloedcellen (functionele ijzerdeficiëntie) en dit is waarschijnlijk 
één van de oorzaken van malaria-geassocieerde anemie. Deze bevindingen suggereren ook dat 
behandeling met ijzersupplementen vroeg na de start van antimalariamiddelen weinig zinvol is.
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In gezonde Nederlandse vrijwilligers die deelnamen aan een experimentele malaria-infectie zijn 
veranderingen in de ijzerhuishouding verder bestudeerd (hoofdstuk 3). Anders dan bij de Tan- 
zaniaanse kinderen ontwikkelen deze vrijwilligers een relatief milde malaria-infectie met een 
laag percentage geïnfecteerde rode bloedcellen en weinig ontsteking. Hoewel het hepcidine 
slechts licht steeg, ontstond er toch een duidelijke daling in het circulerend ijzer en een sterke 
stijging in het ijzeropslageiwit ferritine. Dit had duidelijk functionele gevolgen voor de opname 
van ijzer in het beenmerg; het hemoglobinegehalte van jonge rode bloedcellen (Ret-Hb) -  een 
maat voor de ijzeropname in het beenmerg over de afgelopen 2-4 dagen -  daalde sterk. De 
Wereldgezondheidsorganisatie adviseert in malariagebieden alleen ijzersupplementen te 
geven aan kinderen met een bewezen ijzertekort. Onze studie laat echter zien dat verschillende 
ijzerparameters, waaronder de nogal eens gepropageerde verhouding van de serum-transfer- 
rine receptor (sTfR) met het ferritine, al beïnvloed worden door een milde malaria-infectie. Dit 
beperkt de toepasbaarheid van deze parameters als screeningstest in malariagebieden. Een 
bruikbaar alternatief zou het Ret-Hb en/of hepcidinegehalte kunnen zijn. Aan het eind van 
hoofdstuk 3 wordt een diagnostisch schema met Ret-Hb en hepcidine voorgesteld.
Deze bevindingen bij Nederlandse vrijwilligers zijn bevestigd in Indonesische schoolkinderen 
met asymptomatische malaria (hoofdstuk 4). Met asymptomatische malaria wordt de aan­
wezigheid van malariaparasieten in het bloed zonder verder klinische symptomen bedoeld. Het 
is een veel voorkomende chronische aandoening in malariagebieden die vaak niet of pas laat 
gediagnosticeerd en behandeld wordt. Kinderen met asymptomatische malaria bleken een licht 
verhoogd hepcidine te hebben, ondanks de afwezigheid van een duidelijke ontstekingsreactie, 
met daarbij een lager hemoglobine. De discrete veranderingen in ijzerhomeostase kunnen bij 
deze kinderen bijdragen aan anemie. Daarnaast kan ook de effectiviteit van programma's voor 
universele ijzersuppletie in gebieden met een hoge prevalentie van asymptomatische parasit- 
emie verminderd zijn.
Tijdens zwangerschap zijn ijzerdeficiëntie, anemie en malaria veel voorkomende complicaties. 
Aanwezigheid van malariaparasieten in de placenta (placentamalaria) kan leiden tot bloedar­
moede en ziekte bij zowel de moeder als het kind. In hoofdstuk 5 wordt een studie beschreven 
waarin hepcidine en andere ijzerparameters kort na de bevalling bepaald zijn bij zwangeren 
met en zonder placentamalaria en in het navelstrengbloed van de pasgeborenen. De meest 
interessante bevindingen waren dat -  ondanks het feit dat de zwangere vrouwen vaak een ijz­
ertekort hadden -  de pasgeborenen geen absoluut of functioneel ijzertekort hadden en dat de 
ijzerhuishouding van het kind niet beïnvloed werd door de aanwezigheid van placentamalaria. 
Dit suggereert dat het ijzertransport van moeder naar kind tijdens de zwangerschap zo lang 
mogelijk gehandhaafd blijft voor de foetale erytropoiëse en andere vitale ontwikkelingsproces­
sen.
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In de laatste twee hoofdstukken van deel I worden twee andere factoren besproken die een 
rol kunnen spelen in anemie bij malaria. Het cytokine (eiwit betrokken bij de immuunafweer) 
macrophage migration inhibitory factor (MIF) kan de bloedaanmaak in het beenmerg remmen 
in combinatie met andere cytokines. Of MIF belangrijk is bij de anemie bij malaria is onduidelijk. 
Verwarrend was dat in eerdere onderzoeken zowel verhoogde als verlaagde MIF gehaltes in het 
bloed van malariapatiënten gevonden waren. In onze experimentele malariamodel daalde het 
circulerend MIF gehalte tijdens malaria en de behandeling (hoofdstuk 6). MIF wordt onder an­
dere geproduceerd door bepaalde witte bloedcellen, T-lymfocyten genaamd, en we speculeren 
dat de daling van het aantal circulerende lymfocyten verantwoordelijk is voor de daling in MIF.
Niet alleen de levensduur van geïnfecteerde rode bloedcellen, maar ook die van ongeïnfect­
eerde rode bloedcellen blijkt verkort tijdens een malaria-infectie. Veranderingen in de celmem- 
braan van rode bloedcellen, geïnduceerd door malaria, kan hieraan bijdragen. In de hypothese- 
genererende studie beschreven in hoofdstuk 7, is de eiwitsamenstelling van de membranen 
van enkele Indonesische malariapatiënten bepaald met behulp van een nieuw ontwikkelde 
proteomics techniek. De gegevens laten verschillende veranderingen in verschillende mem- 
braaneiwitten zien (o.a. afbraak van band 3 en binding van hemoglobine aan de celmembraan) 
die suggereren dat malaria resulteert in een versnelde 'veroudering' van rode bloedcellen.
II. MALARIA-GEASSOCIEERDE 
THROMBOCYTOPENIE
Het ontstaan van thrombocytopenie is een kenmerk van malaria-infecties en er is toenemend 
bewijs dat de daling van het aantal bloedplaatjes meer is dan slechts een epifenomeen. De be­
schikbare kennis over de oorzaken en gevolgen van de daling in bloedplaatjes tijdens malaria 
is echter verre van volledig.
Een eiwit dat essentieel is voor de functie van bloedplaatjes is von Willebrand factor (VWF). Dit 
eiwit wordt gemaakt door endotheel en werkt als een bindend eiwit tussen bloedplaatjes en 
het endotheel op plaatsen van vaatschade. In hoofdstuk 8 is de mogelijke rol van VWF in het 
ontstaan van de thrombocytopenie bij malaria bestudeerd. In vrijwilligers die experimenteel 
besmet werden met malaria viel de vroege daling in het aantal bloedplaatjes samen met het 
vrijmaken van VWF uit endotheel; dit vrijgemaakte VWF was in een hyperreactieve vorm dat 
spontaan bloedplaatjes kan binden. Deze gegevens ondersteunen de hypothese dat activer­
ing van endotheelcellen met vrijmaken van VWF primair verantwoordelijk is voor de vroege 
daling van het aantal bloedplaatjes. In deze zin heeft malaria duidelijk overeenkomsten met 
bloedziekten waarin overmatige activering van VWF een centrale rol speelt, zoals de ernstige 
ziekte thrombotisch thrombocytopenische purpura (TTP).
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In een vervolgstudie op het Indonesische eiland Sumba (hoofdstuk 9), werd bevestigd dat een 
toegenomen hoeveelheid hyperreactief VWF gevonden wordt in mensen met een P. falciparum 
('tropische malaria') of P. vivax ('goedaardige malaria') infectie. Een opvallende bevinding in dit 
onderzoek was het ontstaan van een tekort in ADAMTS13 -  het eiwit dat zorgt voor inactivatie 
van hyperreactief VWF. De precieze oorzaak van het verlaagde ADAMTS13 is niet duidelijk; be­
langrijke mutaties in het ADAMTS13-gen of remmers van ADAMTS13 werden niet gevonden.
Andere oorzaken van thrombocytopenie zijn onderzocht in de studie beschreven in hoofdstuk 
10. Een afgenomen aanmaak van bloedplaatjes in het beenmerg (thrombopoiese), activering 
van bloedplaatjes of een sterke activering van de bloedstolling traden niet op in de vrijwilligers 
die experimenteel geïnfecteerd waren met malaria; dit betekent dat deze factoren geen belan­
grijke rol spelen in het ontstaan van thrombocytopenie in de vroege malaria. De meest opval­
lende bevinding was een toename in circulerend glycoproteïne 1b (GP1b) -  de bloedplaatjes- 
receptor voor VWF - in zowel de vrijwilligers als in Indonesische malariapatiënten. Onlangs is 
aangetoond dat de binding van VWF aan bloedplaatjes kan leiden to verlies van GP1b van de 
bloedplaatjesmembraan. Dit proces kan de stijging van het circulerend GP1b verklaring en zou 
excessieve hechting van bloedplaatjes aan endotheel kunnen voorkomen.
Ten slotte trad bij een van de vrijwilligers die deelnamen aan een experimentele malaria-infectie 
een complicatie aan het hart op. Een gedetailleerde klinische beschrijving van deze casus, sa­
men met een analyse van mogelijke oorzakelijke factoren, wordt gegeven in hoofdstuk 11.
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